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ABSTRACT 
 
Non-coding RNAs appear to play a role in gene regulation by modulating chromatin 
structure. There is mounting evidence suggesting an essential role for non-coding RNAs 
in the complex process of the genetic regulation of the β-globin locus. Preliminary 
observations indicate that the BGL3 non-coding transcript may be involved in an RNA-
protein interaction and may be interacting with chromatin in the β-globin locus as part 
of a regulatory function within the locus. However, the expression profile of this non-
coding transcript has not yet been characterized and nothing is known about its mode of 
action. 
Here it is shown that the BGL3 transcript is dynamically up-regulated upon haemin 
induction of the K562 cell line (a human erythroleukemic cell line). To determine 
whether there is a correlation between the BGL3 transcript expression and the 
expression of the γ- and β-globin genes, the levels of the BGL3 transcript in K562 cells 
were perturbed by knocking it down using the RNA interference pathway. The effect of 
the knockdown of the BGL3 transcript was tested on the expression levels of the γ- and 
β-globin genes, which were quantified using qRT-PCR. Our results are the first, to our 
knowledge, that describe a developmentally regulated expression of the BGL3 non-
coding transcript in haemin-induced K562 cells, and provide evidence that suggests that 
this transcript may be involved in the silencing of the β-globin gene. 
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switching. 
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1 Introduction  
This literature review aims to explore the current pool of knowledge of the molecular 
mechanisms that regulate the production of red blood cells from precursor stem cells, as 
well as the mechanisms that control the structure of DNA at the genes that code for 
adult and foetal haemoglobins involved in haemoglobin switching. The molecular and 
cellular mechanisms of red blood cell development will be discussed, with special 
emphasis on how expression of different haemoglobin subunits is controlled, the 
molecular mechanism of red blood cell differentiation, and how non-coding RNAs can 
regulate both of these processes. A better understanding of the molecular and cellular 
mechanisms of globin switching is a prerequisite in the development of rational 
therapies for genetic blood disorders such as sickle cell disease or thalassemias. 
1.1 The β-globin Locus 
1.1.1 Haematopoietic system 
The formation of blood cellular components through the differentiation of 
hematopoietic stem cells is known as haematopoiesis. Haematopoiesis is carried out by 
the haematopoietic system, a well–characterized vertebrate developmental system with 
a highly regenerative capability which maintains tissue homeostasis. It controls 
commitment, proliferation, apoptosis, and maturation of hematopoietic stem and 
progenitor cells (HSCs) in response to environmental signals. These environmental 
changes are perceived by the HSCs, which can undergo self-renewal division or 
differentiation to produce cells of all the blood lineages through a regulated and rapid 
mechanism
1
. This is a sustainable process that continues throughout the lifespan of an 
individual, responsive to temporal physiological needs, such as red cell replacement 
after acute blood loss or leukocytosis in response to infection. Decades of research have 
been devoted to the elucidation of the transcriptional networks involved in 
haematopoiesis. However, it remains unclear how this system dynamically adjusts to the 
body’s needs by replenishing specific lineages of mature blood cells from uncommitted 
HSCs. The control of haematopoiesis and its output in terms of cell types and quantities, 
rely on a complex network of transcription and growth factors
2
. 
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Haematopoiesis takes place in different anatomic sites during development. In the 
embryonic stage it occurs in the yolk sac, liver, and in later stages in the bone marrow. 
In adults, haematopoiesis takes place in marrow and lymphatic tissues. These changes 
of site during development are governed by cell-fate diversification and differentiation
1
. 
Large-scale gene-expression profiling studies of uncommitted HSCs and intermediate 
progenitor cells showed promiscuity in the expression of genes before lineage 
commitment and differentiation, as megakaryocitopoiesis, macrophagopoiesis, 
erythropoiesis and granulocytopoiesis share a common differentiation pathway
2
. This 
promiscuity of HSCs suggests that an important stage of during lineage differentiaition 
may be the down-regulation of groups of genes
3-5
.  
HSCs are the common precursor of the distinct cell lineages of mammalian blood cells. 
HSCs must pass through many critical decision points to differentiate into mature blood 
cells. The first step consists of the differentiation of HSCs to common myeloid 
progenitors (CMPs) or to common lymphoid progenitors (CLPs). Subsequently, CMPs 
differentiate into erythrocytes, megakaryocytes, myeloblasts or mast cells, whilst CLPs 
differentiate into T or B cells or natural killer cells. The hematopoietic system (Figure 
1-1) provides a good model to study cell lineage specification because a large amount of 
information is available about its cellular and transcriptional networks
1
.  
The formation of normal mature blood cells requires the haematopoietic differentiation 
to be carried out in an organized spatial and temporal manner. Haematopoiesis is a 
complicated developmental programme mediated by a large number of regulators. Once 
the progenitors have chosen a specific cell fate, they maintain the lineage specification 
and cannot differentiate to other lineages because of the inactivation of the genes of 
these other lineages
2
.  
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Figure 1- 1 The haematopoietic system. 
Diagrammatic representation of the bone marrow pluripotent stem cell and the cell lines 
that arise from it. Source: Hoffbrand, 2005
2
. 
1.1.2 Erythropoieisis 
The formation of red blood cells is known as erythropoiesis. It is a dynamic and 
sequential process which occurs in different anatomic sites during development. 
Erythroid differentiation begins with the commitment of hematopoietic stem cells 
(HSCs) to the erythroid lineage (Figure 1-2). Erythroid maturation consists of a series of 
cell transformations from erythroid progenitors cells colony-forming unit granulocyte, 
erythroid, monocyte and megakaryocyte (CFU-GEMM), erythroid colony-forming units 
(CFU-Es) and erythroid burst-forming units (BFU-Es), to morphologically distinct 
erythroid precursors called pronormoblasts, basophilic erythroblasts, polychromatic 
erythroblasts and orthochromatophilic erythroblasts, sequentially. Reticulocytes appear 
once the orthochromatophilic erythroblasts extrude the nucleus. As reticulocytes lose 
their polyribosomes they become mature red blood cells
1
. 
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Figure 1- 2 Erythropoietic differentiation. 
Pronormoblasts (Pro), basophilic erythroblasts (Bas), polychromatic erythroblasts (Pol), 
orthochromatic erythroblasts (Ort), reticulocytes (retic), mature red blood cells (RBCs). 
Adapted from: Hoffbrand, 2005, p.15
2
. 
Morphology, gene expression, as well as growth factor dependence are different in 
erythroid cells at different developmental and differentiation stages. For example, as 
erythroid terminal differentiation progresses, cells gradually decrease in volume, there 
are increases in haemoglobinization and chromatin condensation, erythropoietin 
signalling becomes essential and the cell-surface erythroid-specific Ter119 antigen is 
expressed
2
. 
1.1.3 Haemoglobin 
Eyrthrocytes carry O2 to the tissues and CO2 from the tissues to the lungs, using 
haemoglobin
6
. Given the different oxygen requirements during the embryonic, foetal 
and adult stage, different haemoglobins are synthesized at each of these developmental 
stages. All types of haemoglobin consist of two different pairs of globin chains, each 
attached to one haem molecule, to achieve a final tetrameric structure. Two possible 
configurations are available for haemoglobin; oxygenated and deoxygenated (Figure 1-
3)
2
.   
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Figure 1- 3 The two possible conformations of the haemoglobin molecule. 
α- and β-globin chains of normal adult haemoglobin (HbA). 2,3-DPG, 2,3-
diphosphoglycerate. Source: Hoffbrand, 2006, p.17
1
. 
In vertebrate red cells, different haemoglobin tetramers are expressed and assembled at 
different developmental stages in a programmed manner
7
. In embryos, δ-chains 
combine with γ-chains to form Portland (δ2γ2) haemoglobin, or with ε-chains to generate 
Gower 1 (δ2ε2) haemoglobin. When α- and ε-chains combine, Gower 2 (α2ε2) 
haemoglobin is produced. During foetal life foetal haemoglobin is expressed (HbF, 
α2γ2), whereas in adult life the major haemoglobin is haemoglobin A (HbA, α2β2). 
However, during adult life haemoglobin A2 (HbA2, α2δ2) is also expressed together with 
HbF, but both represent less than 2% of the total haemoglobin
8
 (Figure 1-4). A mutation 
un the TATA-box region of the δ-globin gene determines its low expression levels 9. 
Human foetal β-like γ-globin genes and the production of HbF in primates represent a 
rather recent event in evolution respect to other mammals; for example mice don’t have 
γ-globin genes. The development of these genes is thought to be due to the increased 
oxygen affinity of HbF over HbA, which enhances an improved oxygen
 
delivery to the 
foetus in the placental circulation
8; 10
. 
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Figure 1- 4 (a) The α- and β- globin gene clusters on chromosomes 16 and 11 respectively. 
In embryonic, foetal and adult life different globin genes are activated or suppressed. 
The different globin chains are synthesized independently and then combine with each 
other to produce the different haemoglobins. (b) Synthesis of individual globin chains 
in prenatal and postnatal life. Adapted from: Hoffbrand, 2006, p.73
1
. 
In humans the genes of both α- and β-globin clusters are arranged in the order of their 
expression, reflecting the sequence of their expression during development
7; 9
. The β-
like globin genes form a linked cluster on chromosome 11 and are arranged in the order 
5′-ε-Gγ-Aγ-ψβ-δ-β-3′. The α-like globin genes also form a linked cluster, located on 
chromosome 16, and are arranged in the order 5′-δ-ψδ-ψα1-α2-α1-3′. The ψβ, ψδ and ψα 
pseudogenes sequences are similar to those of the β-, δ- or α-genes, but present 
mutations that determine its inviability to translated to proteins. It is thought that these 
pseudogenes could have been functional at previous stages of evolution
2
, or non-
functional duplications of coding genes, or they might be active regulators of gene 
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expression, since endogenous siRNAs (reviewed in section 1.3) have been found in 
mouse embryos that come from pseudogenes
11
. 
1.1.4 β-globin locus 
The human β-globin locus spans over 70 kb in an AT-rich region on chromosome 11 
embedded within an array of olfactory receptor genes
12; 13
 and contains the five β-globin 
genes (ε, Gγ, Aγ, δ and β), which are arranged in the order of their expression during 
development
8; 14; 15
 (Figure 1-5). Unlike the α-globin locus which is present in a GC-rich 
domain on chromosome 16 and whose chromatin structure is constitutively accessible, 
the β-globin locus shows a tissue-specific expression limited to the cells of the erythroid 
lineage
16
. This is supported by the fact that the locus is DNase I-sensitive exclusively in 
erythroid cells
13
. 
 
Figure 1- 5 Diagram of the β-globin locus. 
A linear map with the globin locus control region (LCR) and its hypersensitive (HS) 
sites is indicated by the vertical arrows. The structural ε-, Gγ-, Aγ-, δ- and β- globin 
genes as well as the ψβ gene. Source: Stamatoyannopoulos, 2005,p.26310. 
1.1.5 Haemoglobin switching 
In mammals there is a correlation between the β-globin genes expressed in each of the 
discrete stages of erythropoiesis and the changing sites of erythropoiesis during 
development
10
. Humans undergo two major transitions in the β-globin locus expression 
in accordance to the
 
oxygen requirements of the foetus during its different 
developmental stages
6; 12. The first gene of the β-globin locus to be expressed during the 
early embryonic stage is the β-like ε-globin gene in the erythroid cells located in the 
blood islands of the foetal yolk sac, where the primitive human embryonic 
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erythropoiesis first occurs. This is followed by the activation of the major β-like γ-genes 
(
Gγ, Aγ) during foetal development, when erythropoiesis takes place in the liver and Gγ- 
and 
Aγ-globin genes are transcribed in the definitive circulating enucleated erythrocytes. 
Finally the β-like δ-globin and the β-globin genes are activated in the late foetal stage in 
the erythroid cells in the bone marrow where erythropoiesis occurs in adults, being the 
β-globin gene the most highly expressed in adults10; 17 (Figure 1-6). Thus, each gene in 
the β-globin locus is differentially transcribed during development. This tissue-specific 
and developmental regulation is achieved thanks to the participation of both gene 
proximal and gene distal elements
18; 19
. Although these globin gene switches represent 
one of the classic examples of developmental control in eukaryotes, little is known 
about the mechanisms that mediate them
18
. 
 
Figure 1- 6 Schematic overview of embryonic erythropoiesis. 
The figure shows the formation of embryonic blood islands in the extraembryonic yolk 
sac and the formation of definitive haematopoiesis initially in the aorta–gonad–
mesonephros (AGM) region, with subsequent migration to the liver and bone marrow. 
Ma denotes a macrophage. The specific types of haemoglobin formed at each stage of 
erythropoiesis are indicated. Adapted from Hoffbrand, 2005, p.14
2
. 
1.1.6 Locus Control Region (LCR) 
Enhancers were discovered 30 years ago and are defined as cis-acting DNA regulatory 
elements that enhance gene transcription in eukaryotes. However, enhancers have also 
been found to interact with transcriptional repressors. Enhancers interact with proteins 
to form nucleoprotein complexes, which are able to affect chromatin structure and 
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activate the basal transcriptional machinery. Enhancers mediate DNA folding of 
clusters, which allows the physical interaction between DNA sequences separated by 
several nucleotides, to facilitate the interaction with general transcription factors and 
RNA polymerase II
20; 21
. 
β-globin gene locus expression depends on the cis-regulatory locus control region 
(LCR), which consists of a powerful set of enhancer elements
8
 and is located from 
approximately 5 to 25 kb upstream (5’) of the ε-gene13; 22. The role of the LCR in the 
developmental regulation of individual genes within the locus is unclear
23. The α-globin 
gene cluster also contains an LCR-like region termed HS40
2. The β-globin locus is an 
ideal model to study the interactions between chromatin structure and transcriptional 
regulation
13
.  
LCRs encompass a group of long-range transcriptional control determinants that 
regulate the expression of a large number of genes exerting a dominant transcriptional 
activation function over a chromatin domain
24; 25
. LCRs consists of a cluster of 
deoxyribonuclease (DNase) I hypersensitive (HS) sites
15
. The β-LCR, which is located 
6 to 22 kb upstream (5') of the β-globin structural genes19. The human β-LCR is 
composed of 5 critical developmentally stable DNase I HSs (5’HS1 to HS5) and two 
weak HSs (HS6–7) 13, which represent sites of easy accessibility to interact with 
transcription
 
factors and downstream gene sequences
8; 25
. HSs are 200-400 bp in size 
and are separated from each other by about 2-4 kbp of DNA
9. Downstream (3’) of the β-
globin structural genes, another HS site (3’HS1) is present (Figure 1-5). The β-LCR is 
responsible of the establishment of the erythroid lineage-specific expression on the β-
globin genes
10
. High-level expression within the β-globin locus requires the presence of 
the β-LCR8. 
The HSs of the β-LCR are specific for the cells of the erythroid lineage26. The β-globin 
locus is surrounded at both 5’ and 3’ ends by olfactory receptor (OR) sequences. The 
evolutionary conservation of the flanking elements 5’HS5 and 3’HS1 of the β-globin 
locus  suggest the involvement of these HSs in the control of β-globin gene expression 
by the LCR and, at the same time, in the inactivation of the expression of the olfactory 
receptor genes in erythroid tissues or vice versa
12
. Each of the LCR HSs has its specific 
activities, with the exception of HS1 that appears to be dispensable
14. For example, 5’ 
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HS2 carry the enhancer activity of the β-LCR, HS3 has a domain-opening activity and 
functions as an activator of ε- and γ-globin gene expression. HS4 and HS5 function as 
insulators, being the last one contained within a matrix attachment region
10; 14; 15. 
It has been proposed a model for LCR HS core formation. According to McMorrow et 
al, the first step is the binding of non-erythroid factors such as SP1 or erythroid-specific 
factors such as EKLF to the core forming elements, resulting in the formation of a 
phased nucleosomal array and a weak DNase 1 HS. Then the binding of the 
hematopoietic factors NF-E2 and GATA-1 occurs; the factors act to stabilize the 
nucleosome-free chromatin structure, indicating the formation of a strong HS. The final 
step involves the recruitment of non-DNA-binding factors, which interact with the 
DNA-bound factors, resulting in a functional HS core element
13; 27. 
1.1.7 LCR and genetic activation of the β-globin locus 
Chromatin opening and gene activation are separable. Activation of the β-globin locus 
could occur in open chromatin scenario. Thus, for the activation of the genes of the β-
globin locus, an open chromatin context is necessary bu not sufficient. Chromatin 
opening is driven by multiple redundant elements including the LCR. Acetylation, 
deacetylation and other histone modifications have key roles in chromatin structures and 
gene expression
15
. Schübeler et al. reported that an additional localized H3 
hyperacetylation at the LCR correlates with gene activation at the β-globin locus28. 
The preconception that the LCR is required to open or activate chromatin has been 
challenged by recent studies. Bender et al. generated mice with a targeted deletion of 
5′HS1–6 in order to elucidate the role the β-globin locus of the LCR in chromatin 
opening and transcription during development. They reported that the deletion does not 
affect the open chromatin structure of the locus, remodelling of the β-globin promoter, 
formation of the remaining structural HS or maintenance of the nuclease-sensitive 
state
19
. The work of Reik et al. also supports this idea. They reported that deletion of the 
β-LCR from the native locus results in persistence of a DNase I–sensitive chromatin 
structure
29
. These experiments showed that the LCR is not required for activation or 
maintenance of an active chromatin structure in the β-globin locus, or for protecting it 
from a surrounding repressed chromatin. The correlate of this is that elements capable 
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of opening the β-globin locus by the generation of a permissive chromatin structure 
must exist outside of the LCR.  
1.1.8 Models of LCR mediated stimulation of globin gene 
expression during the haemoglobin switching 
Haemoglobin switching provides a model for the regulation of human gene expression 
during development with direct applications in the treatment of haemoglobinopathies
26
. 
Haemoglobin switching does not correspond to a replacement in stem cell populations 
expressing a fixed transcription profile of β-globin genes, but a modification in the 
transcription programmes of erythroid cells. Thus, the switches in the transcription of β-
globin genes are controlled exclusively at the transcriptional level
10
. 
The human haemoglobin switch has been widely studied using transgenic mice 
containing the human β-globin locus (β-locus mice). These mice models are generally 
considered as a valid system to study human haemoglobin switching. However, recent 
evidence suggests that there are significant differences between humans and these mice. 
For instance, activation of the γ-globin genes in the transgenic mouse occurs during the 
embryonic erythropoiesis at the yolk sac, whereas in humans the activation of these 
genes occurs in the foetal liver. Another significant difference is observed during the 
switching from the foetal to adult globin genes, which in mice occurs during early foetal 
liver erythropoiesis instead of appearing around the time of birth as it occurs in 
humans
30
. Using these transgenic mice, various models have been proposed to explain 
how the LCR functions and activates the human β-globin genes in a developmental-
stage specific manner: the autonomous silencing and competition models, a looping 
model, a linking model, a tracking model, and a sequential model. Unless stated 
otherwise, the switching models explained below have been developed using β-locus 
mice. 
       A) The autonomous silencing and competition models in haemoglobin 
switching 
Expression of one gene in a locus can be negatively influenced by the transcription of 
other genes of the locus during haemoglobin switching. This phenomenon is known as 
transcriptional interference and can be explained assuming that all potentially active 
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genes compete for the LCR
 
activity. Studies of human transgenes in mice showed that 
β-like globin genes compete for LCR interaction in a transcriptional interference 
context
23. Expression suppression of the β-globin genes at the different developmental 
stages is thought to be achieved by at least two mechanisms. Embryonic ε- and foetal γ-
globin genes autonomously suppress their expression. However, the β-globin gene 
silences its expression during the embryonic stage in a competitive fashion for the LCR 
with the other genes of the locus
17
. 
Two models have been proposed to understand how the LCR is involved in the 
expression of β-globin genes. On the one hand, activation of the β-globin genes is 
conducted by an environment of open chromatin provided by the LCR. Thus, β-globin 
genes would be autonomously regulated. On the other hand, a competitive model is 
proposed to explain the sequential activation of the particular β-globin genes. According 
to this model each gene of the β-globin locus competes for the LCR, but only one gene-
LCR interaction would be possible per chromosome
17
. The results of such competition 
might depend on the array of transcription factors interacting with both gene promoters 
and the LCR. Whereas the autonomous model seems to be employed more frequently, 
literature supports the competition model to explain the foetal silencing of the β-globin 
gene, which competes with the y-globin gene for the LCR activity
7
. 
The gene competition is the prevalent model for the developmental silencing of the 
adult
 β-globin gene23. This model is supported by the work of Behringer et al.18 and 
Enver et al.
31
. This group worked with transgenic mice to understand the mechanism of 
γ- to β-globin gene switching. They observed that during the foetal stage there is a 
preferential interaction between the γ-globin genes and the LCR, and the β-globin gene 
is turned off competitively. In contrast, in the adult stage the LCR interacts 
preferentially with the β-globin gene whereas the γ-globin genes are silenced. During 
embryonic erythropoiesis, the β-globin gene is silenced by the competition by the 
upstream ε- and γ-globin genes for the LCR (Figure 1-7)10. 
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Figure 1- 7 The competitive mechanism of haemoglobin switching. 
There is a competition between the adult and foetal globin genes to interact with the 
LCR. During foetal life γ-globin genes interact with the LCR (red circle) and β-globin 
gene is slenced (diffuse arrow). In the adult stage, the β-globin interacts with the LCR 
(blue rectangle) whereas the γ-globin genes are silenced (diffuse arrows). Adapted from: 
Stamatoyannopoulos, 2005, p.26410. 
The autonomous silencing model has been adopted to explain the silencing of the 
embryonic ε-globin gene, which expression is totally restricted in yolk sac 
erythropoiesis and completely dependent on the presence of the LCR
32
.  
       B) Models for LCR-β-globin gene interaction 
                (i) Looping model 
Choi et al. first proposed the looping model assuming that a loop through the 
nucleoplasm is formed by the direct interaction of distal and proximal regulatory 
elements to enhance the expression of the individual genes of the β-globn locus33. The 
looping model suggests that activation of β-globin genes in erythroid cells is preceded 
by a loop between 5’HS5 and 3’HS1, delineating a β-globin chromatin domain12 (Figure 
1-8). It has been proposed that each HS of the LCR, and the transcription factors bound 
to them, contribute cooperativitely to form a larger physical synergistic entity termed 
holocomplex
13; 15
. This complex interacts directly with the genes to activate its 
transcription
17
. The looping of this complex allows the association of the LCR with 
gene-proximal elements that activate the transcriptional machinery
10
. Carter et al., using 
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a so-called RNA TRAP (tagging and recovery of associated proteins) showed that the 
5’HS2 of the β-LCR is very close to the β-globin gene located when this is active, 
suggesting a direct regulatory interaction
34 (Figure 1-8). 
 
Figure 1- 8 Looping model. 
The β-globin locus LCR and adult β-globin gene come in to close proximity in adult 
stage erythroid cells in which that gene is actively transcribed. The embryonic and 
foetal expressed genes that are silent at this stage of development are excluded from the 
close contacts. Adapted from: Kiefer, 2008, p.69
12. 
                (ii) Linking model 
According to the linking model, the LCR activates individual gene promoters by leading 
the formation of a chain of components of the transcriptional machinery that extends in 
the promoter of the gene to be activated
15
. 
                (iii) Tracking model 
Tuan et al. proposed the tracking model from the observation that the HS2 of the LCR 
starts the production of long non-coding RNAs. According to their model, the LCR 
recruits transcription complexes to the β-globin gene promoters35.  
                (iv) The facilitated-tracking model 
In the facilitated-tracking model are combined different aspects of the looping and 
tracking models. According to this model, transcription factors bind to the HSs of the 
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LCR forming a holocomplex that loops to track downstream DNA, and transcription 
factors are released in specific promoter regions
15. 
                (v) Sequential model 
Schübeler et al.
28
 proposed a sequential model for the β-globin gene activation based on 
the dissociation of chromatin opening and transcriptional activation. The first step of the 
model is the relocation, by cis-elements others than the LCR, of the β-globin locus in a 
region free of centromeric heterochromatin to achieve the propagation of an open 
chromatin context. The establishment of an open chromatin structure is marked by 
broad acetylation, which involves the formation of HSs at the LCR and the β-globin 
gene promoters. The next step consists in the localized H4 hyperacetylation at the active 
promoters, process in which the LCR plays an active role. LCR-mediated high-level 
transcription is the final step of the model. The LCR modifies or recruits additional 
components to the remodelled and hyperacetylated promoter. Alternatively, LCR may 
help the elongation efficiency of transcription initiated at the β-globin gene promoter13. 
1.1.9 Haemoglobinopathies associated with the β-globin locus 
Blood disorders are amongst the most common genetic diseases in the world and have 
been associated with serious, long-term disability, lower-than-average life expectancy 
and severe morbidity
6
. These inherited disorders have been used as a models to study 
the developmental regulation of the β-globin locus and haemoglobin switching17. 
Haemoglobinopathies are characterized
 
for the absence of functional α-like or β-like 
globin
 
chains
6
. In addition, a harmless group of mutations known as hereditary 
persistence of foetal haemoglobin also have been shown to interfere with the normal 
haemoglobin production
1
.  
       A) Thalassaemias  
Thalassaemias correspond to the pathological state characterised by the defective 
production in some of the chains that conform the haemoglobin molecule. Thalassemias 
are divided in function to which globin chain is produced in reduced amounts, that is α-, 
β-, δβ- or γδβ-thalassaemias. In α0- or β0-thalassemias no globin chain is synthesized at 
all
2
. 
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                (i) β-Thalassaemias 
The most common and relevant form of thalassemias are those in which no β-chain is 
produced (β-thalassaemias), leading to a severely decreased or absent adult β-globin 
production, which is associated severe anaemia
2
. β-thalassaemias are generally caused 
by point mutations, minor insertions or deletions, which affect different levels in the β-
globin synthesis cascade
36
. In β-thalassaemia, the synthesis of α-globin continues as 
normal, resulting in its accumulation to finally precipitate in the erythroid precursors. 
This causes the formation of inclusion bodies which lead to the premature destruction of 
the erythroid precursors in the bone marrow, a phenomenon known as ineffective 
erythropoiesis
8
. 
       B) Sickle cell disease 
Sickle cell disease is the consequence of the replacemant of a thymine for an adenine in 
the sixth codon of the β-globin gene. This change in the genetic sequence leads to the 
replacement of valine for glutamic acid at the sixth position of the chain of the β-globin. 
When HbS deoxygenates the conformation of the molecule changes, exposing the 
hydrophobic β6 valine at the surface of the βs-globin chain. This acts as a binding site 
for another complentary haemoglobin tetramer, triggering the formation of large 
polymers. These tetramers rapidly form relatively large fibers, which deform red cells 
upon deoxygenation due to the polymerization of the defective globin tetramers. HbS 
polymers reduce red cell deformability, which leads to increased blood viscosity. 
Sickling also damages the red cell membrane, which finally leads to haemolytic 
anaemia, and clogging of
 
small vessels(Figure 1-9)
2; 8
. 
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Figure 1- 9 Induction of red cell sickling. 
As red cells traverse the microcirculation, oxygen is released from oxy-HbS (red 
circles), generating deoxy-HbS (purple circles). Conformational change exposes a 
hydrophobic patch at the site of the β6-valine replacement, shown as a projection (left 
column), which can bind to a complementary hydrophobic site on a subunit of another 
haemoglobin tetramer, shown as an indentation. The middle column shows the 
assembly of deoxy-HbS into a helical fibre, shown as a twisted rope-like structure. As 
deoxy-HbS polymerizes and fibres align, the red cell is distorted into sickle shape 
(right column). Source: Hoffbrand, 2005, p.106
2
.   
       C) Hereditary persistence of foetal haemoglobin 
Hereditary persistence of foetal haemoglobin (HPFH) is a heterogeneous group of 
asymptomatic conditions characterised by persistent foetal haemoglobin production 
during adult life. HPFH is caused by long deletions of the β-globin locus and localized 
mutations in the upstream promoters of the 
Gγ and Aγ-globin genes. These changes 
allow the γ-globin genes to be active in adult life. Despite of his nule clinical symptoms, 
its importance lies on his potential to modify the phenotype of the β-
haemoglobinopathies and sickle cell disease, since it causes a high level of HbF 
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production and hence reduces the severity of the phenotype. Thus, HPFH has been 
proposed as a potential therapy to fight these diseases
2
. 
       D) Therapeutic approaches to reactivation of γ-globin and HbF in adult 
erythroid cells 
A full comprehension of the molecular
 
mechanisms of globin switching is appears to be 
necessary to develop new therapies for β-thalassaemia or sickle cell disease based on 
the reactivation of γ-globin and HbF in adult erythroid cells. Indeed, treatments for red 
blood disorders aim, somewhat unsuccessfully, to reactivate the foetal version of 
haemoglobin. HbF production can be increased by erythropoietin, other cytokines, and 
changes in cell cycle
 
kinetics. Butyrate or hidroxyurea-based treatments can increase 
HbF levels in patients suffering from β-thalassemia and sickle cell disease8, fuelling 
interest in the reactivation of γ-globin as a therapeutic measure10. Characterization of γ-
globin
 
gene regulation and human haemoglobin switching will be useful to develop new 
therapies to reactivate γ-globin expression in adult erythroid cells12.  
1.2 ncRNAs & Chromatin 
1.2.1 Non-coding RNAs 
Most of the genome of mammals, and most of the eukaryotes, is transcribed to produce 
coding and non-coding RNAs (ncRNAs)
37
. ncRNAs are a growing class of RNAs with 
biological functions rather than simple intermediate messengers between DNA and 
proteins. ncRNAs usually do not encode for Open Reading Frame (ORF), but contain a 
high number of stop codons
38
. Several pieces of evidence support that ncRNAs are 
versatile molecules that, due to their chemical properties, can form complex tertiary 
structures that allow them to perform roles that were thought to be exclusive of 
proteins
39
. The abundance of ncRNAs is a distinguishing feature of metazoan 
genomes
40
. ncRNAs are a heterogeneous group which is divided into three subgroups 
according to their length and function
38
: ncRNAs range from about 1) ~18-25 
nucleotides for microRNAs, ~20-300 nucleotides for small RNAs commonly found as 
translational regulators, and up to and beyond 10,000 nucleotides for large RNAs 
involved in gene silencing and other processes
39
 (Figure 1-10). 
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Figure 1- 10 Schematic representation of the emerging ncRNA world. 
microRNAs, siRNAs, small RNAs, and medium/large RNAs. Adapted from: Costa, 
2007, p.2
38
. 
In the past few years, several studies
39
 have demonstrated that the biological functions 
of ncRNAs have been largely underestimated by the emphasis on mutation scanning of 
protein-coding exons
37. Evidence from several studies using a variety of model systems 
demonstrates the key role of ncRNAs during cellular differentiation and organism 
development, through a variety of complex mechanisms such as the recruitment of 
proteins, the control of epigenetic regulation, chromosomal and chromatin structure 
dynamics, long-range interactions, gene silencing, gene transcription, DNA imprinting, 
DNA methylation and RNA interference
38; 41; 42
.  
ncRNAs can control gene expression at the levels of translation, transcription, and post-
transcriptional processing, affecting mRNA stability or processing, including the 
regulation of alternative splicing
43
. ncRNAs not only carry out different functions in the 
nucleus, but also function in dosage compensation and imprinting, and in other type of 
gene regulation, either in cis or in trans
40; 44
.These new evidences challenge the 
assumption that protein-coding genes are also the main controllers of cellular processes, 
suggesting a wide-spread involvement of ncRNAs in regulation
45
. All these data 
together suggest that the transcribed portions of genomes are larger than what was 
thought, where ncRNAs represent more than 50% of cellular RNA
41
, and that a huge 
part of the epigenetic regulation relies in these untranslated transcripts
46
. 
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The complexity of the transcriptome has prompted a shift from the simplistic 
understanding of a linear genomic organization to a modular model, which includes 
coding and non-coding transcripts
37
. ncRNAs have been shown to be part of complex 
regulatory networks, suggesting that the simplistic protein-centric view of the 
mammalian genome is wrong and that intergenic transcription is functional and not just 
transcriptional noise
43
. Data from different studies suggest that almost 90% of the non-
repetitive sequences of the mammalian genome are transcribed, being a large proportion 
of these ncRNAs, originating the alleged paradox that ncRNAs represent the largest 
output of the human genome. These intergenic transcripts also play a crucial role in 
epigenetic transmission of early determined transcription states
44
. It has been shown that 
complex organisms have a greater amount of regulatory information in their genome. 
This is supported by the observation that in bacteria regulatory factors scale 
quadratically with genome size
47
. These regulatory factors include the untranslated 
regions (UTRs) and non-protein-coding intronic and intergenic sequences, which 
increase dramatically in size with increasing developmental complexity in eukaryotes. 
This observation adds to the list of evidences about the regulatory function of ncRNAs 
in gene expression during differentiation and development
43
. 
Most ncRNAs show cell- or tissue- and temporal-specific expression. Furthermore, 
altered expression patterns of ncRNAs are involved in tumour-associated phenotypes 
and other diseases
43
. ncRNAs have been shown to take part in differentiation and 
specific developmental processes in multicellular organisms, acting as both activators 
and repressors of gene expression in complex regulatory circuits integrated at various 
levels
43
. ncRNAs show lower expression levels and lower sequence conservation than 
mRNAs, raising the possibility that ncRNAs arise by illegitimate transcription and are 
no functional
37; 43
. 
1.2.2 ncRNAs and Chromatin Regulation 
Chromatin is composed of nucleosome subunits, which are nucleoprotein complexes 
formed by histone octamers (two copies of each of the four core histones H2A, H2B, 
H3, and H4) that enclose a specific DNA sequence of 147 base pairs in length
42; 48
. 
Chromatin is highly compacted, allowing to pack 2 metres of DNA in an eukaryotic 
nucleus. The problem is that this compacted structure prevents the access of 
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transcription factors to DNA. Thus, during gene expression, a regulated disruption and 
reconstitution of the chromatin structure is needed
48
. 
Chromatin structure can be dynamically altered by methylation of the DNA
43
, and by 
enzymes that disrupt histone-DNA contacts in an ATP dependent way to allow the 
access of the transcriptional machinery to the nucleosomal DNA
48
. Posttranslational 
modifications of the core histone proteins, which can be acetylated, methylated or 
phosphorylated, epigenetically regulate gene expression. For example, Polycomb-group 
proteins catalyze the methylation of H3 lysine 27 (lys27), a modification that promotes 
the compacting of chromatin that in turn negatively regulates transcription
49
. 
It has recently become apparent that transcription affects the nature of chromatin, a 
concept that contrasts with the established idea that transcription is affected by 
chromatin structure
16
. ncRNAs have been shown to be associated with eukaryotic 
chromatin and play an important role in its structure maintenance
39
. Non-coding 
transcription correlates with chromatin structural alterations and locus activation of 
several loc in mammals, which often show developmental regulation. This suggests the 
involvement of intergenic transcription in the establishment of open chromatin 
domains
50; 51
. For example, intergenic transcription correlates with histone modification 
and with domains of highly modified chromatin
50
.  
Non-coding transcription by RNA polymerase II (RNAPII) occurs across intergenic 
regions, introns, and exons. Many cases of intergenic transcription associated with 
promoters have been reported, suggesting that intergenic transcription across promoter 
has a regulating function during gene transcription
52
. As discussed below, different 
types of ncRNAs act as recruiters to specific loci of DNA methyltransferases and 
chromatin-modifying complexes, evidencing the involvement of ncRNAs in the 
modulation of chromatin structure dynamics
43
. 
1.2.3 Examples of ncRNAs in the regulation of gene expression 
       A) Air ncRNA 
Genomic imprinting is an epigenetic phenomenon
53
 characterised by monoallelic 
expression of genes in a parent-of-origin dependent manner
54-56
. The imprinting control 
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region (ICR) H19/Igf2r DMR (insulin-like growth factor 2 differentially methylated 
region) gene is one of the most extensively studied ICRs
54
. The key regulatory elements 
for the imprinted expression on H19 and Igf2r from the paternal and maternal alleles 
respectively, are the ICR upstream of H19 and a set of enhancers downstream of the 
H19
57
. Thorvaldsen et al. found that mouse with a deletion in this sequence lost the 
imprinted expression of the Igf2r and H19 genes
57
. Schoenfelder et al. reported that the 
H19 ICR is biallelicaly transcribed in both sense and antisense directions. They were 
the first group in report the functionality of ncRNAs in the H19 ICR, indicating their 
key roles in the regulation of gene expression
53
. 
The long Air (Anti-sense IGF2r RNA) transcript is initiated from the Igf2r locus in the 
intronic differentially methylated region (DMR) Region 2
58
, regulated by DNA 
methylation specific
 
to the parent of origin
59
. Wutz et al. reported that deletion of 
Region 2 results in the biallelic expression of Igf2r, Slc22a2, and Slc22a3, three 
imprinted genes exclusively expressed only from the maternal alleles
60; 61
. Igf2r is 
overlapped by Air, which is transcribed in the antisense direction through the Ifg2r 
locus and its expression is imprinted from the paternal allele exclusively. Imprinted 
repression of Igf2r, Slc22a2 and Slc22a3 requires transcription of Air beyond the second 
exon of Igf2r
62
. Two models were proposed by Sleutels et al. to explain the mechanism 
of gene silencing by Air: 1) Antisense transcription across the Igf2r locus to repress the 
promoter of the overlapping gene, inducing a silent chromatin state that could spread 
bidirectionally in a limited manner into Slc22a2 and Slc22a3, and 2) Air forms a 
ribonucleoprotein to coat and silence flanking chromatin of the Igf2r locus
63
. 
Nagano et al. reported an interaction in placenta between Air the Slc22a3
 
promoter and 
the H3K9 histone methyltransferase G9a. They reported that there exists a correlation 
between the accumulation of Air at the Slc22a3 pomoter and localized H3K9 
methylation and transcriptional repression of the Slc22a3 gene. 
They concluded that Air epigenetically silences the Slc22a3 gene via
 
the recruitment to 
the Slc22a3 gene promoter of G9a, which leads to targeted H3K9
 
methylation and 
allelic silencing
59
. All these data together evidence that the Air ncRNA is directly 
involved in lineage-specific transcriptional repression
64
, based on the recruitment
 
of 
repressive histone-modifying activities to epigenetically
 
silence transcription
59
. 
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       B) HOTAIR ncRNA 
The HOX gene clusters are a classic model for studying gene regulation during 
embryonic development
65
. Thirty-nine HOX transcription factors have been reported in 
mammals. They are clustered in four chromosomal loci consisting of 9 to 11 HOX genes 
arranged in tandem
66
, termed HOXA through HOXD. It has been described a complex 
epigenetic regulation behind the maintenance of HOX expression patterns. Their 
complex clustering on the chromosomes and the large number of HOX ncRNAs, 
suggest that ncRNAs have a key role in HOX genes transcriptional cis regulation
40
. 
HOX genes are present in all bilaterian animals and their genomic organization is highly 
conserved
66
. These transcription factors have central roles in embryonic patterning and 
in developing of adult organs, and have been shown to be essential in the specification 
of the positional identities of cells
66
. Hundreds of ncRNAs are transcribed from the 
regulatory regions of HOX clusters and have been shown to be involved in Polycomb-
mediated regulation, counteracting Polycomb repression
43
. The Polycomb group 
proteins (PcG) work as large complexes that act on nucleosome structure and the RNA–
Polymerase II complex, leading to the inhibition of transcriptional activation. PcG 
complexes are involved in the control of developmental regulators, including all four 
HOX clusters
44
. These complexes are associated with trimethylated K27 on histone H3, 
a modification frequently required for this epigenetic silencing
65
. The initiation of 
histone modification is carried out by the Polycomb Repressive Complex 2 (PRC2) 
which consists of a H3K27 histone methyl transferase (HMTase) EZH2 and the core 
components Suz12 and EED, whereas the maintenance of these modifications and the 
promotion of chromatin compaction is done by the Polycomb Repressive Complex 1 
(PRC1)
40
. 
Sessa et al. showed that opposite strand-intergenic transcripts are coexpressed with 
adjacent coding HOXA genes. They concluded that the HOXA cluster shows a highly 
complex profile of non-coding transcripts, and that non-coding transcription is essential 
for the opening and maintenance of the active state of HOX clusters. They also 
suggested that PcG proteins have a role in HOX gene regulation
44
. Their results are in 
consonance with the work of Bernstein et al., which also concluded that the 
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transcription of intergenic sequences, which represent methylated and transcriptional 
active chromatin domains, are needed for the maintenance of HOX gene expression
67
. 
Rinn et al. identified 231 long ncRNAs in the four HOX human clusters by combining 
the powers of ultrahigh-resolution tiling microarrays and bioinformatics algorithms in a 
collection of primary human fibroblasts with 11 distinct positional identities
40
. They 
also showed that these ncRNAs are collinearly expressed along developmental axes and 
share some common sequence motifs
43
. Most of these transcripts are intergenic, are 
transcribed in the direction opposite the HOX genes, and are differentially expressed in 
different cell types in function of their original position along the body axis
65
. One of 
the ncRNAs identified by Rinn et al. showed a surprising feature. HOTAIR acts in trans 
interacting with PcG proteins and recruits the Polycomb complex to the HOXD region 
where it trimethylates lysine 27 residues (me3K27) of histone H3 to induce 
heterochromatin formation and repress gene expression
37
(Figure 1-11).  
 
 
Figure 1- 11 Chromatin remodelling by HOTAIR 
HOTAIR recruits the Polycomb complex to the HOXD locus where it trimethylates 
lysine 27 residues (me3K27) of histone H3 to induce heterochromatin formation and 
repress gene expression. Adapted from: Mercer, 2009, p.158
37
. 
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This observation of a HOX ncRNA binding to an epigenetic regulatory complex to 
change methylation patterns on a different HOX cluster on a different chromosome was 
unexpected
65
. The characterization of HOTAIR raises the question if are there other 
trans-acting ncRNAs from the HOX cluster or elsewhere that have not yet been found
65
. 
       C) ncRNAs in X chromosome dosage compensation 
The X chromosome carries genes required for both sexes, whereas the Y chromosome 
has little information. As many animals have a single X chromosome in males (XY 
karyotype) and two in females (XX karyotype), it results in an imbalance of X-linked 
genes in one sex
68
. The balance between X-chromosome and autosome expression in 
both sexes is achieved through an epigenetic regulatory mechanism termed dosage 
compensation, which modulates global expression of an X chromosome.  This 
modulation, which is very important for proper development
39
, is achieved by directed 
chromatin modifications targeting one of the X chromosomes
68
. Normalization of the 
copy number of X chromosome between male and female cells
42
 by dosage 
compensation is one of the best examples for understanding the role of ncRNAs in the 
formation of euchromatin versus heterochromatin. ncRNAs are intimately involved in 
dosage compensation in both Drosophila and mammals. Long ncRNAs, such as Xist in 
mammals and roX in flies, have been shown to have key roles in X-chromosome dosage 
compensation
68
, which spread in cis to coat the X chromosome
42
. In both systems X 
chromosome dosage compensation by ncRNAs leads to changes in chromatin structure 
and act as recruiting entities or scaffolding factors in the cooperative binding of 
chromatin-associated complexes
42
, but different strategies are used
43
. In flies this 
epigenetic process is characterized by an up-regulation of almost twofold of most of 
genes on the single X chromosome in males, whereas in mammals consists in the 
silencing of most genes in one of the two X chromosomes in females
42
.  
                (i) X chromosome dosage compensation in mammals 
X chromosome inactivation (XCI) in mammals involves silencing of one of the two X 
chromosomes in females. This process is controlled by the X-inactivation centre (Xic), 
which counts the number of X chromosomes, chooses one to remain active and silences 
the inactive X chromosome. Xic contains three ncRNAs essentials for this process: X 
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inactive-specific transcript (Xist) and Tsix, which form a sense-antisense pair, and Xite. 
One of the early steps of XCI consists in the sequential recruitment of two Polycomb 
complexes to repress transcription by establishing repressive histone methylation marks. 
The point of no return in XCI, i.e. when the X chromosome silencing is irreversible is 
achieved some days later in a process that involves DNA methylation
43
. XCI randomly 
selects the X chromosome to be silenced in females when Xist is exclusively transcribed 
from the future inactive X chromosome. Xist silences in cis the selected X chromosome 
by coating him and recruiting Polycomb-group proteins to establish and spread 
heterochromatin
43
. This process is achieved via trimethylation of histone H3 on lysine 
27 (H3K27me3), rendering the chromosome transcriptionally silent in a similar way to 
HOTAIR
40. It has been observed a correlation between the coating by Xist of the entire 
chromosome that will become the inactive X (Xi), and the establishment and 
maintenance of the transcriptional silencing along the Xi
42; 62
. Tsix ncRNA, which is 
transcribed in the antisense direction through the Xist locus, negatively regulates Xist. 
The key role of Tsix consists in decide which X chromosome will become the active X 
(Xa) and the Xi by overlapping the full length of Xist
62
. 
                (ii) X chromosome dosage compensation in fruit flies 
In Drosophila melanogaster X chromosome dosage is addressed by doubling the 
transcription rate from the single X chromosome in XY males relative to XX females
62
 
by a ribonucleoprotein complex that binds to hundreds of sites along the male X 
chromosome. This complex, termed Male-specific lethal (MSL) complex, consists of 
five core proteins: MSL1, an acidic protein that can interact with MSL2, MSL3 and 
MOF through distinct domains; MSL2, a Ring-finger protein that regulates assembly of 
the complex and is only expressed in males; MSL3, a chromodomain protein that 
carries a MRG [Mortality factor on chromosome 4 (MORF4)-related gene] domain 
necessary for X localization; Maleless (MLE), a RNA helicase; Males absent on first 
(MOF), a chromodomain-containing histone acetyltransferase. In addition a H3 Ser 10 
kinase known as JIL-1 interacts with the MSL proteins
42; 68
 (Figure 1-12). 
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The function of MSL is to spread hyperactive chromatin along the X chromosome. This 
process is ATPase dependent for the activity of the MEL helicase and the acetyl 
transferase activity of MOF
62
. MOF is the key regulatory component of the MSL 
complex, which hyperacetylates histone H4 at Lys16, resulting in the up-regulation of 
transcription from the X chromosome
62
. It has been suggested that Lys 16 acetylation 
either could help to recruit a positively acting effector to the male X chromosome or to 
displace a silencing factor
42
. The roX1 and roX2 ncRNAs, encoded on the X 
chromosome, are also components of the MSL complex
62
. These ncRNAs are 
incorporated into the MSL complex by MLE. Both roX ncRNAs act in cis on the male 
X chromosome from which are transcribed
62
 by guiding the localization of the MSL 
proteins to hundreds of sites on the male X chromosome
68
. This process is thought to be 
guided by base-pairing between the roX RNAs and DNA. Thus, roX ncRNAs enhance 
the targeting and the processivity of MSL
62
. Unlike Xist ncRNA in mammals, roX 
ncRNAs direct activation, rather than silencing, of target genes. These RNAs have key 
roles in the epigenetic establishment of correct genome expression by a mechanism of 
RNA-directed chromatin regulation
68
. 
 
Figure 1- 12 The MSL complex. 
The MSL complex comprises five proteins and roX RNA and binds to hundreds of sites 
along the male X chromosome to mediate dosage compensation. MSL1, MSL2, MSL3 
and MOF interact directly with each other. MLE and JIL-1 are enriched on the male X 
chromosome but are thought to have a more peripheral association and also bind to 
autosomal sites. Adapted from: Deng, 2006, p.527
68
. 
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       D) SRG1 ncRNA 
Martens et al. reported that in Saccharomyces cerevisiae the repression of the SER3 
gene, which encodes a phosphoglycerate dehydrogenase that catalyses a step in serine 
biosynthesis, is mediated by regulated transcription across SER3 from the upstream 
SRG1 promoter. They observed that the regulatory region of SER3 gene was highly 
transcribed and produces a ncRNA called SRG1 when the yeast is grown in rich 
medium. The repression of SER3 transcription by SRG1 is driven by a transcription-
interference mechanism in which the transcription of the ncRNA across the SER3 
promoter interferes with the binding of activators to the promoter
69
. 
       E) ncRNAs and disease 
Evidence that ncRNAs are implicated in diseases come from the work of Sonkoly et al. 
and Lu et al
39
. The first group identified a long ncRNA involved in psoriasis termed 
PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress)
70
. Lu et al. 
showed that the long ncRNA KLK3IP was associated with the prostate cancer
71
. 
       F) Remarks of the importance of ncRNAs 
Taken together, the data of the studies described here are just the tip of the iceberg of 
the broadly used mechanism of intergenic transcription for transcriptional regulation
72
. 
In the near future bioinformatic tools will generate more accurate databases of predicted 
ncRNAs to be used to describe new ncRNA examples
39
. Deletion, over-expression or 
down-regulation have been shown to underlie and act as markers for the severity of 
several complex diseases
39
. It is becoming clear that ncRNAs are essential molecules in 
the complex network of interactions that controls gene expression and they are not 
simply transcriptional noise or evolutionary junk
38
. The phenomenon of whole-genome 
transcription in metazoa and probably all eukaryotes, suggest that genome physiology is 
regulated in a developmental manner by ncRNAs that orchestrate the precise patterns of 
gene expression during morphogenesis
43
. Genetic programming of complex eukaryotes 
has been evolutionary linked with the expansion of ncRNAs, as it is observed in the 
concomitant increase in non-coding content with organism complexity
37
. 
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1.2.4 Chromatin structure and remodelling in the control of β-globin 
locus expression 
The onset of erythropoiesis in erythrocyte precursors and the differential expression of 
the different genes of the β-globin locus during development correlate with wide 
epigenetic modifications in the locus
10. In the β-globin locus, as in other structural gene 
loci, acetylation of histones in chromatin leads to increased expression
 
of the locus 
genes, by making gene sequences more available to transcription factors. The human β-
globin locus shows a complex pattern of histone modifications, extremely different 
between foetal and adult erythrocytes. There is a correlation between H3 and H4 
acetylation and H3K4 methylation, which are modifications associated with genetic 
activation, and DNase I hypersensitivity sites in the β-LCR50. During differentiation, 
within the β-globin locus the active genes and the LCR acquire positive histone 
modifications. In contrast, inactive genes are marked with silencing histone 
12 (Figure 1-
13). 
 
Figure 1- 13 Epigenetic changes during development of the β-globin locus. 
The coloured boxes indicate domains of H3K4 di-methylation and histone acetylation 
during different developmental stages of the β-globin locus. Source: Kiefer, 2008, 
p.73
12
. 
When the LCR interacts with the proximal promoter of one of the β-globin genes, it 
recruits histone acetyl transferases (HATs) to acetylate histones.  Then, the 
transcriptional machinery binds to the hyperacetylated promoter and the gene 
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transcription is activated. When the individual gene is to be inactivated, the acetylation 
level is decreased, leading to the spread of repressed chromatin structure. The sequential 
activation of the individual β-globin genes during development is attributed to this 
propagation
15
.  
1.2.5 Intergenic transcription in the β-globin locus 
Although the human β-globin locus is amongst the most extensively characterized gene 
clusters in the human genome at the gene and protein levels
8; 12
, the extent of 
transcription throughout the locus remains to be studied
25
. Non-coding RNAs span 
across the human β-LCR and intergenic regions of the β-globin locus in erythroid 
cells
12
, but at a lower abundance than the gene transcripts
50
. Intergenic transcription of 
the β-globin locus may be ligated to β-LCR activity if it is assumed that the function of 
transcription establishes and maintains an open chromatin context within the locus. 
However, intergenic transcription within the locus could just be the consequence of its 
open chromatin context. The arguments against this last assertion are based on the 
apparent strand specificity of transcription and specificity of the sites at which 
transcription initiates in the intergenic regions
24; 25
. 
Chromatin structure can be affected by transcription, since RNA polymerase II (RNAP 
II) complexes exhibit chromatin-remodelling activity. The elongating form of RNA 
polymerase II is associated with histone modifying and chromatin remodelling activities 
that could be responsible of modified domains observed in the regions of intergenic 
transcription within the β-globin locus. Thus, intergenic transcription could control the 
increase in histone acetylation initiated from the LCR in the β-globin locus via RNA 
polymerase II. 
The precise role of intergenic transcription in the β-globin locus remains largely 
unclear, but it has been suggested that the establishment of active chromatin domains 
and the transcriptional regulation of the locus are mechanistically related to intergenic 
transcription and histone modification
12. One of the roles of the β-LCR and intergenic 
transcripts may be to deliver proteins and/or RNA polymerase II to the globin gene 
promoters, as it is proposed in the tracking model
25
. There is a good correlation between 
the acetylation of the different subdomains of the locus and intergenic transcription at 
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different developmental stages, suggesting that these non-coding transcripts are 
developmentally regulated
12
. 
       A) Evidence for intergenic transcription within the β-globin locus  
In 1992 Tuan et al. proposed the tracking model for haemoglobin switching based on 
the observation that in addition to genic transcription in the β-globin locus, LCR HS2 
initiates the formation of long non-coding transcripts which transform the chromatin 
conformation of the individual genes of the locus to an open context to activate their 
transcription. According to their model the LCR recruits transcription complexes that 
track along the DNA until they reach the β-globin gene promoters35. The work of Tuan 
et al. was supported by the experiments of Johnson et al., who demonstrated that RNA 
polymerase II (Pol II) binds the β-LCR far upstream of the β-globin promoters, 
concretely to HSs within the LCR
73
. 
Tuan et al. have recently further analyzed the HS2 enhancer-initiated RNAs and their 
mode of transcription from the HS2. They suggested that the generation of these non-
coding intergenic RNAs could help to facilitate tracking of the transcriptional complex 
through the intervening DNA to reach the basal promoter complex and activate efficient 
mRNA synthesis from the promoter
74
. 
It could be concluded from this data that intergenic transcription could have a role in 
propagating DNAse sensivity in the β-globin locus initiated by the binding of 
transcription factors, and thus be correlated to chromatin opening within the locus
16
. 
This conclusion is supported by the work of Reik et al., who generated a targeted 
deletion of 5’HS2 to HS5 in the human β-LCR. Although globin gene expression was 
disrupted by this deletion,
 the β-globin locus retained its erythroid-specific DNase I 
sensitivity
75
. 
Ashe et al. analyzed the nascent transcription across the human β-globin locus in 
erythroid and non-erythroid cells. They reported that is possible to induce intergenic 
transcription from the β-globin locus in non-erythroid cell lines by transient transfection 
of a plasmid containing an actively transcribed gene of the locus. In contrast, the genic 
transcripts of the β-globin locus were not induced due to the absence of specific 
erythroid transcription factors
25
. 
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       B) Distinctive histone methylation patterns in transcribed coding and non-
coding human β-globin sequences 
Kim et al. studied the differences in histone modifications between the coding and non-
coding regions within the β-globin locus. They found that inactive genes and intergenic 
transcription were broadly marked by K4, K9, and K36 monomethylations. However, 
the coding regions of the highly transcribed genes were H3K4, K9, and K36 
trimethylated. These observations indicate that the transcriptional activation of the genic 
and intergenic transcription is modulated by independent mechanisms
76
. 
       C) Intergenic transcription in relation to development 
Gribnau et al. investigated LCR and intergenic transcription and chromatin structure 
during development in the human β-globin locus. They showed that the β-globin locus 
is divided into three differently active subdomains and they can change their status 
according to the activated gene of the locus at different developmental times: the 
embryonic
 
and foetal εγ subdomain, the foetal and adult δβ subdomain, and an LCR 
subdomain are active at all developmental stages (Figure 1-15). They reported that the 
production of intergenic transcripts in each case is congruent with increased DNase I 
sensitivity and in the case of the εγ and δβ subdomains coincided with the activities of 
the genes themselves
77
. 
This group investigated the extent of intergenic transcription in the β-globin locus 
during development using RNA fluorescence in situ hybridisation (FISH) with multiple 
gene-specific intron probes (a-g) targeted to transcripts of intergenic regions of the β-
gobin locus (Figure 1-14). Their results showed that intergenic transcripts are 
developmentally regulated and delineate large regions of 15–30 kb surrounding active 
genes. They also observed that transcripts in the εγ and δβ subdomains are 
independently regulated. Probes c, d and e targeted intergenic transcripts which 
expression was predominant during embryonic stage, but decreases in adult stages of 
development. In the other hand, transcripts targeted by probes f and g showed 
preferential expression in foetal and adult developmental stages
77
. 
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Figure 1- 14 Intergenic activity in the β-globin locus. 
Vertical arrows indicate the positions of HSs 1–5 of the LCR. Genes are shown as black 
boxes, and the pseudogene (ψβ) as an open box. Coloured boxes (a–g) indicate the 
position of the restriction fragments used as probes for RNA FISH to detect intergenic 
transcripts. Adapted from: Gribnau, 2000, p.378
78
. 
       D) Cell-cycle-specific timing of intergenic transcription  
Intergenic transcription levels change over time as it is a cell-cycle- and locus-
dependent mechanism. Gribnau et al. showed that intergenic transcripts are only 
detected in a proportion of cells in an unsynchronized population, suggesting that are 
generated in a cell-cycle-dependent manner; detectable predominantly during G1 phase 
and in a small percentage in early S-phase
77
. Miles et al. performed a high-resolution, 
locus-wide analysis of intergenic transcripts and histone modifications across the human 
β-globin locus during development in yeast artificial chromosome (YAC) transgenic 
mice and in primary human erythroid cells. They showed that the locus is composed of 
multiple chromatin sub-domains that are developmentally regulated, which can be 
distinguished by differential general sensitivity to DNase I, intergenic transcription and 
active histone modifications primarily to H3.  They observed that the intergenic 
transcription pattern is complex and extensive and that active histone modifications 
strongly correlate with areas of non-S phase intergenic transcription linking the cell-
cycle-specific timing of intergenic transcription with large chromatin domains of 
modified histones
50. All these results support the link between intergenic transcription 
and the developmentally regulated chromatin remodelling across the β-globin locus. 
       E) Developmental changes in chromatin structure in the β-globin locus 
The results of Gribnau et al. for intergenic transcription and hence for domain activation 
suggested that a progressive mechanism exists for opening and closing the β-globin 
locus domains during development (Figure 1-15). During embryonic and early foetal 
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stage, the LCR and εγ domains adopt an open configuration to enhance the expression 
of the ε- and γ-globin genes. As development continues, ε-globin gene is silenced and 
the δβ domain adopts now the accessible configuration. In the adult developmental 
stage γ-globin gene silencing is preceded by the adoption of a close configuration by the 
εγ domain77.  
 
Figure 1- 15 Schematic Depiction of the Chromatin Structure Changes in the β-globin Locus 
during Development. 
Shown are hypothetical, higher order chromatin structures to represent areas of high 
(straight line) and intermediate (coiled line) general sensitivity to DNase I. LCR HSs 
are shown as vertical arrows. Open boxes indicate active genes, whereas black boxes 
correspond to inactive genes. Shaded boxes indicate the region containing the putative 
chromatin boundary and δβ domain transcript initiation site. Areas delineated by 
intergenic transcripts are indicated by dashed arrows. Question marks stand for the 
initiation site of the εγ domain transcript and the 3′ end of the δβ domain transcript, 
which have not been establishedyet. Source: Gribnau, 2000, p.384
77. 
       F) Intergenic transcription and DNase sensitivity in the β-globin locus 
The group of Gribnau et al. previously reported that intergenic regions in the β-globin 
locus are unidirectionally transcribed by RNAPII in a subset of erythroid cells in vivo
25
. 
These transcripts were predominantly detected in the LCR and adult β-globin genes and 
thus increased DNase I sensitivity. These results show a precise correlation between 
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chromatin structural domains and the extent of intergenic transcription, indicating that 
domains of active chromatin are delineated by intergenic transcription. They reported a 
correlation between histone acetylation, which is associated with modest changes in the 
regional DNase I sensitivity in the locus, and the domain-restricted intergenic 
transcription. Since histone acetyltransferases are associated with RNA–pol II 
complexes, intergenic transcription could play a role in decondensation of chromatin 
domains and gene activation. They also observed that a deletion of a 2.5 kb region 
between the γ- and δ-globin genes containing the putative adult sub-domain intergenic 
promoter results in a sub-domain-wide failure to adopt the accessible characteristic 
DNase I sensitive chromatin conformation during development, and an abnormally low 
and variegated expression of the adult β-globin gene. They concluded that intergenic 
transcription is an essential component of the remodelling process of chromatin 
subdomains to a hyperaccessible structures that determine which genes are able to 
interact with the LCR in erythroid cells
77
. 
       G) Conflictive studies 
The work of Plant et al.
16
 appears to be contradictory to the suggested idea of Gribnau 
et al.
77
 and Miles et al.
50
 of a developmentally regulated intergenic transcription in the 
β-globin locus. Plant et al., according to their results, show TSA-induced intergenic 
transcription along the β-globin locus, reported that intergenic transcription can be 
found along the β-globin locus in a not necessarily developmentally regulated manner. 
More recently, Haussecker and Proudfoot argued that the results of their work were not 
consistent with the activation-linked models based on the interaction between intergenic 
transcript abundance and chromatin conformation. Their data support that there is no 
correlation between intergenic transcription and chromatin activation in the β-globin 
locus. Instead, they found that in cells with Dicer knocked down, there was an 
upregulation of the intergernic transcription within the β-globin locus, suggesting the 
involvement of the RNA interference pathway in the regulation of the non-coding 
transcription within the locus. Thus, they proposed that chromatin activation at the locus 
correlates with Dicer knockdown. Hence, their conclusion was that in erythroid cells, in 
transcriptional-inactive regions of the β-globin locus, chromatin is silenced by default 
intergenic transcription
22
. 
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1.3 RNA Interference and RNA Silencing 
RNA interference (RNAi) is a natural pthway by which double-stranded RNA (dsRNA) 
induces gene silencing by targeting complementary mRNA for degradation in 
eukaryotes
79. Like the discovery of splicing, the unearthing of RNAi has everyone’s 
attention focused on posttranscriptional phenomena
80
. RNAi represents a breakthrough 
in understanding how genes are turned on and off in cells
81
. One of the reasons for the 
interest in RNA silencing in recent years has been the potential to use this mechanism to 
study gene function, validate candidate drug targets, and perhaps even treat disease
82
. 
RNAi represents an evolutionarily conserved phenomenon first described in plants in 
1990 and has subsequently been found in most eukaryotes
83; 84
. RNA silencing 
mechanisms were first identified as a cellular RNA-based immune system designed to 
interfere with the uncontrolled production of aberrant RNA molecules, which could be 
interpreted by the body as an opportunistic viral infection. The RNAi mechanism is 
extremely specific in targeting these RNA molecules. In fact, they are identified for 
degradation by well-defined complementarity rules between the targeting small RNA 
and target messenger RNA
85
. Although the RNAi is also involved in the prevention of 
genomic instability caused by mobile genetic elements such as transposons and 
repetitive elements which produce dsRNA intermediates inside the cells, they also 
employ these pathways to regulate the expression of their own genes
82; 86; 87;88
.  
1.3.1 History 
The first experimental observation of what later became understood as RNAi was 
observed in plants in 1990 from the work of Napoli et al. attempting to create more 
attractive petunia flowers by genetically engineering additional flower pigmentation 
genes into the plant genome
89
. Surprisingly, instead of producing plants with more 
colourful flowers, many had lost most or all pigmentation and became white. When they 
looked at the expression of genes involved in the natural pigmentation biosynthesis 
pathway, they found that the mRNA level of the gene that corresponded to the newly 
introduced pigment gene had been strongly reduced
90
. This phenomenon, now 
collectively called RNA silencing, was originally named co-suppression (also termed 
post-transcriptional gene silencing) and quelling, respectively
85
. The first major 
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breakthrough in understanding the RNAi silencing mechanism came from studies of 
worms conducted by Fire et al. in 1998
91
. They tested the phenotypic effects of RNA 
molecules injected into the nematode worm C. elegans and found dsRNA, but neither 
antisense nor sense RNA reduced target mRNA levels suggesting that RNA-silencing 
was specific for dsRNA homologue to the corresponding mRNA
86
.  
1.3.2 small RNAs  
For decades small RNAs have been ignored as mere degradation products of bigger 
transcripts
92
. According to their origin or function, two main categories of small RNAs 
involved in RNAi have been defined: short interfering RNAs (siRNAs), and 
microRNAs (miRNAs), which differ primarily in the nature of their respective 
precursors (Figure 1-16). siRNAs are generated from perfectly base-paired dsRNA 
precursors. miRNAs are generated from single-stranded precursor transcripts that fold 
into imperfectly base-paired hairpin structures
82; 87
. siRNAs were originally identified as 
intermediates in the RNA interference pathway by exogenous dsRNA. siRNAs are 21–
25 bp dsRNA with a phosphate group at both 5' ends, and hydroxyl groups and two-
nucleotide overhangs at both 3' ends, all hallmarks of RNaseIII-mediated cleavage
93
. 
Although siRNAs are typically thought of as originating from exogenous precursors or 
triggers, there have been identified siRNAs generated from endogenous precursors in 
plants, fungi, and animals
90
. 
 
Figure 1- 16 Small RNA duplexes. 
siRNA duplex shows a perfect  match, whilst miRNA duplex has a mismatch or a 
bulge in the centre. Adapted from: Siomi, 2004, p.401
93. 
Small RNAs are processed by two dsRNA-specific RNase-III-type endonucleases, 
termed Drosha and Dicer. Drosha is only required for the maturation of miRNA 
precursors, but not in the cleavage of long dsRNAs
87
. Dicer processes both long dsRNA 
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into siRNAs and cytoplasmic miRNA precursors (pre-miRNAs) into mature miRNAs 
(Figure 1-17) 
88
. 
 
Figure 1- 17 Small RNA biogenesis in animals. 
(A) miRNA are produced by the successive actions of two RNase III ribonucleases. 
After their transcription by RNA polymerase II, primary miRNA (pri-miRNA) are 
cleaved in the nucleus by Drosha. Drosha cleavage generates the pre-miRNA, which 
binds Exportin 5 and is exported to the cytoplasm. In the cytoplasm, Dicer is thought to 
bind the base of the pre-miRNA stem defined in the nucleus by Drosha. Dicer cleavage 
liberates a duplex comprising the miRNA and miRNA* strands of the pre-miRNA. (B) 
Long dsRNA is a substrate for Dicer, but not for Drosha. Dicer must make two 
successive pairs of cuts to yield an siRNA duplex. Dicer is thought to preferentially 
initiate dsRNA cleavage at the ends of dsRNA, a phenomenon that sometimes 
produces a phased string of siRNAs along the dsRNA. Source: Tomari, 2005, p.519
94. 
1.3.3 Mechanism of RNAi 
While the RNA gene silencing pathway is used by both siRNAs and miRNAs, there 
exist some important differences. The siRNA pathway begins with cytoplasmic 
cleavage of long double-stranded RNA by Dicer that result in short double-stranded 
RNA duplexes (siRNAs)
95
. siRNAs are then unwound, and only one strand is loaded 
into RISC. If the siRNA strand loaded into RISC has perfect sequence complementarity 
Introduction 
39 
 
with its target mRNA sequence, then site-specific mRNA cleavage takes place. This 
cleavage is a catalytic event, involving repeated cleavage of multiple copies of the target 
mRNA, leading to reduced copies of target mRNA and ultimately to inhibition of the 
target protein. In contrast to the siRNA pathway, the miRNA pathway begins with 
endogenously encoded primary miRNA transcripts in the cell nucleus that are processed 
into precursor microRNA and then exported from the nucleus into the cytoplasm. Here, 
Dicer further processes them for RISC loading. Unlike siRNAs, mature miRNAs 
typically have imperfect sequence complementarity to their RNA target sites which are 
typically limited to the 3’ untranslated regions of the mRNA. Furthermore, interaction 
of a microRNA with its RNA target usually leads to direct translational inhibition rather 
than specific site-directed cleavage of the mRNA. Regardless of translational inhibition 
or cleavage, both microRNAs and siRNAs are able to regulate protein production at the 
RNA level in a very specific sequence-based manner
80; 85
.  
1.3.4 Assembly into RNA silencing effector complexes 
Mature RISC, fully assembled with the guide strand of the siRNA direct mRNA 
cleavage, while RISCs loaded with a miRNA guide strand direct mRNA cleavage in 
plants but repression of translation in animals
88
.  
1.3.5 mRNA cleavage and translational repression 
The target mRNA is cleaved by RISC whith the assistance of an RNA helicase in this 
process
87
. The products of the mRNA cleavage are further processed by cellular 
exonuclease activity
95 (Figure 1-18). 
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Figure 1- 18 The RNAi natural process. 
Small interfering RNA (siRNA), a 21-25 base pair RNA strand, is targeted to a specific 
gene. Within cells, siRNA unwinds and is incorporated into RISC. siRNA is directed to 
a targeted messenger RNA (mRNA). The mRNA undergoes degradation, thereby 
interrupting the protein synthesis of the targeted gene. Source: Anylam, 2009, p.7
85
. 
1.3.6 RNAi techniques 
It has been shown that the delivery of a dsRNA trigger can artificially induce the RNAi 
pathway. Long double-stranded RNAs (>200 nt) have been used to silence the 
expression of target genes in a variety of non-mammalian organisms and cell types. 
Introduced long dsRNAs trigger the RNAi pathway, being first processed into 20-25 
nucleotide siRNAs by Dicer. Then, the siRNAs unwind and assemble into RISC. RISC 
is guided by the antisense siRNA strand to its complementary mRNA target, which will 
be eventually cleaved by RISC, in order to obtain specific gene silencing
79
.  
RNAi has been established today as a standard technique to investigate gene function or 
to identify cellular targets for specific intervention in many biological systems. RNAi 
can be activated at different stages by specific forms of regulatory RNAs, such as 
synthetic siRNAs, RNAs expressed as short hairpins RNAs (shRNA) and artificial 
miRNAs, efficiently targeting and causing degradation of the cognate RNAs
86
. The two 
most common methods used to activate RNAi are the transfection of cells with synthetic 
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siRNA duplexes, which then act to engage RISC. Intoduction into the cells of 
expression vectors that produce short haipin RNAs (shRNAs) which are then 
endogenously cleaved into siRNAs, represent an alternative to methods indicated above 
to trigger the RNAi pathway
83
 (Figure 1-19). 
 
Figure 1- 19 Three Ways to Trigger the RNAi Pathway. 
(1) In non-mammalian systems, the RNAi pathway commences when dsRNA (usually 
longer than 30 bp) is introduced into cells. In mammalian systems, RNAi can be 
triggered by siRNA molecules (2) or by DNA based expression vectors designed to 
express short hairpin RNA (shRNA) molecules (3). In each case, gene silencing results 
from destruction of mRNA that is complementary to the input siRNA (2) or the siRNA 
molecules created by Dicer cleavage of longer dsRNA (1) or shRNA (3) molecules. 
Source: Applied, 2009, p.3
79
. 
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       A) Synthetic siRNAs 
Chemically synthesized or in vitro transcribed siRNAs are directly loaded into RISC 
after its transfection into the target cells. However, high intracellular siRNA 
concentrations (>100 nM) may induce non-specific effects due to saturation of the 
RNAi machinery, and the RNAi effect achieved is transient, lasting typically for 3–7 
days
88
. In addition, the experimental phenotypes observed depend on the transduction 
rates, which may significantly differ between different cell types especially for primary 
cells
86
.  
       B) Pol III promoter vector-based siRNA expression  
Vector-based siRNA provide a low-cost alternative to the chemically synthesized 
siRNAs, which cost is high and their effect is transient
95
. In contrast to directly 
transfected siRNAs, shRNAs are endogenously transcribed, thanks to the development 
of vectors mediate transient or persistent gene silencing after stable viral-integration 
into the host genome
86
. The shRNA contains a perfectly double stranded stem of 19–29 
bp with one strand identical in sequence to the target mRNA and 3′ U overhangs. The 
two strands of the stems are linked by a 9-bp long loop sequence, and the shRNA is 
processed by Dicer to generate functional active siRNA
86
 (Figure 1-20). The eukaryotic 
H1 and U6 pol III promoters are the most commonly used to transcribe shRNAs. These 
promoters generate high levels of small, non-coding RNA transcripts lacking the polyA-
tail and initiate from position +1 of the transcripts without any restriction by an 
inhibitory 5'-nucleotide. Furthermore, pol III promoters show high activity in all cell 
types and transcription terminates at a stretch of 4 thymidines, making it possible to 
produce short RNA with 1-4 uridines at the 3’ end86. 
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Figure 1- 20 Diagrammatic presentation of stem loop type siRNA driven by U6 vector. 
Source: Wadhwa, 2004, p.80
95
. 
1.3.7 Mammalian RNAi Experiments 
In mammalian cells, transfection of dsRNAs longer than 30 nt induced an antiviral 
response, which eventually leads to cell suicide. This obstacle was overcome in 2001 by 
Elbashir et al., who showed that synthetic versions of short double-stranded RNA 
molecules result in potent RNAi gene silencing in mammalian cells without inducing 
the interferon response
96
. These siRNA are long enough to induce RNAi, but small 
enough to avoid inducing an immune response
85
. For performing RNAi experiments in 
mammalian cell systems is necessary a gene specific siRNA or shRNA that effectively 
targets the gene of interest (RNAi trigger), an efficient delivery method for the siRNA 
or shRNA (generally transfection or electroporation), and robust transcriptomc and 
phenotypic assays to detect the RNAi effect, and proper controls both for siRNA 
delivery and for the phenotypic assay
88
. 
1.4 The k562 cell line 
In 1975, Lozzio and Lozzio established the K562 cell line from leukemic cells obtained 
in December 1970 from a pleural effusion of a 53-year-old female suffering from 
chronic myeloid leukaemia (CML) for about 4 years, at the terminal stage of an acute 
blast crisis. The successful establishment of this cell line was due to the active 
proliferative capacity (K562 has a mean doubling time of 12 hr) of the highly 
undifferentiated cells obtained from the patient, which were already growing as a cell 
suspension in the pleural fluid and were not overgrown by the proliferation of normal 
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cells, as has occurred with most permanent cell-lines established from human leukemic 
blood
97
. K562 cells are thought to be very early precursors of erythroid cells. This cell 
line has also been widely employed in the investigation of alternative treatments for 
thalassemias and sickle cell disease
98
. 
The K562 cell line is composed of undifferentiated blast cell with a diameter of about 
20 µm (Figure 1-21), and has properties in common with erythroid cells. In particular, 
cells of this line are rich in glycophorin A, which is found exclusively in human 
erythrocytes, and spectrin in their membranes, and may be induced to produce
 
foetal and 
embryonic haemoglobin in the presence of 0.1 mM haemin
99
. 
 
Figure 1- 21 Morphological characteristics of K562-undifferentiated blasts. 
Adapted from: Koeffler, 1980, p.346
99
. 
The K562 cell has a basophilic cytoplasm containing no granules and there are two or 
more prominent nucleoli. The K562 cells have nearly 1.5 times the normal number of 
chromosomes: 70 XXX, - 13, - 17, +7, +9 (p11), plus small metacentric chromosome, 
Xp-, 3p-, 9p-, t(15;18) (q21;q23), r(22), or 22q-. Furthermore, they also have a small 
ring chromosome r(22) or retain the Philadelphia chromosome (22q-), demonstrating 
that this cell line is of CML origin
99
 (Figure 1-22). 
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Figure 1- 22 Karyotype of K562 cells. 
The modal number for K562 is between 66~72. Marker chromosomes are classified 
according to their centromeric origin and indicated with arrows. This cell only has two 
chromosome 11 homologues, while other cells have 3. There is cell-to-cell variation in 
the number of structurally normal chromosomes. Source: Gribble, 2000, p.4
100
. 
1.4.1 Induction of K562 cell line by haemin  
Haemin is the ferric chloride salt of haem (ferric protoporphyrin IX), which is an iron-
containing protoporphyrin that serves as the prosthetic group of the haemoglobin 
molecule. Haemin uptake by cultured erythroid cells down-modulates their surface 
receptors for tranferrin and for acid isoferritin, thus suggesting that the uptake of haemin 
is physiologically regulated. Uptake of haemin during the early stages of maturation 
may accelerate haemoglobin formation by affecting the rate of transcription of the 
globin genes, the processing and stability of their mRNA, or the efficiency of translation 
into globin chains. Externally supplied haemin is taken up and has a profound effect on 
proliferation and differentiation of haematopoietic progenitors, inducing a program of 
erythroid maturation in the K562 cell line, which includes the production of embryonic 
and foetal, but not adult, haemoglobin. Rutherford et al. investigated the capacity of 
K562 cells to differentiate in vitro and reported that they are induced by haemin to 
synthesise large amounts of haemoglobin. They found that the K562 cells showed a 
stable pattern of erythroid differentiation in response to haemin and that embryonic 
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haemoglobins were synthesized but adult haemoglobin synthesis was strictly 
repressed
101
. 
Fibach et al. reported that uptake of exogenously supplied haemin in erythroid cultures 
increased preferentially the production of foetal haemoglobin compared with adult 
haemoglobin; this was associated with a selective twofold elevation in y-mRNA levels. 
Thus, γ-globin levels in K562 cells can serve as a marker of induced cells.  They 
suggested that the preferential increase in foetal haemoglobin is related to haemin’s 
ability to accelerate early haemoglobin synthesis, involving more efficient processing of 
the primary transcripts. Haemin may also have a posttranslational effect, by providing 
heme for completion and stabilization of the haemoglobin molecules
102
.  
1.5 Project summary 
1.5.1 The BGL3 non-coding transcript 
Non-coding RNAs appear to play a role in gene regulation by modulating chromatin 
structure. RNA FISH using probes against the intron of a gene produces compact 
signals; even the most actively transcribed genes only give small signals. Recent 
evidence shows that some ncRNAs can aggregate in RNA-protein complexes and bind 
at the promoters of genes, producing a much more diffuse visualisation pattern in RNA 
FISH images. Previous unpublished work from the Fraser lab shows that the RNA FISH 
images of a short non-coding transcript in the globin locus (termed BGL3) are intense 
diffuse signals (Figure 1-23).  
Introduction 
47 
 
 
Figure 1- 23 Unpublished RNA FISH image from the Fraser lab at the Babraham Institute. 
Probe against the intron of the β-globin gene produces compact signals. Probe against 
the BGL3 transcript produces intense diffuse signals. 
This pattern of FISH signals suggests that the BGL3 transcript may be involved in an 
RNA-protein interaction and may be interacting with chromatin in the β-globin locus as 
part of a regulatory function within the locus (Figure 1-24). 
 
Figure 1- 24 Position of the BGL3 transcript on the β-globin locus. 
Adapted from: Stamatoyannopoulos, 2005, p.263
10
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1.5.2 Aims and objectives 
This project aims to test the role of BGL3 in the regulation of the human β-globin locus 
during development. The first step of the project will be to determine the expression 
profile of the BGL3 transcript and the γ- and β-globin genes, using qRT-PCR, in 
haemin-induced K562 cells, which have strikling similarities with erythrocytes and have 
been widely used for studying developmental expression across the β-globin locus.  
The next step will be to test if the BGL3 transcript actually plays a role in regulating 
transcription within the β-globin locus. To this end, it will be attempted to perturb the 
levels of BGL3 using overexpression and knockdown plasmids, which will be 
transfected onto K562 cells. The effect of the overexpression and knockdown of the 
BGL3 transcript will be tested on the activity of the γ- and β-globin genes, which will 
be quantified using qRT-PCR. The results that will stem from this research project 
might be useful to obtain a deeper understanding of the role of intergenic transcription 
within the β-globin locus and its involvement on chromatin remodelling and in 
haemoglobin switching, providing a new tool for the development of treatments for 
sickle cell disease and β-thalassaemia. 
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2 Materials and methods 
2.1 Bioinformatic tools 
2.1.1 UCSC Genome Browser 
The University of California, Santa Cruz, (UCSC) Genome Browser (available at 
http://genome.ucsc.edu/) was used to extract the genomic sequence of the BGL3 gene of 
the β-globin locus. A custom track was also generated so that designed primers and 
siRNAs could be viewed alongside the BGL3 gene. 
2.1.2 BLAT 
The BLAT tool (available at http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) 
was used to check for complementarities between the designed siRNAs and primers and 
the rest of the human genome.  
2.1.3 Primer3 
Primer3 is an open source, community-development program used to design PCR 
primers, hybridisation probes and sequencing primers (available at 
http://frodo.wi.mit.edu/primer3/). Primer3 was used to design paired primers and the 
hybridisation probe for the RT-PCR experiments on BGL3 expression.  
2.1.4 NEBcutter  
NEBcutter (available at http://tools.neb.com/NEBcutter2/index.php) was used to check 
that the pattern of restriction digestions used in the cloning procedure of the pEF6/V5-
His A vector is compatible with the DNA sequence of the BGL3 gene. 
2.1.5 RNAfold 
The RNAfold web server (available at http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
was used to predict and visualize the secondary structure of the BGL3 ncRNA. 
2.1.6 Translate Tool 
The Translate Tool (available at http://www.expasy.ch/tools/dna.html) from the 
ExPASy web server was used to translate nucleotide sequence of the BGL3 transcript to 
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a protein sequence in order to determine the translation stop codons content of the 
BGL3 transcript. 
2.2 Cell biological methods 
During this project K562 cells were utilized, which were kindly provided by Peter 
Fraser (Babraham Institute, Cambridge). Manipulation of the cells, culture medium and 
plasticware was performed in a laminar flow cabinet precleaned with 70% isopropyl 
alcohol according to the standard cell biology procedures. 
2.2.1 Materials 
Component  Supplier Catalogue number 
RPMI medium 1640 (1X) 
+L-glutamine 
Gibco 21875 
Foetal bovine serum Gibco 10270-106 
Penicillin-Streptomycin Gibco 15140 
DMSO Sigma-Aldrich D-5879 
Haemin Fluka 51280 
Isopropyl alcohol Sigma-Aldrich I9516 
2.2.2 Medium preparation 
The K562 cell line was maintained in logarithmic growth in RPMI medium 1640 (1X) 
+L-glutamine. The medium was supplemented with a suspension of 50 U/mL penicillin 
and streptomycin and 10% (v/v) of foetal bovine serum (FCS).  
2.2.3 Cultivation of K562 cells 
1. The cell suspension stored in liquid nitrogen was warmed up from -170°C to 
room temperature by dipping the vial in a 37°C water bath.  
2. 1 mL of cell suspension (1 x 107 cells) was dilutssed in 9 mL of RPMI 1640 
medium with supplements and centrifuged for 5 minutes at 1,000 x g. The 
supernatant was discarded.  
3. The cell pellet was then resuspended in 2 mL of fresh medium and the cells were 
transferred into a T25 cell culture flask and incubated overnight at 37°C and 5% 
CO2.  
4. After 24 hours 10 mL of fresh medium were added and the cells were incubated 
for two more days.  
5. Cells were split in a 1:5 ratio three times per week with a final culture volume of 
40 mL in a T75 flask and incubated as before.  
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2.2.4 Induction of K562 cells with haemin 
As described in the introduction, exogenously supplied haemin in K562 cultures 
preferentially increases the production of foetal haemoglobin compared with adult 
haemoglobin; this is associated with a selective elevation in γ-mRNA levels. The globin 
induction experiments were performed supplementing the media with a concentration of 
100 µM of haemin. 
2.2.5 Cryopreservation 
1. A suspension of 40 mL of K562 cells, with a concentration of 1.25x105 
cells/mL, was centrifuged at 1,000 x g for 5 minutes and the pellet was 
subsequently resuspended in freezing medium, which is the medium used for 
cultivation supplemented with 5% DMSO.  
2. Finally 1 mL of cell suspension with a concentration of 5x106 cells/mL was 
transferred into a cryo vial, wrapped in tissue and stored in a box at -80°C over 
night. 
3. The next day, cells were transferred into the liquid nitrogen tank and kept at -
170°C.  
2.3 Molecular biology methods 
2.3.1 Haemoglobin quantification in K562 cells 
Haemoglobin production in K562 was quantified by measuring haem content in cells. 
       A) Materials 
Component Supplier Catalogue number 
Igepal CA-630 Sigma-Aldrich I8896-50ML 
Tris 7.5 Fisher BPE 152-1 
NaCl BDH 102415K 
MgCl2 BDH 101494V 
Spectrophotometer  WPA S2000 
       B) Protocol 
1. 10X RSB buffer was prepared as follows: 
Component Concentration 
Tris 7.5 100 mM 
NaCl 100 mM 
MgCl2 30 mM 
R.O. water To a final volume of 1 L 
2. 106 K562 cells were centrifuged for 5 minutes at 1,000 x g. 
3. The supernatant was discarded and the pellet was resuspended in 1 mL of ice 
cold 0.5X RSB. 
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4. The cell suspension was incubated on ice for 5 minutes. 
5. 50 µL of Igepal CA-630 was added to the suspension. 
6. The cell suspension was biefly vortexed  and centrifuged for 5 minutes at 1,000 
x g. 
7. Absorbance of the supernatant at 415 nm (visible) was measured using a 
spectrophotometer. 
8. Absorbance of 1.0 at 415 nm is equivalent to 0.0945 mg/mL of haemoglobin.  
2.3.2 RNA extraction from K562 cells 
RNA extraction from K562 cells was performed with the RNeasy Mini Kit, 
QIAshredder and microcentrifuge. 
       A) Materials 
Component Supplier Catalogue number 
RNeasy Mini Kit  Qiagen 74104 
QIAshredder Qiagen 79654 
       B) Protocol 
1. 5 x 106 K562 cells grown in suspension were pelleted by centrifuging for 5 
minutes at 1,000 x g. The supernatant was discarded. 
2. Cells were disrupted by adding 600 µl of Buffer RLT and vortexing them. This 
buffer contains guanidine-thiocyanate, which immediately inactivates RNases to 
ensure purification of intact RNA. 
3. The lysate was transferred directly into a QIAshredder spin column placed in a 2 
ml collection tube, which was the centrifuged for 2 minutes at full speed, in 
order to homogenise the cell lysate. 
4. 600 µl of 70% ethanol was added to the homogenized lysate and mixed by 
pipetting to provide appropriate binding conditions. 
5. The sample was then transferred to an RNeasy spin column placed in a 2 ml 
collection tube, which was centrifuged for 15 seconds at 8,000 x g. The flow-
through was discarded. 
6. 700 µl of Buffer RW1 was added to the RNeasy spin column, which was then 
centrifuged for 15 seconds at 8,000 x g to wash the spin column membrane. The 
flow-through was discarded. 
7. 500 µl of Buffer RPE were added to the RNeasy spin column, which was then 
centrifuged for 15 seconds at 8,000 x g to wash the spin column membrane. The 
flow-through was discarded. 
8. 500 µl of Buffer RPE were added to the RNeasy spin column, which was then 
centrifuged for 2 minutes at 8,000 x g to wash the spin column membrane. The 
flow-through was discarded. 
9. The RNeasy spin column was placed in a new 2 ml collection tube and was 
centrifuged at full speed for 1 minute. 
10. The RNeasy spin column was placed in a new 1.5 ml collection tube and 50 µl 
of RNase-free water were added directly to the spin column membrane. The 
column was centrifuged at 8,000 x g for 1 minute to elute the RNA. 
11. Step 10 was repeated reusing the same collection tube. 
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12. Finally, the extracted RNA was stored at -20 °C until further treatment. 
2.3.3 DNase treatment 
DNase treatments were performed to obtain genomic
 
DNA-free RNA. 
       A) Materials 
Component Composition Supplier Catalogue number 
Amplification 
Grade DNase I 
1 mL of 1 unit/μL 
of enzyme in 50% 
glycerol, 10 mM 
Tris- HCl, pH 7.5, 
10 mM CaCl2, 10 
mM MgCl2 
Sigma-Aldrich D 5307 
 
10X Reaction 
Buffer 
1 mL of 200 mM 
Tris-HCl, pH 8.3, 
20 mM MgCl2 
Sigma-Aldrich R 6273 
Stop Solution 1 mL of 50 mM 
EDTA 
Sigma-Aldrich S 4809 
       B) Protocol 
1. The DNase reactions were set up as follows in 0.2 mL tubes: 
Component Volume 
RNA in water 8 µL 
10X Reaction Buffer 1 µL 
Amplification Grade DNase I (1 
unit/μl) 
1 µL 
2. The tubes were mixed gently and incubated at room temperature for 15 minutes. 
3. The DNase reactions were stopped by adding 1 μL of Stop Solution to bind 
calcium and magnesium ions and to inactivate the DNase I. 
4. The tubes were incubated at 70 °C for 10 minutes to denature both the DNase I 
and the RNA. 
5. The tubes were stored at -20°C until the reverse transcriptase reactions were 
performed. 
2.3.4 Reverse Transcriptase reaction 
Single-stranded cDNA from total, DNase-treated RNA was synthesized using the High 
Capacity RNA-to-cDNA Kit. This kit consolidates the components of the reverse 
transcription reaction into two tubes, 2x RT Buffer and 20x Enzyme mix, including 
RNase inhibitor. The reverse transcriptase (RT) products were further used in PCR and 
qPCR reactions.  
Materials and methods 
54 
 
       A) Materials 
Component Supplier Catalogue number 
High Capacity RNA-to-
cDNA Kit 
Ambion 4387406 
       B) Protocol 
1. The components of the kit were thawed on ice. 
2. The RT reactions, including the negative control, were set up in 0.2 mL tubes as 
follows: 
Component Volume per reaction 
+RT reaction -RT reaction 
2X RT Buffer 10 µL 10 µL 
20X Enzyme Mix 1 µL - 
RNA sample 9 µL 9 µL 
Nuclease-free water - 1 µL 
3. The tubes were centrifuged to spin down the contents and to eliminate air 
bubles. 
4. The RT reactions were performed in a thermal cycler using the following 
program: 
Step Temperature Time 
1 37°C 60 minutes 
2 95°C 5 minutes 
3 4°C ∞ 
5. The cDNA was stored at -20°C until it was used for PCR or qPCR reactions. 
2.3.5 Strand specific reverse transcriptase on the BGL3 gene 
Two-step RT-PCR in which cDNA is generated in the first step with a specific primer 
was performed to assess the contribution of sense and antisense transcripts to the global 
expression of the BGL3 transcript. 
       A) Materials 
Component Supplier Catalogue number 
Cloned AMV First-Strand 
cDNA Synthesis Kit 
Invitrogen 12328-032 
Primers Sigma Genosys  See section 2.3.5.B 
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       B) Protocol 
The primer pair used to synthesize the BGL3 cDNA and in the further PCR was: 
Primer Sequence (5’->3’) 
Forward GATCAAGCCTGTGCCAGACA 
Reverse GAACATCTAATAGTGTTGGGG 
Amplicon length (bp) 113 
1. In a 0.2 mL tube were mixed: 
Component Volume per reaction 
DNase-treated RNA in water 9 µL 
10 µM Primer (Forward, reverse or 
both) 
1 µL (0.5 µL of each in case of using 
both) 
10 mM dNTP Mix 2 µL 
2. RNA and primer were denatured by incubating at 65°C for 5 minutes and then 
placed on ice. 
3. The master reaction mix was prepared on ice by combining: 
Component Volume per reaction 
5x cDNA Synthesis Buffer 4 µL 
0.1 M DTT 1 µL 
RNaseOUT (40 U/µL) 1 µL 
DEPC-treated water 1 µL 
Cloned AMV RT (15 U/µL) 1 µL 
4. 8 µL of the master reaction mix was pipetted into each reaction tube on ice. 
5. The reaction tube was transferred into a thermal cycler and was incubated at 
50°C for 60 minutes. 
6. Reaction was terminated by incubating at 85°C for 5 minutes. 
7. cDNA was stored at -20°C until used for amplification with PCR (second step). 
2.3.6 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify the cDNA gene sequences to be 
cloned into the pEF6/V5-His A vector, as well as the cDNA sequences from the two-
step RT-PCR experiment. After PCR the obtained products were assessed on an agarose 
gel.  
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       A) Materials 
Component Concentration Supplier Catalogue 
Number 
HIFI PCR Buffer  x10  Invitrogen  52045 
MgSO4  50 mM Invitrogen 52044 
2’deoxyguanosine 
5’ triphosphate  
100mM  NEB  28406521V  
2’deoxythymidine 
5’ triphosphate  
100mM  NEB  28406531V  
2’deoxyadenosine 
5’ triphosphate  
100mM  NEB  28406501V  
2’deoxycytidine 5’ 
triphosphate  
100mM  NEB  28406511V  
Platinum Taq DNA 
Polymerase HIFI 
500 rxn Invitrogen 11304-029 
Primers  Supplied 
lyophilised 
Sigma Genosys  See section 3.5.2 
Nuclease free H2O  - Sigma-Aldrich W4502 
       B) Protocol 
1. 5X PCR Mix was prepared as follows and stored at -20°C until required: 
Component Volume 
10X PCR buffer 250 µL 
MgSO4 50 mM 100 µL 
Nuclease-free water 130 µL 
dNTPs 5 µL each 
2. Master Mix was prepared as follows just before performing the PCR: 
Component Volume per reaction 
5X PCR Mix 4 µL 
cDNA template 1.5 µL 
Nuclease-free water 12.4 µL 
Taq DNA polymerase 0.1 µL 
3. Primers synthesised by Sigma Genosys were supplied lyophilised. Primers were 
reconstituted with the correct volume of TE buffer (stated on the product 
information sheet) providing a 100mM stock solution. 
4. Primers were subsequently diluted to a 10 µM concentration. 
5. The following was added to each PCR tube: 
Component Volume 
Forward primer (10 µM) 1 µL 
Reverse primer (10 µM) 1 µL 
Master Mix 18 µL 
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Reaction tubes containing RNase-free water instead of cDNA template were 
used as non-template control for the PCR reaction. The products of the –RT 
reactions were also used as a negative controls for the PCR reactions to show the 
effectiveness of the DNAse treatment. 
6. The reaction tubes were then transferred to the thermal cycler for amplification 
of the cDNA template. The thermal cycler conditions were set up as follows: 
Step Temperature Time PCR Stage 
1 95°C 5 minutes 
Initial 
denaturation 
2 95°C 1 minute Denaturation 
3 60°C 1 minute Annealing 
4 72°C 1 minute Extension 
5 Repeat steps 2-4 
39 additional 
cycles 
Amplification 
6 72°C 5 minutes Final extension 
7 4 °C ∞ End of PCR 
2.3.7 Real-Time Polymerase Chain Reaction 
Relative quantification assays were used to analyze changes in BGL3 expression, as 
well as the γ- and β-globin genes of the β-globin locus, using Real-time Polymerase 
Chain Reaction (RT-PCR). RT-PCR was performed with a CFX96 Real-Time
 
PCR 
Detection System coupled to a C1000 Thermal Cycler (Bio-Rad) using TaqMan 
chemistry. TaqMan Gene Expression Assays were performed using as a template 
single-stranded cDNA from total genomic DNA-free RNA samples. To quantify the 
normalized fold expression of the studied genes, three replicates were performed and all 
data were normalized using the endogenous GAPDH control.  
       A) Materials 
Component Supplier Catalogue number 
Inventiored TaqMan Gene 
Expression Assay 
Applied Biosystems 4331182 
Made-to-order TaqMan 
Gene Expression Assay 
Applied Biosystems 4351372 
TaqMan Gene Expression 
Master Mix 
Applied Biosystems 4370048 
C100 Thermal Cycler Bio-Rad 184-1000 
CFX96 Real-Time
 
PCR 
Detection System 
Bio-Rad 185-5096 
Individual PCR tubes Bio-Rad TLS0801 
Flat cap strips Bio-Rad TCS0803 
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TaqMan chemistry was used to study the expression levels of the BGL3, β-globin 
(TaqMan Gene Expression Assay Hs00747223_g1) and γ-globin (TaqMan Gene 
Expression Assay Hs00361131_g1) genes. The expression levels were normalized 
respect to the expression levels of endogenous GAPDH (TaqMan Gene Expression 
Assay Hs99999905_m1).  
       B) Protocol 
1. The cDNA samples and TaqMan Gene Expression Assays were thawed on ice 
and resuspended by gentle vortexing. 
2. The TaqMan Gene Expression Master Mix was gently mixed swirling the bottle. 
3. The number of reactions was calculated taking in account that for each assay and 
cDNA sample three duplicates will be performed. No template controls (NTCs) 
reactions for each gene expression assay were also included. 
4. The PCR reaction mix were prepared as follows: 
PCR reaction mix 
component 
Volume per 20 µL reaction 
Single reaction Three replicates* 
20X TaqMan Gene 
Expression Assay 
1 µL 3.3 µL 
2X TaqMan Gene 
Expression Master Mix 
10 µL 33 µL 
cDNA template 1 µL 3.3 µL 
RNase-free water 8 µL 26.4 µL 
* Replicate volumes include 10% excess for volume loss from pipetting. 
5. 20 µL of PCR reaction mix were transferred into each well of the reaction strips. 
6. The wells were sealed with the cap strips and then loaded into the instrument. 
7. A plate document was created and the RT-PCR was ran using the following 
thermal cycler parameter values: 
Step Temperature Time 
1 50°C 2 minutes 
2 95°C 10 minutes 
3 95°C 15 seconds 
4 60°C 1 minute 
5 Repeat steps 3-4 39 addtional cycles 
8. Results were analyzed using the software of the CFX96 Real-Time PCR 
Detection System. Controls and samples were normalized for endogenous 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression when 
endogenous transcript levels were measured.  
2.3.8 Transformation of competent K12 E. coli cells 
Competent K12 E.coli cells were used to clone the plasmids pSilencer 2.1-U6 and 
pEF6/V5-His A. These plasmids contain an ampicillin resistance gene, therefore growth 
Materials and methods 
59 
 
of bacteria was regulated by inclusion of ampicillin into the LB agar once they had 
undergone the transformation procedure. All growth incubations were carried out in a 
shaking incubator at 37°C unless stated otherwise. 
       A) Materials 
Component Supplier Catalogue number 
LB Broth Fisher 17328 
Nutrient agar No2  Fluka 70116 
Ampicillin Boehringer 835 269 
NaCl BDH 102415K 
MgCl2 BDH 101494V 
CaCl2 Sigma-Aldrich C-3881 
KCl BDH 295945C 
Tryptone LAB MC5 
Yeast extract Oxoid L21 
Glucose Sigma-Aldrich G7528-1KG 
       B) Generation of competent K12 E. coli cells  
1. Sterile LB broth was prepared (25 g/L) and sterilized at 121°C for 20 minutes.  
2. 1 colony was picked off from an agar plate and aseptically transferred into a 
sterile 5 mL aliquot of LB broth and then incubated at 37°C overnight whilst 
been shaken (approximately 150 rpm). 
3. The culture was placed on ice for 10 minutes. 
4. Cells were harvested by centrifuging the 5mL culture at 1,600 x g for 5 minutes.  
5. The supernatant was discarded and the cells re-suspended in 10 mL of sterile 
0.1M cold MgCl2.  
6. The cells were spun down again at 1,600 x g for 5 minutes and re-suspended in 
1ml of sterile cold CaCl2 and then kept on ice for 2 hours.  
       C) Transformation of competent K12 E. coli cells  
1. Super optimal broth with catabolite repression (SOC) medium was prepared and 
autoclaved as follows: 
Component Quantity 
Tryptone 20 g 
Yeast extract 5 g 
NaCl 0.5 g 
KCl 0.186 g 
MgCl2 0.952 g 
Glucose 3.603 g 
Water To a final volume of 1 litre  
2. 200μl of competent cells were added to 10μl of ligated plasmid. The mix was 
then incubated on ice for 30 minutes.  
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3. Cells were then heat shocked at 42°C for 2 minutes and placed immediately on 
ice for another 2 minutes before adding 400 µL of pre-warmed SOC medium.  
4. The cells were then incubated for 1 hour at 37°C in a shaker incubator to allow 
the ampicillin resistance gene to become active.  
5. The bacterial suspension was then aseptically transfered into a 50 mL tube 
containing 5 mL of LB broth with a concentration of 100 µg/mL of ampicillin. 
The bacterial cells were incubated overnight at 37°C in a shaker incubator 
6. The bacterial suspension was diluted to 1/106. 200 µL of the dilution was plated 
onto 100 µg/mL ampicillin-containing LB agar plates. 
7. Bacterial colonies were counted following overnight incubation at 37°C. Single 
colonies were picked and placed into a 50 mL tube containing 5 mL of LB broth 
with a concentration of 100 µg/mL of ampicillin. These were grown overnight at 
37°C in a shaker incubator prior to plasmid extraction. 
8. Glycerol (20%) stocks of the colonies were also prepared and kept at -80°C for 
long-term storage. 
2.3.9 Plasmid extraction 
Plasmid extractions from transformed bacterial cultures were performed using the 
QIAprep Spin Miniprep Kit and a Microcentrifuge. 
       A) Materials 
Component Supplier Catalogue number 
QIAprep Spin Miniprep 
Kit 
Qiagen 27104 
       B) Protocol 
1. A 5 mL overnight culture of transformed E.coli was centrifuged at 1,600 x g for 
5 minutes and the supernatant was discarded.  
2. LyseBlue reagent and 20 μL of RNase A provided within the kit were added to 
Buffer P1. Following mixing the solution was stored at 2-8°C.  
3. Pelleted bacterial cells were resuspended in 250 μL of Buffer P1 and transferred 
to a microcentrifuge tube whilst ensuring there were no clumps of cells within 
the suspension. 
4. 250 μL of Buffer P2 were then added and mixed by gently inverting 4-6 times 
until the solution became viscous and homogenously blue.  
5. 350 μL of Buffer N3 were added and mixed immediately by inverting the tube 
4–6 times until mixed until all trace of blue had gone and the suspension was 
colorless. 
6. The suspension was then centrifugated for 10 minutes at 10,000 x g in a 
microcentrifuge. 
7. The supernatant was applied to a QIAprep spin column by decanting and 
centrifuged for 30 seconds. The flow-through was discarded. 
8. To remove trace nuclease activity the column was washed by adding 0.5 mL of 
Buffer PB and centriguging at 10,000 x g for 30 seconds. The flow-through was 
discarded. 
9. Ethanol (96-100%) was added to buffer PE as directed. 
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10. The column was washed again adding 0.75 mL of Buffer PE and centrifuging 
for 30 seconds.  
11. The flow-through was discarded and the column was centrifuged for 1 minute to 
remove residual wash buffer. 
12. To elute plasmid DNA the spin column was placed in a clean 1.5 mL 
microcentrifuge tube. 50 μL of Buffer EB (10mM Tris-Cl, pH 8.5) was added to 
the column. The column was left to stand for 5 minutes and then centrifuged at 
10,000 x g for 1 minute.  
13. The eluted plasmid DNA was stored at -20°C. 
2.3.10 Restriction enzyme digestion of plasmid DNA and PCR 
products 
Restriction enzyme digestions were performed to linearise the extracted plasmids and 
produce cohesive ends for subsequent ligations. PCR products were also digested to 
produce cohesive ends compatible with those of the linearized plasmid. Restriction 
enzyme digestions were also used to demonstrate the presence of the insert in the 
pEF6/V5-HIS A plasmid construct. 
       A) Materials 
Component Concentration Supplier Catalogue number 
BamH I 20,000 units/mL New England 
Biolabs 
R0136S 
Hind III 20,000 units/mL New England 
Biolabs 
R0104S 
Xba I 20,000 units/mL New England 
Biolabs 
R0145S 
Kpn I 10,000 units/mL New England 
Biolabs 
R0142S 
BSA 10 mg/mL New England 
Biolabs 
B9001S 
NEBuffer 2 10X New England 
Biolabs 
B7002S 
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       B) Protocol 
                (i) Digestion of pSilencer 2.1-U6 vector 
1. Digestion reaction was set up as follows in a 1.5 mL tube: 
Component Volume per reaction 
Plasmid 23 µL 
NEBuffer 2 (10X) 3 µL 
BSA (10 mg/mL) 3 µL 
BamH I (20 U/mL) 1.5 µL 
Hind III (20 U/mL) 1.5 µL 
2. All components were kept on ice whilst preparing the reaction. The digestion 
was started by the addition of the enzymes. 
3. The reaction mixture was incubated at 37°C for 90 minutes. 
4. Following digestion enzymes were heat inactivated by incubating at 65°C for 20 
minutes. 
5. The digested plasmid was stored at -20°C following asses by gel electrophoresis 
of the digests (see section 2.3.11). 
                (ii) Digestion of pEF6/V5-HIS A vector 
1. Digestion reaction was set up as follows in a 1.5 mL tube: 
Component Volume per reaction 
Plasmid 23 µL 
NEBuffer 2 (10X) 3 µL 
BSA (10 mg/mL) 3 µL 
BamH I (20 U/mL) 1.5 µL 
Xba I (20 U/mL) 1.5 µL 
2. All components were kept on ice whilst preparing the reaction. The digestion 
was started by the addition of the enzymes. 
3. The reaction mixture was incubated at 37°C for 90 minutes. 
4. Following digestion enzymes were heat inactivated by incubating at 65°C for 20 
minutes. 
5. The digested plasmid was stored at -20°C following asses by gel electrophoresis 
of the digests (see section 2.3.11). 
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                (iii) Digestion of PCR products to be ligated into pEF6/V5-HIS A vector 
1. Digestion reaction was set up as follows in a 1.5 mL tube: 
Component Volume per reaction 
PCR product 23 µL 
NEBuffer 2 (10X) 3 µL 
BSA (10 mg/mL) 3 µL 
BamH I (20 U/mL) 1.5 µL 
Xba I (20 U/mL) 1.5 µL 
2. All components were kept on ice whilst preparing the reaction. The digestion 
was started by the addition of the enzymes. 
3. The reaction mixture was incubated at 37°C for 90 minutes. 
4. Following digestion enzymes were heat inactivated by incubating at 65°C for 20 
minutes. 
5. The digested PCR product was stored at -20°C following asses by gel 
electrophoresis of the digests (see section 2.3.11). 
                (iv) Digestion of ligated pEF6/V5-HIS A plasmid construct to demonstrate the 
presence of the insert 
1. Digestion reaction was set up as follows in a 1.5 mL tube: 
Component Volume per reaction 
Plasmid 23 µL 
NEBuffer 2 (10X) 3 µL 
BSA (10 mg/mL) 3 µL 
Kpn I (20 U/mL) 1.5 µL 
Xba I (20 U/mL) 1.5 µL 
2. All components were kept on ice whilst preparing the reaction. The digestion 
was started by the addition of the enzymes. 
3. The reaction mixture was incubated at 37°C for 90 minutes. 
4. Following digestion enzymes were heat inactivated by incubating at 65°C for 20 
minutes. 
5. The digested plasmid was assessed by gel electrophoresis of the digests (see 
section 2.3.11). 
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2.3.11 Gel electrophoresis of plasmid DNA and PCR products 
       A) Materials 
Component Supplier Catalogue number 
Electrophoresis Tank  Bio-Rad Sub-Cell GT 
GeneSnap  Syngene Product version 7.07 
MassRuler (x6) loading 
dye solution 
Fermentas R0621 
MassRuler (ready to use) 
DNA ladder 
Fermentas #SM0403 
Ethidium Bromide Sigma-Aldrich E7637 
Agarose Fisher BP1356-100 
Trisma Base Fisher BP152-1 
Acetic acid Fisher A/0360/PB17 
EDTA Sigma-Aldrich E7889 
       B) Protocol 
1. 50X TAE buffer was prepared as follows: 
Component  Quantity 
Trisma base (2M final concentration) 242g 
Acetic acid (1M final concentration) 57.1 mL 
EDTA (50 mM final concentration) 200 mL 
R.O. water Volume was adjusted to 1 L 
2. Agarose gels (0.8-2% w/v) were prepared by weighting agarose and mixing in 
1X TAE buffer. 
3. Agarose was dissolved by boiling the solution in a microwave. 
4. When the gel was at 60°C approximately it was poured into the cast with the 
comb and allowed to set. 
5. The gel was placed into the electrophoresis tank, which was then filled with 
sufficient 1X TAE buffer to cover the gel. 
6. 10 µL of DNA ladder were added to the first lane 
7. 1 volume of loading dye solution was mixed with 3 volumes of DNA sample to 
a maximum volume of 30 µL. 
8. Gels were run at 200 V for 3 hours as a maximum depending on the agarose 
concentration and length of the gel. 
9. Gels were stained placing them in an ethidium bromide solution (1µg/mL) for 
30 minutes. 
10. Gels were exposed to UV light and gel images were captured using the 
GeneSnap software. 
2.3.12 Extraction of digested plasmids and PCR products form 
agarose gels 
In preparation for ligation, linear plasmids and PCR products were extracted from 
agarose gels using the QIAquick Gel Extraction Kit and a microcentrifuge. 
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       A) Materials 
Component Supplier Catalogue number 
QIAquick Gel Extraction 
Kit 
Qiagen 28704 
       B) Protocol 
1. DNA fragments were excised from a 2% (w/v) agarose gel with a clean, sharp 
scalpel trying to minimize the size of the gel slice by removing extra agarose. 
2. Gel slices were weighed in a colourless tube. 3 volumes of QG buffer were 
added to 1 volume of gel (100 mg~100 μL). Buffer QG solubilizes the agarose 
gel slice and provides the appropriate conditions for binding of DNA to the 
silica membrane. 
3. Samples were then incubated at 50°C  until the gel had completely dissolved. 
4. 1 gel volume of isopropanol was added to the sample and then mixed. 
5. To bind DNA, the sample was applied to a QIAquick spin column and 
centrifuged for 1 minute at 10,000 x g. The flow-through was discarded. 
6. 0.5 mL of Buffer QG was added to the column and centrifuged for 1 minute to 
remove all traces of agarose. The flow-through was discarded. 
7. The column was then washed by the addition of 0.75 mL of Buffer PE was left 
to stand for 5 minutes. The column was then centrifuged at 10,000 x g for 1 
minute. 
8. Flow-through was discarded from the collection tube; the column was then 
centrifuged for an additional 1 minute at 10,000 x g in order to remove any 
residual ethanol.  
9. The column was placed into a clean microcentrifuge tube. DNA was eluted by 
the addition of 30 μL of Buffer EB (10mM Tris-Cl, pH 8.5). The column was 
left to stand for 5 minutes followed by centrifugation for 1 minute at 10,000 x g. 
10. Extracted DNA was stored at -20°C.  
2.3.13 pEF6/V5-His A  
       A) Materials 
Component Supplier Catalogue number 
pEF6/V5-His A  Invitrogen V961-20 
       B) Description 
pEF6/V5-His A is a 5.8 kb vector designed for over-expression of recombinant proteins 
in mammalian cell lines (Figure 2-1). The vector contains the following elements:  
1. Human elongation factor 1α-subunit promoter (hEF-1α) for high-level 
expression across a broad range of species and cell types.  
2. Three reading frames to facilitate in-frame cloning with a C-terminal tag 
encoding the V5 epitope and a polyhistidine metal-binding peptide.  
3. Blasticidin resistance gene (bsd) to allow for selection of stable cell lines using 
blasticidin.  
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4. Episomal replication in cell lines that are latently infected with SV40 or that 
express the SV40 large T antigen.  
 
Figure 2- 1 Map of pEF6/V5-His. 
This figure summarizes the features of the pEF6/V5-His vectors.  
2.3.14 Blastidicin kill curve of K562 cells 
Blastidicin in culture medium at 2-10 µg/ml is commonly used to select cells with an 
integrated plasmid containing the resistance gene. Cells without the resistance gene are 
normally killed within 3–5 days. 
       A) Materials 
Component Supplier  Catalogue number 
Blastidicin Sigma-Aldrich 15205-25MG 
Trypan Blue Sigma-Aldrich T8154-20ML 
       B) Protocol 
1. 20,000 K562 cells were plated into each well of a 24 well dish containing 1 mL 
of RPMI 1640 culture medium supplementd with FCS and antibiotics as 
described above. 
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2. After 24 hr, 500 μL of culture medium containing blastidicin concentrations of 
10 µg/mL, 1 µg/mL, 100 ng/mL and 10 ng/mL were added into each of the 2 
wells of each of the 4 sub group of wells of the dish. The rest of the wells were 
used as a control wells where were cultured without blastidicin. 
3. Cells were cultured for 3 days and then the dishes were examined for viable 
cells. Cell viability was assessed each 24 hours using a haemocytometer and a 
solution of Trypan Blue 0.4% for vital staining.  
4. The lowest blastidicin concentration that begins to give massive cell death in 3 
days was used to select K562 cells containing the pEF6/V5-His A plasmid after 
transfection. 
2.3.15 pEF6/V5-His A Ligation reactions 
Digested PCR products were inserted into the pEF6/V5-His A vector performing the 
ligation reactions explained below. 
       A) Materials 
Component Concentreation Supplier  Catalogue number 
T4 DNA ligase 400,000 cohesive 
end units/ml 
NEB M0202L 
Ligase buffer 10X NEB B202S 
Nuclease-free water - Sigma-Aldrich W4502 
       B) Protocol 
1. Two 10 μL ligation reactions were set up; a plus-insert ligation, and the minus-
insert negative control. To each tube, the following reagents were added: 
Component Volume 
Plus-insert reaction Minus-insert reaction 
Digested and purified 
PCR product 
1 µL - 
Nuclease-free water - 1 µL 
10X T4 DNA Ligase 
Buffer 
1 µL 1 µL 
Linear pEF6/V5-His A 
vector 
7 µL 7 µL 
T4 DNA ligase  1 µL 1 µL 
2. The reactions were incubated for 3 hours at room temeperature and then the 
tubes were stored at –20°C for future transformation of E. coli. 
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2.3.16 pSilencer 2.1-U6 puro siRNA Expression Vector 
The pSilencer 2.1-U6 puro siRNA Expression Vector was used to induce RNAi by the 
expression of siRNA within K562 cells.  
       A) Materials 
Component Supplier  Catalogue number 
pSilencer 2.1-U6 puro 
siRNA Expression Vector 
Ambion AM5762 
       B) Description 
The pSilencer 2.1-U6 puro siRNA Expression Vector features a human U6 RNA pol III 
promoter (Figure 2-2). The pSilencer 2.1-U6 puro vector contains the puromycin 
resistance gene pac from Streptomyces alboniger, which encodes puromycin N-acetyl-
transferase and conveys resistance to puromycin to enable antibiotic selection in 
mammalian cells. The pSilencer 2.1-U6 puro vector also contains an ampicillin 
resistance gene, and an E. coli origin of replication. These two latter features are 
important to clone and amplify the plasmid in E. Coli. The plasmid can be linearized 
with both BamH 1 and Hind III to facilitate directional cloning.  
 
Figure 2- 2 pSilencer 2.1-U6 puro siRNA Expression Vector map. 
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2.3.17 Puromycin dihydrochloride kill curve of K562 cells 
Puromycin was used to select cells carrying the pSilencer plasmid containing antibiotic 
the resistance gene. 
       A) Materials 
Component Supplier  Catalogue number 
Puromycin dihydrochloride Sigma-Aldrich P8833-25MG 
Trypan Blue Sigma-Aldrich T8154-20ML 
       B) Protocol 
1. 20,000 K562 cells were plated into each well of a 24 well dish containing 1 mL 
of RPMI 1640 culture medium supplementd with FCS and antibiotics as 
described above. 
2. After 24 hr, 500 μL of culture medium containing puromycin concentrations of 
10 µg/mL, 1 µg/mL, 100 ng/mL and 10 ng/mL were added into each of the 2 
wells of each of the 4 sub group of wells of the dish. The rest of the wells were 
used as a control wells where were cultured without puromycin. 
3. Cells were cultured for 3 days and then the dishes were examined for viable 
cells. Cell viability was assessed each 24 hours using a haemocytometer and a 
solution of Trypan Blue 0.4% for vital staining.  
4. The lowest puromycin concentration that begins to give massive cell death in 3 
days was used to select K562 cells containing the pSilencer 2.1-U6 puro plasmid 
after transfection. 
2.3.18 siRNA Template Design 
Complementary 55–60 mer oligonucleotides with 5' single-stranded overhangs were 
designed for the target gene to be ligated into the pSilencer 2.1-U6 puro siRNA 
Expression Vector. The oligonucleotides encode 19-mer hairpin sequences specific to 
the mRNA target, a loop sequence separating the two complementary domains, and a 
polythymidine tract to terminate transcription.  
       A) siRNA Target Finder 
Ambion’s online siRNA Target finder (available at http://www.ambion.com/techlib/ 
misc/siRNA_finder.html) was used to find potential sequences based on the design 
guidelines described in the reference Ambion, 2008
103
. The mRNA sequence was pasted 
into the window and the program generated a report indicating the potential siRNA 
target sites. 
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2.3.19 Hairpin siRNA Template Oligonucleotid Design 
Below each siRNA target reported by the Ambion’s online siRNA Target finder there 
was a link that sends the target directly to the web-based Insert Design tool for the 
pSilencer Vectors (available at http://www.ambion.com/techlib/misc/psilencer 
_converter.html). The hairpin oligonucleotides were designed according to the 
guidelines described in the reference Ambion, 2008
103
. 
2.3.20 Synthesis of hairpin siRNA template oligonucleotides for 
ligation into pSilencer 2.1-U6 puro siRNA Expression Vector  
Oligonucelotides were synthesised by Sigma Genosys and were supplied lyophilised. 
Oligonucelotides were reconstituted with the correct volume of TE buffer (stated on 
product information sheet) providing a 100mM stock solution. 
2.3.21 Cloning Hairpin siRNA Inserts into the pSilencer Vector 
       A) Materials 
Component Concentreation Supplier  Catalogue number 
T4 DNA ligase 400,000 cohesive 
end units/ml 
NEB M0202L 
Ligase buffer 10X NEB B202S 
Annealing solution  1X Ambion 9613G2 
Nuclease-free water - Sigma-Aldrich W4502 
       B) Annealing of siRNA template oligonucleotides 
1. A 1 μg/μL solution of each oligonucleotide in TE (10 mM Tris, 1 mM EDTA) 
was prepared 
2. The 50 μL annealing mixture was assembled as follows: 
Component Amount 
Sense siRNA template oligonucleotide 2 µL 
Antisense siRNA template 
oligonucleotide 
2 µL 
1X DNA Annealing Solution 46 µL 
3. The mixture was hetaed to 90°C for 3 min, and then placed in a 37°C incubator 
for 1 hour. 
4. The annealed hairpin siRNA template insert was stored at –20°C for future 
ligation into the plasmid. 
       C) Ligation annealed siRNA template insert ino pSilencer 2.1-U6 Vector 
1. 5 μL of the annealed hairpin siRNA template insert were diluted with 45 μL 
nuclease-free water for a final concentration of 8 ng/μL. 
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2. Two 10 μL ligation reactions were set up; a plus-insert ligation, and the minus-
insert negative control. To each tube, the following reagents were added: 
Component Volume 
Plus-insert reaction Minus-insert reaction 
Diluted siRNA insert 1 µL - 
1X DNA Annealing 
Solution 
- 1 µL 
10X T4 DNA Ligase 
Buffer 
1 µL 1 µL 
Linear pSilencer 2.1-U6 
Vector 
7 µL 7 µL 
T4 DNA ligase  1 µL 1 µL 
3. The reactions were incubated for 3 hours at room temperature and then the tubes 
were stored at –20°C for future transformation of E. coli. 
2.3.22 Sequencing of plasmids 
pSilencer plasmid constructs were sequenced to confirm that the inserts were correctly 
ligated into the plasmids and that there were no unwanted mutations. Purified plasmids 
were sent for sequencing at Geneservice Ltd. Plasmids were sequenced using the 
Forward T7 sequencing primer (5’-TAATACGACTCACTATAGGG-3’). Sequencing 
results were received by e-mail and analyzed using the FinchTV software (available at 
http://www.geospiza.com/Products/finchtv.shtml).  
2.3.23 Transfection of K562 cells 
Plasmids were transfected into the K562 cells using the electroporation method. 
       A) Materials 
Component Supplier Catalogue number 
RPMI medium 1640 (1X) 
+L-glutamine 
Gibco 21875 
Electroporator Bio-Rad Gene Pulser 
Electroporator Cuvettes Bio-Rad 1652088 
       B) Protocol 
1. 107 K562 cells were centrifuged at 1,000 x g for 5 minutes and resuspended in 
RPMI 1640 medium without FCS or antibiotics to a final volume of 0.4 mL. 
2. 100 µL of plasmid (10 µg approximately) were added to the cell suspension. 
3. The mix was transferred to a sterile electroporation cuvette (0.4 cm of cuvette 
gap) and kept at room temperature for 15 minutes. 
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4. The electroporation cuvette was placed in the Gene Pulser Transfection 
Apparatus and the electroporation was performed under the following 
conditions: 
Parameter Value 
Voltage 0.6 kV 
Field Strength 1.5 V/cm 
Capacitor 25 µF 
Resistor None 
Time constant 0.6 milliseconds  
5. After receiving the electric pulse, cells were centrifuged at 1,000 x g for 5 
minutes and maintained pelleted for 20 minutes. 
6. The electroporation medium was then removed and the pellet was resuspended 
in 10 mL of RPMI 1640 1X +L-glutamine medium supplemented with a 
suspension of 50 U/mL penicillin and streptomycin and 10% of FBS.  
7. The culture was transferred to a T25 flask and was incubated for 24 hours at 
37°C and 5% CO2. 
8. The culture was transferred to a T75 flask containing 30 mL of culture medium 
and was incubated for 48 hours at 37°C and 5% CO2. The culture medium also 
contained of selective antibiotic (1 µg/mL of puromycin or 0.1 µg/mL of 
blastidicin) to enrich the culture for cells that were successfully transfected with 
the vector by killing off cells that lack the plasmid.  
9. Cell viability was determined by Trypan blue exclusion method (see section 
2.3.14). 
10. 15 mL of the culture was used to extract RNA for further quantitative PCR 
analysis. 
11. The remaining 15 mL culture was centrifuged at 1,000 x g for 5 minutes and 
resuspended in 30 mL of normal culture medium without selective antibiotic and 
was incubated at 37°C and 5% CO2 for 7 days. 
12. Cell viability was determined by Trypan blue exclusion method. 
13. 15 mL of the culture was used to extract RNA for further quantitative PCR 
analysis. 
14. The remaining 15 mL culture was splitted in two 7.5 mL cultures. 7.5 mL of 
culture media without selective antibiotic was added to each culture. One of the 
cultures was grown in the presence of haemin at concentration of 100 µM. 
15. Cell cultures were incubated 84 hours at 37°C and 5% CO2. Cell viability was 
determined by Trypan blue exclusion method. 
16. RNA extractions were performed for further quantitative PCR analysis. 
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3 Results 
As described in the introduction, this project aims to test the role of BGL3 on the 
regulation of the human β-globin locus during development, as well as attempting to 
influence the expression levels of γ- and β-globin. First of all, the expression profile of 
the BGL3 transcript and the γ- and β-globin genes was analyzed in induced K562 cells 
using quantitative PCR. Then, two different approaches were taken to attempt to 
influence the expression of the BGL3 transcript in K562 cells. First, in order to over-
express the BGL3 transcript, it was attempted to clone the BGL3 transcript in the 
pEF6/V5-His A plasmid, which is a constitutively expressed vector. Second, it was 
attempted to knockdown the BGL3 transcript using the pSilencer 2.1-U6 puro siRNA 
Expression Vector to induce RNAi pathway against the BGL3 transcript within the 
K562 cells. The main purpose of these experiments was to determine if there is a 
correlation between the expression levels of the BGL3 transcript and the γ- and β-globin 
genes of the human β-globin locus. 
3.1 Characterization of the BGL3 transcript 
The intense and diffuse signals yielded by the probes against the BGL3 transcript in the 
FISH images from the Fraser lab at the Babraham Institute (Figure 1-23) suggest that 
the transcript may be involved in an RNA-protein interaction and may be interacting 
with chromatin in the β-globin locus as part of a regulatory function within the locus. 
Thus, it is worthwhile to further investigate the expression profile of the BGL3 
transcript to determine if it has a regulatory function within the β-globin locus. 
3.1.1 Location of the BGL3 transcript within the β-globin locus 
The UCSC genome browser (see section 2.1.1) was used to extract the sense and 
antisense sequence of the BGL3 gene (AY034471) from the human genome on 
chromosome 11, position chr11:5,222,361-5,223,352 (Figure 3-1). The UCSC genome 
browser displays results in a 5’ end to 3’ end design. However, the β-globin locus 
happens to be orientated in the opposite direction compared to how it is traditionally 
displayed (i.e. LCR on left, genes on right). 
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Figure 3- 1 BGL3 gene (AY034471) location on the β-globin locus.  
Green rectangles: adult β-globin (HBB) and δ-globin genes; Blue rectangles: foetal Gγ- and Aγ- globin 
genes (HBG1 and HBG2); Orange rectangle: embryonic ε-globin gene (HBE1); Red rectangle: BGL3 
gene (AY034471). 
3.1.2 Coding potential of the BGL3 transcript 
One of the ways of assessing the coding potential of the BGL3 transcript is translating 
its nucleotide sequence to its theoretical protein sequence. This was done using the 
Translate Tool from the ExPASy web server (see section 2.1.6). As can be seen in 
Figures 3-2 and 3-3, the protein sequences for the three reading frames of both sense 
and antisense BGL3 transcripts contain high numbers of translation stop codons, which 
prevent the translation of the transcript into protein and confirm its status of non-coding 
RNA. 
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Figure 3- 2 Translated sequences corresponding to three reading frames of the sense BGL3 
sequence. 
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Figure 3- 3 Translated sequences corresponding to three reading frames of the antisense BGL3 
sequence. 
3.1.3 Secondary structure of the BGL3 transcript 
The secondary structures of the sense and antisense BGL3 transcripts were predicted 
and visualized using the RNAfold software (see section 2.1.5) (Figures 3-4 and 3-5). 
Both sense and antisense transcripts have complex secondary structures, which could be 
involved in their mechanism of action, and may affect the effectiveness of the designed 
siRNAs (see below) to target the sense and antisense BGL3 RNAs. 
Results 
77 
 
 
Figure 3- 4 Predicted secondary structure of the sense BGL3 transcript using the RNAfold 
software. 
Bases are coloured according to the pair probability. 
The optimal sense BGL3 transcript secondary structure corresponds to a minimum free 
energy of -255.60 kcal/mol. The free energy of the thermodynamic ensemble is -278.80 
kcal/mol. 
 
Figure 3- 5 Predicted secondary structure of the antisense BGL3 transcript using the RNAfold 
software. 
Bases are coloured according to the pair probability. 
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The optimal sense BGL3 transcript secondary structure corresponds to a minimum free 
energy of -278.45 kcal/mol. The free energy of the thermodynamic ensemble is -299.85 
kcal/mol. 
3.2 Induction of K562 cells with haemin 
Externally supplied haemin induces a program of erythroid maturation in the K562 cell 
line, which includes the production of large amounts of embryonic and foetal, but not 
adult, haemoglobin; this is associated with a selective elevation in γ-globin mRNA 
levels. Thus, elevated γ-globin levels in K562 cells can serve as a marker of induced 
cells (see section 1.4.1).  
To check the reproducibility of the K562 cell line in our hands as a model of study to 
investigate intergenic transcription in the β-globin locus, as well as to determine the 
expression profile of the BGL3 gene, it was first tested if it was possible to induce our 
culture of K562 cell with haemin. As markers of induction the haemoglobin production 
levels and the γ-globin expression levels were compared between induced and non-
induced K562 cells. 
3.2.1 Experimental design 
The main objective of this experiment was to compare different time course data from 
haemoglobin quantification and quantitative PCR experiments after induction of K562 
cells.  A culture of K562 cells was expanded and used to seed 28 flasks at a 
concentration of 2x10
4 
cell/mL (total volume 30 mL/flask). Cells were grown for 24 
hours and split into two groups of 14 flasks. Haemin was added to one group of flasks at 
a final concentration of 100 µM. The cells in each flask were allowed to grow for a 
different amount of time (at 0 hours and every 24 hours until 144 hours) before 
haemoglobin production was quantified or RNA was extracted.  Thus for each time 
point there are two biological replicates for both induced and non-induced K562 cells.  
3.2.2 Haemoglobin production in K562 cells 
Production of haemoglobin in K562 cells was quantified measuring haem (absorbs at 
415 nm) content using a spectrophotometer (see section 2.3.1). As shown in Figure 3-6, 
there is a significant increase in the production of haemoglobin in haemin-induced 
compared to non-induced K562 cell cultures. The overproduction of haemoglobin 
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begins to be evident after 96 hours of culture in presence of haemin. The increase in 
haemoglobin production in non-induced K562 cells could be attributed to a fraction of 
cells that naturally stop proliferation and undergo erythroid differentiation even in the 
absence of haemin in the culture medium. Externally supplied haemin has been proved 
to induce the overproduction of haemoglobin (presumably embryonic and foetal, but not 
adult, haemoglobin) in our culture of K562 cells, indicating that the erythroid 
differentiation program has been triggered within the cells. 
 
Figure 3- 6 Haemoglobin production in K562 cells. 
Data obtained from two biological replicates for each time point with or without 
addition of haemin to the K562 cell cultures. Error bars represent standard deviation. 
3.2.3 β-globin locus expression profile in K562 cells 
The β-globin locus expression profile of induced and non-induced K562 cells was 
analyzed using quantitative RT-PCR. RNA form K562 cells was extracted using the 
RNeasy Mini Kit (Qiagen) (see section 2.3.2). Genomic
 
DNA-free RNA was obtained 
with a DNase I treatment (Sigma-aldrich) and cDNA was synthesised using the High 
Capacity RNA-to-cDNA Kit (Ambion) (see section 2.3.4).  TaqMan chemistry was 
used to study the expression levels of the BGL3, β-globin and γ-globin genes (see 
section 2.3.7). The expression levels were normalized respect to the expression levels of 
endogenous GAPDH. Normalized fold expression of the genes mentioned above in 
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induced K562 cells was calculated with respect to non-induced control K562 cultures 
grown in equivalent conditions. Results were analyzed using the software of the CFX96 
Real-Time
 
PCR Detection System. No genomic DNA was detected in the controls 
without the reverse transcriptase. PCR controls using water instead of cDNA as a 
template demonstrated no contamination.  
       A) Custom design of TaqMan Gene Expression Assay for the BGL3 gene 
Since the BGL3 gene has no inventoried TaqMan Gene Expression Assay, the Primer3 
software (see section 2.1.3) was used to design the primers (forward 5’- AGTGTTGG 
GGGAGAAGTGTG-3’ and reverse 5’- TAGATCAAGCCTGTGCCAGA-3’) and 
FAM probe (5’-ATAGGAGATTCCGTGGCCCGTG-3’) for the custom-made BGL3 
TaqMan Gene Expression Assay. 
       B) β-globin gene expression profile 
As shown in Figure 3-7, the expression level of the β-globin gene in induced K562 cells 
does not show significant variations during the 144 hours of culture after addition of 
haemin to the culture medium. 
 
Figure 3- 7 β-globin gene expression profile of K562 induced cells by quantitative PCR. 
Data obtained from three technical replicates of two biological replicates for each time 
point after addition of haemin to the induced K562 cell cultures normalised to non-
induced cells. Error bars represent standard error of the mean. 
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       C) γ-globin gene expression profile 
As shown in Figure 3-8, the expression level of the γ-globin gene in induced K562 cells 
shows a significant increase of up to 3 fold 96 hours after addition of haemin to the 
culture medium. 
 
Figure 3- 8 γ-globin gene expression profile of K562 induced cells by quantitative PCR. 
Data obtained from three technical replicates of two biological replicates for each time 
point after addition of haemin to the induced K562 cell cultures normalised to non-
induced cells. Error bars represent standard error of the mean. 
       D) BGL3 gene expression profile 
As shown in Figure 3-9, there is a significant increase of up to 3 fold in the expression 
level of the BGL3 gene 96 hours after addition of haemin to the culture medium. 
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Figure 3- 9 BGL3 gene expression profile of K562 induced by quantitative PCR. 
Data obtained from three technical replicates of two biological replicates for each time 
point after addition of haemin to the induced K562 cell cultures normalised to non-
induced cells. Error bars represent standard error of the mean. 
       E) β-globin locus gene expression profile 
Plotting together all our data referent to the expression levels of the BGL3, β-and γ-
globin genes, interesting things can be observed (Figure 3-10).  
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Figure 3- 10 β-globin locus gene expression profile of K562 induced by quantitative PCR. 
Data obtained from three technical replicates per target of two biological replicates for 
each time point after addition of haemin to the induced K562 cell cultures normalised 
to non-induced cells. Error bars represent standard error of the mean. 
As it was expected, due to the nature of the K562 cells, haemin-induced K562 cells 
undergo a program of erythroid maturation associated with a selective elevation in γ-
globin mRNA levels of up to three fold. No significant changes can be observed in the 
expression levels of the β-globin gene. However, the big surprise comes from the 
expression profile of the BGL3 transcript in haemin-induced K562 cells. The data 
clearly shows that the BGL3 expression levels are actively regulated during 
differentiation of K562 cells into erythrocytes, suggesting a possible role of this non-
coding transcript in the maturation program of the cells. Furthermore, the BGL3 
transcript upregulation occurs just before the γ-globin gene reaches the peak of its 
expression. This suggests that the BGL3 transcript could be involved in the regulation 
of the γ-globin gene. Another possible explanation could be that the BGL3 transcript is 
associated with the repression of the β-globin gene during the K562 cells erythroid 
differentiation. 
All these results, in addition to the haemoglobin quantification results, suggest that our 
K562 cells undergo erythroid differentiation upon haemin induction and that can be 
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used as a model to study intergenic transcription within the human β-globin locus. 
Moreover, the BGL3 expression levels have been shown to be actively regulated during 
erythroid differentiation of K562 cells, warranting further study of this non-coding 
transcript.  
3.3 Direction of BGL3 transcription 
The annotation of the BGL3 transcript suggests it is expressed in the same direction as 
the coding genes in the β-globin locus. As noted in Figure 3-1 this is termed as the sense 
transcript. However, it is known that some ncRNAs are transcribed in both directions, it 
is therefore important to determine the direction of BGL3 in K562 cells. By performing 
two-step RT-PCR (see section 2.3.5) in which cDNA is generated in the first step with a 
specific primer it is possible to assess the contribution of sense and antisense transcripts 
to the perceived levels relative to GAPDH shown in Figure 3-10. As shown in figure 3-
11 the level of BGL3 product obtained when the reverse primer is used (which 
amplified the sense transcript) is greater than that obtained with the forward primer 
(which amplifies the antisense transcript). This suggests that the majority of BGL3 
transcript is produced in the sense direction (as shown on Figure 3-1). However, some 
antisense product is still detected and it is therefore important in subsequent 
experiments to assess the effect of perturbing both sense and antisense transcripts.  
 
Figure 3- 11 Direction of BGL3 transcription 
7 µL of PCR products were run on a 1.2% agarose gel for 45 minutes at 100 V with 5 
µL of DNA ladder (range 80 – 10,000 bp). Negative controls confirmed the absence of 
contamination or residual genomic DNA. PCR reactions produced one clear band of 
approximately 100 bp in size.  
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3.4 Generation of pSilencer 2.1-U6 puro plasmid constructs 
To test wether the BGL3 transcript plays a direct role in regulating transcription in the 
human β-globin locus it was attempted to perturb the levels of BGL3 by knocking it 
down using the RNAi pathway. Vector-based siRNA provides a low-cost alternative to 
the chemically synthesized siRNAs, whose cost is high and effect is transient. In 
contrast to directly transfected siRNAs, shRNAs are endogenously transcribed. The 
eukaryotic H1 and U6 pol III promoters are the most commonly used to transcribe 
shRNAs. These promoters generate high levels of small, non-coding RNA transcripts 
and show high activity in all cell types.  
For all these reasons it was decided to use the pSilencer 2.1-U6 puro siRNA Expression 
Vector (Ambion) to knockdown BGL3 expression via the RNAi pathway within the 
K562 cells (see section 2.3.16). This vector expresses siRNAs within mammalian cells 
using a U6 pol III promoter and permits selection and long-term RNAi experiments 
through an antibiotic resistance gene. To elicit BGL3 silencing, short hairpin RNAs 
(shRNAs) targeting the non-coding transcript were cloned into the vector downstream 
of the promoter. Once transfected into the K562 cell line, the insert-containing vector 
expresses the shRNA, which is rapidly processed by the cellular machinery into siRNA. 
3.4.1 Hairpin siRNA Template Oligonucleotide Design 
The first step to knockdown the BGL3 transcript using the pSilencer 2.1-U6 puro 
siRNA Expression Vector was to design complementary 60-64 mer oligonucleotides for 
the BGL3 sense and antisense transcripts (see sections 2.3.18 and 2.3.19). These 
oligonucleotides were later ligated into the pSilencer 2.1-U6 puro siRNA Expression 
Vector. The oligonucleotides encode 21-mer siRNAs specific to the BGL3 targets, a 
loop sequence separating the two complementary domains, and a polythymidine tract to 
terminate transcription and 3' overhanging UU dinucleotides to enhance their 
effectiveness. Addition of GGAA immediately downstream of the RNA pol III 
terminator site improves the efficiency of gene silencing, though the mechanism for this 
effect is unknown
103
. All designed siRNAs have Bam HI and Hind III to facilitate 
directional cloning into the pSilencer 2.1-U6 puro siRNA Expression Vector (Figure 3-
12). 
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Figure 3- 12 Schematic overview of the designed oligonucleotides to be cloned into the pSilencer 
2.1-U6 puro siRNA Expression Vector. 
Adapted from: Ambion, 2008, p. 9
103
. 
Six different siRNAs were designed to target different regions of the BGL3 sense and 
antisense transcripts, in order to increase the probabilities to effectively target the non-
coding transcript. Furthermore, siRNAs were designed to target different regions along 
the length of the BGL3 sense and antisense transcripts, to increase the chances of 
targeting a region of BGL3 without significant higher order structures or regulatory 
proteins bound (Figures 3-4 and 3-5). siRNAs were also selected with G/C contents 
ranging from 30 to 50%, which are more active than those with a higher G/C content.  
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       A) Sense BGL3 siRNAs 
Four shRNAs were designed for the sense transcript of BGL3. Figure 3-13 displays the 
four siRNA targets selected using Ambion’s Target Finder. 
>Sense BGL3 transcript 
TTAGCAGTAACTGCTGAATTCCTGGTTGGCTGATGGAAAGATGGGGCAGCTGTTCACTGGTACGCAGGGT
TTTAGATGTATGTACCTAAGGATATGAGGTATGGCAATGAACAGAAATTCTTTTGGGAATGAGTTTTAGG
GCCATTAAAGGACATGACCTGAAGTTTCCTCTGAGGCCAGTCCCCACAACTCAATATAAATGTGTTTCCT
GCATATAGTCAAAGTTGCCACTTCTTTTTCTTCATATCATCGATCTCTGCTCTTAAAGATAATCTTGGTT
TTGCCTCAAACTGTTTGTCACTACAAACTTTCCCCATGTTCCTAAGTAAAACAGGTAACTGCCTCTCAAC
TATATCAAGTAGACTAAAATATTGTGTCTCTAATATCAGAAATTCAGCTTTAATATATTGGGTTTAACTC
TTTGAAATTTAGAGTCTCCTTGAAATACACATGGGGGTGATTTCCTAAACTTTATTCTTGTAAGGATTTA
TCTCAGGGGTAACACACAAACCAGCATCCTGAACCTCTAAGTATGAGGACAGTAAGCCTTAAGAATATAA
AATAAACTGTTCTTCTCTCTGCCGGTGGAAGTGTGCCCTGTCTATTCCTGAAATTGCTTGTTTGAGACGC
ATGAGACGTGCAGCACATGAGACACGTGCAGCAGCCTGTGGAATATTGTCAGTGAAGAATGTCTTTGCCT
GATTAGATATAAAGACAAGTTAAACACAGCATTAGACTATAGATCAAGCCTGTGCCAGACACAAATGACC
TAATGCCCAGCACGGGCCACGGAATCTCCTATCCTCTTGCTTGAACAGAGCAGCACACTTCTCCCCCAAC
ACTATTAGATGTTCTGGCATAATTTTGTAGATATGTAGGATTTGACATGGACTATTGTTCAATGATTCAG
AGGAAATCTCCTTTGTTCAGATAAGTACACTGACTACTAAATGGATTAAAAAACACAGTAATAAAACCCA
GTTTTCCCCTTAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Figure 3- 13 Selected siRNA target sites (in red) for the sense BGL3 transcript. 
shRNAs were designed using Ambion’s Design tool for the pSilencer Vectors. The 
details of the design of the shRNAs for these siRNA target sites are indicated below. 
siRNA target sequence: 
1. AAGGATATGAGGTATGGCAAT 
Position in gene sequence: 88  
GC content: 38.1%  
Sense strand siRNA: GGAUAUGAGGUAUGGCAAUUU  
Antisense strand siRNA: AUUGCCAUACCUCAUAUCCUU 
shRNA design:    
BamH1    Sense Strand  Loop      Antisense strand     Hind III 
5'-GATCC GGATATGAGGTATGGCAAT TTCAAGAGA ATTGCCATACCTCATATCC TTTTTT GGAA A-3' 
    3'-G CCTATACTCCATACCGTTA AAGTTCTCT TAACGGTATGGAGTATAGG AAAAAA CCTT TTCGA-5' 
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2. AAACTGTTTGTCACTACAAAC 
Position in gene sequence: 288  
GC content: 33.3%  
Sense strand siRNA:  ACUGUUUGUCACUACAAACUU  
Antisense strand siRNA: GUUUGUAGUGACAAACAGUUU 
shRNA design: 
   BamH1    Sense Strand Loop    Antisense strand      Hind III 
5'-GATCC ACTGTTTGTCACTACAAAC TTCAAGAGA GTTTGTAGTGACAAACAG TTTTTTT GGAA A-3' 
    3'-G TGACAAACAGTGATGTTTG AAGTTCTCT CAAACATCACTGTTTGTC AAAAAAA CCTT TTCGA G-5' 
 
3. AAGGATTTATCTCAGGGGTAA 
Position in gene sequence: 482  
GC content: 38.1%  
Sense strand siRNA:  GGAUUUAUCUCAGGGGUAAUU  
Antisense strand siRNA: UUACCCCUGAGAUAAAUCCUU 
shRNA design: 
   BamH1    Sense Strand   Loop     Antisense strand     Hind III 
5'-GATCC GGATTTATCTCAGGGGTAA TTCAAGAGA TTACCCCTGAGATAAATCC TTTTTT GGAA A-3' 
    3'-G CCTAAATAGAGTCCCCATT AAGTTCTCT AATGGGGACTCTATTTAGG AAAAAA CCTT TTCGA -5' 
 
4. AAATGACCTAATGCCCAGCAC 
Position in gene sequence: 763  
GC content: 47.6%  
Sense strand siRNA:  AUGACCUAAUGCCCAGCACUU  
Antisense strand siRNA: GUGCUGGGCAUUAGGUCAUUU 
shRNA design: 
BamH1    Sense Strand   Loop     Antisense strand     Hind III 
5'-GATCC ATGACCTAATGCCCAGCAC TTCAAGAGA GTGCTGGGCATTAGGTCA TTTTTTT GGAA A-3' 
    3'-G TACTGGATTACGGGTCGTG AAGTTCTCT CACGACCCGTAATCCAGT AAAAAAA CCTT TTCGA-5' 
All these siRNA target sequences are specific for the BGL3 transcript and do not have 
homology with any other human gene, as confirmed using the BLAT tool. 
       B) Antisense BGL3 siRNAs 
Using the same procedure described above, two shRNAs were designed for the 
antisense transcript of BGL3.  Figure 3-14 shows the two siRNA targets selected form 
the report of the Ambion’s Target Finder. 
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>Antisense BGL3 transcript 
TTTTTTTTTTTTTTTTTTTTTTTTTTTAAGGGGAAAACTGGGTTTTATTACTGTGTTTTTTAATCCATTT
AGTAGTCAGTGTACTTATCTGAACAAAGGAGATTTCCTCTGAATCATTGAACAATAGTCCATGTCAAATC
CTACATATCTACAAAATTATGCCAGAACATCTAATAGTGTTGGGGGAGAAGTGTGCTGCTCTGTTCAAGC
AAGAGGATAGGAGATTCCGTGGCCCGTGCTGGGCATTAGGTCATTTGTGTCTGGCACAGGCTTGATCTAT
AGTCTAATGCTGTGTTTAACTTGTCTTTATATCTAATCAGGCAAAGACATTCTTCACTGACAATATTCCA
CAGGCTGCTGCACGTGTCTCATGTGCTGCACGTCTCATGCGTCTCAAACAAGCAATTTCAGGAATAGACA
GGGCACACTTCCACCGGCAGAGAGAAGAACAGTTTATTTTATATTCTTAAGGCTTACTGTCCTCATACTT
AGAGGTTCAGGATGCTGGTTTGTGTGTTACCCCTGAGATAAATCCTTACAAGAATAAAGTTTAGGAAATC
ACCCCCATGTGTATTTCAAGGAGACTCTAAATTTCAAAGAGTTAAACCCAATATATTAAAGCTGAATTTC
TGATATTAGAGACACAATATTTTAGTCTACTTGATATAGTTGAGAGGCAGTTACCTGTTTTACTTAGGAA
CATGGGGAAAGTTTGTAGTGACAAACAGTTTGAGGCAAAACCAAGATTATCTTTAAGAGCAGAGATCGAT
GATATGAAGAAAAAGAAGTGGCAACTTTGACTATATGCAGGAAACACATTTATATTGAGTTGTGGGGACT
GGCCTCAGAGGAAACTTCAGGTCATGTCCTTTAATGGCCCTAAAACTCATTCCCAAAAGAATTTCTGTTC
ATTGCCATACCTCATATCCTTAGGTACATACATCTAAAACCCTGCGTACCAGTGAACAGCTGCCCCATCT
TTCCATCAGCCAACCAGGAATTCAGCAGTTACTGCTAA 
Figure 3- 14 Selected siRNA target sites (in red) for the antisense BGL3 transcript. 
Below appear the details of the designed shRNAs for the selected siRNA target sites. As 
before shRNAs were designed using the Ambion’s Design tool for the pSilencer 
Vectors. siRNA target sequence: 
1. AATATTCCACAGGCTGCTGCA 
Position in gene sequence: 342  
GC content: 47.6%  
Sense strand siRNA: UAUUCCACAGGCUGCUGCAUU  
Antisense strand siRNA: UGCAGCAGCCUGUGGAAUAUU 
shRNA design: 
BamH1    Sense Strand       Loop      Antisense strand      Hind III 
5'-GATCC GTATTCCACAGGCTGCTGCA TTCAAGAGA TGCAGCAGCCTGTGGAATATT TTTT GGAA A-3' 
    3'-G CATAAGGTGTCCGACGACGT AAGTTCTCT ACGTCGTCGGACACCTTATAA AAAA CCTT TTCGA-5' 
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2. AACATGGGGAAAGTTTGTAGT 
Position in gene sequence: 699  
GC content: 38.1%  
Sense strand siRNA: CAUGGGGAAAGUUUGUAGUUU  
Antisense strand siRNA: ACUACAAACUUUCCCCAUGUU 
shRNA design: 
 
BamH1    Sense Strand       Loop  Antisense strand      Hind III 
5'-GATCC GCATGGGGAAAGTTTGTAG TTTCAAGAG AACTACAAACTTTCCCCA TGTTTTT TGGAA A-3' 
    3'-G CGTACCCCTTTCAAACATC AAAGTTCTC TTGATGTTTGAAAGGGGT ACAAAAA ACCTT TTCGA 
BLAT analysis confirmed that all these siRNA target sequences are specific for the 
BGL3 transcript and do not have homology with any other region of the human 
genome. 
       C) BGL3 siRNAs UCSC custom track 
A UCSC custom track was created to display the designed BGL3 shRNAs and show 
their targeted position within the BGL3 transcript (Figure 3-15). 
 
Figure 3- 15 UCSC custom track showing the designed siRNAs for the BGL3 transcript 
(AY034471). 
3.4.2 Cloning strategy for the pSilencer 2.1-U6 puro siRNA 
Expression Vector 
The cloning strategy of the designed shRNA inserts into the pSilencer 2.1-U6 puro 
siRNA Expression Vector was designed as follows (Figure 3-16). First, the plasmid was 
propagated and extracted from E. coli. Second, the scrambled shRNA insert was 
removed by digesting the plasmid with Bam HI and Hind III. Third, the linearised 
plasmid was purified from an agarose gel. Fourth, the designed shRNAs with 
compatible ends were annealed and ligated into the plasmid, and the constructs were 
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selected and propagated in E. coli. Finally, extracted plasmids were used to transfect 
K562 cells. 
 
Figure 3- 16 Schematic overview of the cloning strategy for the pSilencer 2.1-U6 puro plasmid. 
3.4.3 Propagation and extraction of pSilencer 2.1-U6 puro plasmid 
pSilencer 2.1-U6 puro siRNA Expression Vector was kindly provided by Peter Fraser 
(Babraham Institute, Cambridge). The plasmid was in a circular configuration and 
contained a scrambled shRNA insert without significant homology to any gene of the 
human genome. Chemically competent K12 E.coli cells were transformed with 5 µL of 
the circular pSilencer 2.1-U6 puro plasmid to create stock of the plasmid (see section 
2.3.8). Plasmid was then extracted from 5 mL overnight broth cultures with ampicillin 
using the QIAprep Spin Miniprep Kit (Qiagen) (see section 2.3.9). The extracted 
plasmid was then assessed on an agarose gel (see section 2.3.11). Electrophoresis 
produced one band of approximately 3500 bp in size (Figure 3-17). 
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3.4.4 Restriction digestion of the extracted pSilencer 2.1-U6 puro 
plasmid 
The pSilencer 2.1-U6 puro plasmid was linearised with the restriction enzymes BamH I 
and Hind III to remove the scrambled shRNA insert (see section 2.3.10). The plasmid 
was digested with the restriction enzymes BamH I and Hind III. The resulting digests 
were electrophoresed on an agarose gel (Figure 3-17). Digestion of the plasmids 
produced one clear band of approximately 4500 bp in size and confirmed the presence 
of the pSilencer 2.1-U6 puro plasmid which is 4455 bp in length. 
 
Figure 3- 17 Gel electrophoresis of digested pSilencer 2.1-U6 puro plasmid. 
7 µL of extracted and digested plasmids were run on a 1.2% agarose gel for 45 minutes 
at 100 V with 5 µL of DNA ladder (range 80 – 10,000 bp). The extracted plasmid 
produced one clear band of approximately 3500 bp in size. The digested plasmids 
produced one clear band of approximately 4500 bp in size. 
3.4.5 Extraction of digested pSilencer 2.1-U6 puro plasmid from 
agarose gels 
In order to generate sufficient linear plasmid for subsequent ligation reactions, 6 
additional digestions of the extracted plasmid were performed using both BamH I and 
Hind III restriction enzymes. The resulting digests were run in an agarose gel (Figure 3-
18). 
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Figure 3- 18 Gel electrophoresis of digested pSilencer 2.1-U6 puro plasmid. 
30 µL of extracted and digested plasmids were run on a 1.2% agarose gel for 30 
minutes at 100 V. The digested plasmids produced one clear band. 
The electrophoresed digests were subsequently excised and extracted from the agarose 
gel using the QIAquick Gel Extraction Kit (see section 2.3.12). The purified linear 
pSilencer 2.1-U6 puro plasmid was subsequently run on an agarose gel to assess the 
recovery of the linear plasmid (Figure 3-19). 
 
Figure 3- 19 Gel electrophoresis of digested and purified pSilencer 2.1-U6 puro plasmid. 
7 µL of extracted, digested and purified plasmids were run on a 1.2% agarose gel for 
30 minutes at 100 V with 5 µL of DNA ladder (range 80 – 10,000 bp). The extracted 
plasmid produced one clear band of approximately 3500 bp in size. The digested and 
purified plasmids produced one clear band of approximately 4500 bp in size. 
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3.4.6 Ligation of the shRNA oligonucleotides into the pSilencer 2.1-
U6 puro plasmid 
Prior to the ligation reactions, the approximate DNA concentration of the purified linear 
pSilencer 2.1-U6 puro plasmid was estimated to be 25 ng/µL using a 
spectrophotometer. Since the synthesised shRNA inserts were diluted to 8 ng/µL, the 
volumes of the individual inserts and plasmid required were worked out for optimal 
reaction ligations at a 3:1 molar ratio of insert to plasmid. 
       A) Calculation of molar ratios of purified linear pSilencer 2.1-U6 puro 
plasmid to shRNA insert 
The initial molar ratio of plasmid to insert was: 
𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑏𝑝
𝐼𝑛𝑠𝑒𝑟𝑡 𝑏𝑝
=
4455 𝑏𝑝
64 𝑏𝑝
= 69.6 
Dividing 69.6 by 3 it provides a 3:1 shRNA insert to purified linear pSilencer 2.1-U6 
puro plasmid of 23.2. Therefore 1 ng of shRNA insert to 23.2 ng of plasmid is 
equivalent to a 3:1 molar ratio of insert to plasmid. Finally, referring to the 
concentrations of plasmid and insert indicated above, 1 µL of the diluted shRNA insert 
requires approximately 7 µL of purified linear pSilencer 2.1-U6 puro plasmid to give a 
3:1 molar ratio. 
The final volume of the ligation reactions was adjusted to 10 µL adding 1 µL T4 DNA 
ligase and 1 µL T4 DNA ligase buffer (see section 2.3.21). This ligation procedure was 
repeated for each of the 6 designed shRNAs to target the BGL3 transcript. 
3.4.7 Transformation of chemically competent K12 E. coli cells with 
ligated pSilencer 2.1-U6 puro plasmid 
Chemically competent K12 E.coli cells were transformed with 10 µL of ligated 
pSilencer 2.1-U6 puro plasmid (see section 2.3.8). This process was repeated for the six 
ligated plasmids. For each transformation, three colonies were picked-up and growth on 
LB broth in the presence of ampicillin. No colonies were detected in the minus-insert 
ligation control cultures. Plasmids were then extracted from the resulting 18 overnight 5 
mL broth cultures with ampicillin using the QIAprep Spin Miniprep Kit (see section 
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2.3.9). The extracted plasmids were then assessed on an agarose gel (see section 2.3.11) 
(Figure 3-20).  
 
Figure 3- 20 Gel electrophoresis of ligated pSilencer 2.1-U6 puro plasmids. 
7 µL of extracted plasmids were run on a 1.2% agarose gel for 30 minutes at 100 V with 
5 µL of DNA ladder (range 80 – 10,000 bp). The extracted plasmids produced one clear 
band of approximately 3500 bp in size. 
All the plasmid extractions yielded strong signal in the agarose gels. Bacterial clones 
and the extracted plasmids were kept frozen as glycerol stocks for further analysis. 
3.4.8 Verification of the presence of the shRNA insert in the 
extracted pSilencer 2.1-U6 puro plasmid 
Extracted pSilencer 2.1-U6 puro plasmids were sent for sequencing to check if the 
transformed E. coli actually contained the plasmid with the insert correctly ligated and 
that there were no unwanted mutations (see section 2.3.22). 10 µL of extracted plasmid 
of one randomly selected clone of each shRNA insert was sequenced. Sequencing 
reactions confirmed the presence of the correct shRNA inserts in the clone A of the 
sense BGL3 shRNA 3, clone C of the sense BGL3 shRNA 4 and clone A of the 
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antisense BGL3 shRNA 1. Sequencing reactions for the clone A of the sense BGL3 
shRNA 1, clone C of the sense BGL3 shRNA 2 and clone C of the antisense BGL3 
shRNA 2 generated short reads that prevented the confirmation of the presence of the 
shRNA inserts. This could be caused by the secondary structure of the shRNAs, 
which may be responsible for preventing the extension of the read. 
Furthermore, the original pSilencer 2.1-U6 puro plasmid was also sent for sequencing in 
order to determine the sequence of the scrambled insert that will be used as a control. 
BLAT analysis of the sense strand of the siRNA contained in the shRNA scrambled 
sequence (5’-GATCCACTACCGTTGTTATAGGTGTTCAAGAGACACCTATAAC 
AACGGTAGTTTTTTGGAAA-3’) showed that the scrambled shRNA insert does not 
have homology with any region of the human genome. 
3.5 Generation of pEF6/V5-His A plasmid constructs 
In this project it was also attempted to alter the levels of the BGL3 transcript by cloning 
it into the constitutively expressed pEF6/V5-His A plasmid (Invitrogen) in order to 
observe if the over-expression of the non-coding transcript perturbs the expression 
levels of the β- and γ-globin genes within the human β-globin locus in K562 cells. 
Although the pEF6/V5-His A plasmid is designed for overproduction of recombinant 
proteins, this plasmid was selected to over-express the BGL3 transcript because it 
contains the human elongation factor 1α-subunit promoter (hEF-1α). This promoter 
provides high-level expression across a broad range of species and cell types. The 
pEF6/V5-His A plasmid also contains the blasticidin resistance gene (bsd), which 
allows selection of stable cell lines using blasticidin in the culture medium. 
3.5.1 Primers design 
The first step to clone the BGL3 transcript into the pEF6/V5-His A plasmid was to 
amplify the cDNA of the non-coding transcript. Paired primers were designed to 
amplify the BGL3 transcript. In the Figure 3-21 it is indicated the region of the BGL3 
cDNA amplified by the primers. 
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Figure 3- 21 Region of the BGL3 cDNA amplified by the designed primers. 
3.5.2 Addition of restriction enzyme sites to the primers 
Bam HI and Xba I recognition sites were added onto the 5’ end of the primers to 
generate PCR products with cohesive ends for ligation into the pEF6/V5-His A plasmid. 
Furthermore, working with two different recognition sites gave us the possibility to 
ligate the insert into the plasmid in both sense and antisense directions (Figure 3-22). 
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Figure 3- 22 Schematic overview of the strategy for the sense and antisense insertion of the BGL3 
PCR products into the pEF6/V5-His A plasmid. 
Since the cleavage sites were added at the end of the PCR products, the recognition sites 
were altered by adding additional bases in order to allow efficient cleavage. In the case 
of the Bam HI recognition site (5’-GGATCC-3’), two bases were added at each end 
resulting in the recognition site 5’-CGGGATCCCG-3’. The same procedure was 
followed in the case of the recognition site of Xba I (5’-TCTAGA-3’), in which two 
bases were added at each end resulting in the recognition site 5’-GCTCTAGAGC-3’. 
The two recognition sites indicated above were added to the 5’ end of the designed 
primer as shown in the table below. 
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Primer name Direction Sequence (5’->3’) 
Sense BGL3 insertion For Forward CGGGATCCCGGGGAAAACTGGGTT
TTATTAC 
Sense BGL3 insertion Rev Reverse GCTCTAGAGCTTAGCAGTAACTGCT
GAATTC 
Antisense BGL3 insertion 
For 
Forward GCTCTAGAGCGGGAAAACTGGGTT
TTATTAC 
Antisense BGL3 insertion 
For 
Reverse CGGGATCCCGTTAGCAGTAACTGC
TGAATTC 
The expected PCR products were 1012 bp in length for each primer pair. The 
NEBcutter tool confirmed that the BGL3 sequence does not contain any recognition 
sites for the Bam HI and Xba I restriction enzymes (Figure 3-23). 
 
Figure 3- 23  Map of the restriction enzyme recognition sites present in the BGL3 DNA sequence. 
3.5.3 Amplification of the BGL3 transcript 
Using the designed primers indicated above, the BGL3 cDNA was amplified by PCR 
(see section 2.3.6). Negative controls, including a non-template controls and the –RT 
controls, were run for each reaction  Gel electrophoresis (see section 2.3.11) showed 
PCR products of approximately 1000 bp in length, a size in accordance to the expected 
1012 bp products (Figure 3-24; Lanes 1 and 5). 
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Figure 3- 24  Gel electrophoresis of PCR products of BGL3 transcripts for sense and antisense 
insertion into the pEF6/V5-His A plasmid. 
7 µL of PCR products and digested and purified products were run on a 1.2% agarose 
gel for 45 minutes at 100 V with 5 µL of DNA ladder (range 80 – 10,000 bp). Negative 
controls confirmed the absence of contamination or residual genomic DNA. PCR 
reactions produced one clear band of approximately 1000 bp in size. The digested and 
purified PCR products also produced one clear band of approximately 1000 bp in size. 
3.5.4 Restriction digestion of PCR products 
Once it was confirmed the correct amplification of the BGL3 transcripts by PCR, four 
additional PCR reactions were performed for both BGL3 sense and antisense transcript 
insertions in order to generate sufficient stock for further ligation reactions. Following 
PCR, products were digested with Bam HI and Xba I (see section 2.3.10) in order to 
generate cohesive ends compatible with those of the linear pEF6/V5-His A plasmid (see 
below). Digests were then electrophoresed in an agarose gel (see section 2.3.11) (Figure 
3-25). 
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Figure 3- 25 Gel electrophoresis of the digested PCR products of BGL3 sense and antisense 
transcripts. 
30 µL of digested PCR products were run on a 1.2% agarose gel for 45 minutes at 100 
V with 5 µL of DNA ladder (range 80 – 10,000 bp). The digested PCR products 
produced one clear band of approximately 1000 bp in size. 
3.5.5 Extraction of digested PCR products from agarose gels 
The electrophoresed digests were subsequently excised and extracted from the agarose 
gel using the QIAquick Gel Extraction Kit (see section 2.3.12). The purified digested 
PCR products were subsequently run on an agarose gel (see section 2.3.11) to assess the 
recovery of the amplified transcripts (Figure 3-24; Lanes 4 and 8) and kept frozen for 
further ligation into the pEF6/V5-His A plasmid. 
3.5.6 Cloning strategy for the pEF6/V5-His A plasmid 
The cloning strategy of the BGL3 PCR products into the pEF6/V5-His A plasmid was 
designed as follows (Figure 3-26). First, the plasmid was propagated and extracted from 
E. coli. Second, the plasmid was digested with Bam HI and Xba I. Third, the linearised 
plasmid was purified from an agarose gel. Fourth, the BGL3 PCR products with 
compatible ends were ligated into the plasmid and the constructs were propagated in E. 
coli. Finally, extracted plasmids will be used to transfect K562 cells. 
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Figure 3- 26 Schematic overview of the cloning strategy for the pEF6/V5-His A plasmid. 
3.5.7 Propagation and extraction of pEF6/V5-His A plasmid 
pEF6/V5-His A plasmid was kindly provided by Stephen Best (Kings College, 
London). The plasmid was in a circular configuration and contained no insert. 
Chemically competent K12 E.coli cells were transformed with 5 µL of the circular 
pEF6/V5-His A plasmid to create stock of the plasmid (see section 2.3.8). Plasmid was 
then extracted from 5 mL overnight broth cultures with ampicillin using the QIAprep 
Spin Miniprep Kit (see section 2.3.9). The extracted plasmid was then assessed on an 
agarose gel (see section 2.3.11). Electrophoresis produced one band of approximately 
5000 bp in size  
3.5.8 Restriction digestion of the extracted pEF6/V5-His A plasmid 
The pEF6/V5-His A plasmid was linearised to be used in further ligation reactions. The 
plasmid was digested with the restriction enzymes BamH I and Xba I (see section 
2.3.10). The resulting digests were electrophoresed on an agarose gel (see section 
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2.3.11) (Figure 3-27). Digestion of the plasmids produced one clear band of 
approximately 5800 bp in size and confirmed the presence of the pEF6/V5-His A 
plasmid which is 5800 bp in length. 
 
Figure 3- 27 Gel electrophoresis of extracted pEF6/V5-His A plasmid. 
7 µL of extracted plasmid were run on a 1.2% agarose gel for 45 minutes with 5 µL of 
DNA ladder (range 80 – 10,000 bp). The extracted plasmid produced one clear band of 
approximately 5000 bp in size. The digested and purified plasmids produced bands of 
5800 bp in size approximately.  
3.5.9 Extraction of digested pEF6/V5-His A plasmid from agarose 
gels 
In order to generate sufficient linear plasmid for further ligation reactions, 6 additional 
digestions of the extracted plasmid were performed using both BamH I and Xba I 
restriction enzymes. The resulting digests were run on an agarose gel (see section 
2.3.11) (Figure 3-28). 
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Figure 3- 28 Gel electrophoresis of digested pEF6/V5-His A plasmid. 
30 µL of extracted and digested plasmids were run on a 1.2% agarose gel for 30 
minutes. The digested plasmids produced one clear band of approximately 5800 bp in 
size. 
The electrophoresed digests were subsequently excised and extracted from the agarose 
gel using the QIAquick Gel Extraction Kit (see section 2.3.12). The purified linear 
pEF6/V5-His A plasmid was subsequently run on an agarose gel to assess the recovery 
of the linear plasmid (see section 2.3.11) (Figure 3-27). 
3.5.10 Ligation of the sense and antisense BGL3 transcripts 
into the pEF6/V5-His A plasmid 
Prior to the ligation reactions, the approximate DNA concentration of the purified linear 
pEF6/V5-His A plasmid was estimated to be 15 ng/µL using a spectrophotometer. The 
concentration of the amplified BGL3 transcripts was also estimated using a 
spectrophotometer to be approximately 50 ng/µL. Thus, the volumes of the inserts and 
plasmid required were worked out for optimal reaction ligations at a 3:1 molar ratio of 
insert to plasmid. 
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       A) Calculation of molar ratios of purified linear pEF6/V5-His A plasmid to 
BGL3 transcript insert 
The initial molar ratio of plasmid to insert was: 
𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑏𝑝
𝐼𝑛𝑠𝑒𝑟𝑡 𝑏𝑝
=
5800 𝑏𝑝
1012 𝑏𝑝
= 5.73 
Dividing 5.73 by 3 it gives a 3:1 shRNA insert to purified linear pSilencer 2.1-U6 puro 
plasmid of 1.91. Therefore 1ng of insert to 1.91 ng of plasmid is equivalent to a 3:1 
molar ratio of insert to plasmid. Finally, according to the concentrations of plasmid and 
insert indicated above, 1 µL of the diluted shRNA insert requires approximately 7 µL of 
purified linear pSilencer 2.1-U6 puro plasmid to give a 3:1 molar ratio. 
The final volume of the ligation reactions was adjusted to 10 µL adding 1 µL T4 DNA 
ligase and 1 µL T4 DNA ligase buffer (see section 2.3.15). This ligation procedure was 
repeated for both sense and antisense insertions of the BGL3 transcript into the 
pEF6/V5-His A plasmid. 
3.5.11 Transformation of chemically competent K12 E. coli cells 
with ligated pEF6/V5-His A plasmid 
Chemically competent K12 E.coli cells were transformed with 10 µL of ligated 
pEF6/V5-His A plasmid (see section 2.3.8). This process was repeated for both 
plasmids containing the sense or antisense insertion of the BGL3 PCR product. For each 
transformation, three colonies were picked-up and growth on LB broth. Plasmids were 
then extracted from the resulting 6 overnight 5 mL broth cultures with ampicillin using 
the QIAprep Spin Miniprep Kit (see section 2.3.9). The extracted plasmids were then 
assessed on an agarose gel (see section 2.3.11) (Figures 3-30 and 3-31). All the plasmid 
extractions yielded strong signals in the agarose gels. Bacterial clones and extracted 
plasmids were stored frozen for further analysis. 
3.5.12 Verification of the presence of the BGL3 inserts in the 
extracted pEF6/V5-His A plasmid 
To check if the isolated colonies contained the ligated insert in the plasmid, plasmid 
extracts were digested with Xba I and Kpn I (see section 2.3.10). Recognition site for 
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Kpn I, as well as for the other restriction enzymes used, is within in the multicloning 
site of the pEF6/V5-His A plasmid (Figure 3-29). 
 
Figure 3- 29 Multicloning site of pEF6/V5-His A plasmid. 
Restriction sites are labelled to indicate the cleavage site. 
 
Figure 3- 30 Gel electrophoresis of ligated pEF6/V5-His A plasmids with the sense BGL3 insert. 
7 µL of extracted, and extracted and digested plasmids were run on a 1.2% agarose gel 
for 100 minutes at 100 V with 5 µL of DNA ladder (range 80 – 10,000 bp). All the 
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extracted plasmids produced one clear band of approximately 5000 bp in size. All the 
digested plasmids produced one clear band of approximately 5800 bp in size. 
As shown in Figure 3-30, the cloning did not work in any of the three selected clones 
expected to contain the sense insertion of the BGL3 transcript. The digestion pattern of 
the ligated plasmid is identical to the digestion pattern of the control (neat pEF6/V5-His 
A plasmid; lanes 1 to 4). Furthermore, no bands are detected in the 1000 bp region in 
the lanes of the double digested plasmids. All this evidence indicates that the BGL3 
sense insert (1000 bp in size approximately) was not ligated into the pEF6/V5-His A 
plasmid. 
 
Figure 3- 31 Gel electrophoresis of ligated pEF6/V5-His A plasmids with the antisense BGL3 insert. 
7 µL of extracted, and extracted and digested plasmids were run on a 1.2% agarose gel 
for 100 minutes at 100 V with 5 µL of DNA ladder (range 80 – 10,000 bp). All the 
extracted plasmids produced one clear band of approximately 5000 bp in size. All the 
digested plasmids produced one clear band of approximately 5800 bp in size. 
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As shown in Figure 3-31 the digestion patterns of the ligated plasmids with the 
antisense insertion of the BGL3 PCR product are identical to the digestion pattern of the 
control (neat pEF6/V5-His A plasmid; lanes 1 to 4). No bands were detected in the 1000 
bp region in the lanes of the double digested plasmids indicating that again, the cloning 
did not work in any of the three selected clones expected to contain the antisense BGL3 
transcript insertion.  
Due to time constrains, the cloning of the BGL3 PCR product was not pursued further. 
Attention was therefore focused on transfecting the confirmed pSilencer constructs into 
the K562 cells. 
3.6 Antibiotic kill curves for K562 cells 
In order to generate cell lines expressing the plasmid of interest, it is important to 
determine the minimum amount of antibiotic required to kill non-transfected cells. This 
was achieved generating antibiotic kill curves to determine the antibiotic dose-response 
of K562 cells. So it is necessary to identify the lowest level of antibiotic that kills non-
transfected cells within approximately 3 days by testing antibiotic concentrations 
ranging from 0.01 to 10 µg/mL while keeping all other culture conditions equal.  
3.6.1 Puromycin kill curve 
The pSilencer 2.1-U6 puro vector contains the puromycin resistance gene pac from 
Streptomyces alboniger, which encodes puromycin N-acetyl-transferase and conveys 
resistance to puromycin to enable antibiotic selection in mammalian cells (see section 
2.3.17). The puromycin dose-response of K562 cells is displayed in the Figure 3-32.  
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Figure 3- 32 Puromycin kill curve for K562 cells. 
Cell viability was assessed using the Trypan Blue exclusion method. Data were 
obtained from two biological replicates for each time point after addition of puromycin 
to the K562 cell cultures. Error bars represent standard deviation. 
As shown in Figure 3-32, the lowest puromycin concentration that gives massive cell 
death in 3 days is 1 µg/mL. This concentration was used to select K562 cells containing 
the pSilencer 2.1-U6 puro plasmid after transfection. 
3.6.2 Blastidicin kill curve 
The pEF6/V5-His A plasmid contains the blastidicin resistance gene bsd from 
Streptomyces griseochromogenes, which encodes a blastidicin S deaminase and 
conveys resistance to blastidicin to enable antibiotic selection in mammalian cells (see 
section 2.3.14). The blastidicin dose-response of K562 cells is displayed in the Figure 3-
33. 
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Figure 3- 33 Blastidicin kill curve for K562 cells. 
Cell viability was assessed using the Trypan Blue exclusion method. Data were 
obtained from two biological replicates for each time point after addition of blastidicin 
to the K562 cell cultures. Error bars represent standard deviation. 
As shown in Figure 3-33, the lowest blastidicin concentration that gives massive cell 
death in 3 days is 0.1 µg/mL. This concentration would have to be used to select K562 
cells containing the pEF6/V5-His A plasmid after transfection. 
3.7 Transient transfection of K562 cells with pSilencer 
constructs 
The last step of this project involved transfecting the K562 cells with pSilencer 
constructs containing the inserts against the BGL3 transcript in order to actually perturb 
the expression levels of the non-coding transcript by knocking it down using the RNAi 
pathway (see section 2.3.23). The effect of the knockdown of the BGL3 transcript was 
tested on the activity of the γ- and β-globin genes, which were quantified using qRT-
PCR, as well as the actual BGL3 transcript. 
The pSilencer 2.1-U6 puro plasmids that were confirmed by sequencing to contain the 
correct shRNA insert were used to transiently transfect K562 cells. Thus, K562 cells 
were transfected with the pSilencer2.1-U6 puro plasmids containing the sense BGL3 
shRNA 3, the sense BGL3 shRNA 4 and the antisense BGL3 shRNA 1. The original 
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pSilencer 2.1-U6 puro plasmid containing the scrambled shRNA was also transfected 
into the K562 cell to be used as a control. 
3.7.1 Experimental design 
Twelve 40 mL cultures of K562 (C1 to C12) cells were set up and incubated as 
indicated before until the cultures reached a cell density of 2.5 x 10
5
 cells/mL. Then 
cultures C1 to C4 were transfected by electroporation with the pSilencer2.1-U6 puro 
plasmids containing the sense BGL3 shRNA 3, the sense BGL3 shRNA 4, the antisense 
BGL3 shRNA 1 and the scrambled shRNA respectively. Cultures C5 to C8 where 
transfected with the same plasmids as cultures C1 to C4 in order to obtain two 
biological samples (i.e. two independent K562 cell cultures) for each transfected 
plasmid. Cultures C9 to C12 followed the same electroporation procedure but without 
any plasmid in the electroporation cuvette (Figure 3-34).  
 
Figure 3- 34 Schematic overview of the experimental design after transfection of the K562 cells 
with the pSilencer constructs. 
After transfection of the plasmids by electroporation into the K562 cells, the cells were 
left for recovery for 24 hours in normal culture conditions. A short term puromycin 
selection of 48 hours was used to enrich the cultures of cells that transiently expressed 
the shRNA insert (i.e. the cells that contained the plasmid). Thus, puromycin was added 
to the culture medium of cultures C1 to C8 to a final concentration of 1 µg/mL. 
According to Figure 3-32, after this 48 hours period of puromycin selection, it was 
expected to have killed approximately 80% of the K562 cells that were not transfected 
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with the ligated pSilencer2.1-U6 puro plasmids. This enrichment for transfected cells is 
useful for reducing background when analyzing BGL3 gene knockdown. C9 and C10 
non-transfected control cultures were also subjected to puromycin selection as a control 
for the fraction of cells that survive selection. C11 and C12 non-transfected control 
cultures were grown without puromycin selection as a positive control for cell viability. 
The two cultures transfected with the plasmid encoding the scrambled hairpin siRNA, 
whose sequence has not homology with any region of the human genome, act as 
negative controls for analysis of BGL3 gene knockdown.  
After 48 hours of puromycin selection, the cultures were pelleted and the medium 
containing puromycin was replaced by normal culture medium. Then cells were 
cultured in normal culture conditions for 144 hours to expand the cultures expressing 
the shRNAs. After this second recovery period, each culture was split again into two 
subcultures. One of the subcultures was supplemented with haemin to a final 
concentration of 100 µM to trigger the erythroid differentiation programme in the K562 
cells. The purpose of this experiment was to check the effect of the knockdown of the 
BGL3 transcript on the expression levels of the β- and γ-globin genes during 
erythropoietic differentiation of K562 cells. RNA samples from the induced cultures 
were extracted after 84 hours of haemin addition to the K562 cultures. According to 
Figure 3-10, after 84 hours of haemin induction, the maximum expression levels of the 
BGL3 and γ-globin genes overlap. Thus, this is an ideal time point to check if the 
knockdown of the BGL3 transcript has worked and what are the effects of its silencing 
on the γ- and β-globin genes within the human β-globin locus during development. 
3.7.2 β-globin locus expression profile in transiently transfected 
K562 cells 
After transecton of K562 cells, the expression levels of the BGL3, γ- and β-globin genes 
were tested using quantitative RT-PCR (see section 2.3.17). The expression levels were 
normalized respect to the expression levels of endogenous GAPDH. Normalized fold 
expression of the genes mentioned above in transfected K562 cells was calculated 
respect to non-transfected control K562 cultures grown in equivalent conditions (i.e. 
cultures C9/C10). Results were analyzed using the software of the CFX96 Real-Time
 
PCR Detection System. No genomic DNA was detected in the controls without reverese 
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transciptase. No PCR contamination was detected in the controls using water as a 
template. 
       A) Expression levels after 48 hours of puromycin selection 
As shown in Figure 3-35, after 48 hours of puromycin selection the expression levels of 
the BGL3, β- and γ-globin genes in the K562 cells transfected with the pSilencer 
construct containing the scrambled shRNA insert showed no significant variations 
respect to the non-transfected cells. This indicates that the introduction of the pSilencer 
construct into the K562 cells has no effects on the expression levels of the studied 
genes. 
Respect to non-transfected K562 cells, no significant variations were observed in the 
expression levels of the BGL3 transcript in the K562 cell cultures transfected with the 
pSilencer constructs containing the BGL3 sense shRNA 3 and BGL3 antisense shRNA 
1. However, a significant decrease was observed in the expression levels of the BGL3 
transcript in the K562 cell cultures transfected with the pSilencer construct containing 
the BGL3 sense shRNA 4. This indicates that this shRNA is effectively targeting the 
BGL3 transcript and triggering the RNAi pathway against it. 
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Figure 3- 35 β-globin locus gene expression profile of K562 transfected with the psilencer constructs 
containing the scrambled shRNA, the BGL3 sense shRNA 3, the BGL3 sense shRNA 4 and BGL3 
antisense shRNA 1 inserts after 48 hours of puromycin selection. 
Data obtained from three technical replicates of two biological replicates after 48 hours 
of puromycin selection of K562 cell cultures. Expression levels were normalized to 
endogenous GAPDH. Error bars represent standard error of the mean. 
In the K562 cell cultures expressing the BGL3 sense shRNA 4 no significant variances 
are observed in the expression levels of the β- and γ-globin genes respect to non-
transfected cells. However, looking at the expression of these genes in the two 
biological replicates of the experiment separately (Figures 3-36 and 3-37), it can be 
observed that the silencing of BGL3 transcript has only been achieved in the biological 
replicate 1 of the experiment. In this biological replicate, when the BGL3 transcription 
is effectively repressed there is a significant increment in the expression level of the β-
globin gene of up to 3.5 fold. Of course that these data is not statistically significant 
because it is based in just one biological replicate, but it is indicating that suppression of 
BGL3 transcription could trigger the u-pregulation of the β-globin gene in K562 cells, a 
cell line characterized for its tendency to produce embryonic and foetal, but not adult 
haemoglobin. This could suggest that the BGL3 plays an important role in the 
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regulation of the human β-globin locus in K562 cells. More replicates are needed to test 
the reproducibility of these results. 
 
Figure 3- 36 Biological replicate 1 - β-globin locus gene expression profile of K562 transfected with 
the psilencer construct containing the BGL3 sense shRNA 4 insert after 48 hours of puromycin 
selection. 
Data obtained from three technical replicates after 48 hours of puromycin selection of 
the K562 cell culture. Expression levels were normalized to endogenous GAPDH. Error 
bars represent standard error of the mean. 
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Figure 3- 37 Biological replicate 2 - β-globin locus gene expression profile of K562 transfected with 
the psilencer construct containing the BGL3 sense shRNA 4 insert after 48 hours of puromycin 
selection. 
Data obtained from three technical replicates after 48 hours of puromycin selection of 
the K562 cell culture. Expression levels were normalized to endogenous GAPDH. Error 
bars represent standard error of the mean. 
       B) Expression levels after 144 hours of culture without puromycin 
After 48 hours of puromycin selection, medium containing puromycin was replaced by 
normal culture medium. Then cells were cultured in normal culture conditions for 144 
hours to expand the cultures expressing the shRNAs. After this period, RNA was 
extracted from all the transfected and non-transfected K562 cultures. Due to the 
financial constraints of this project, our attention was focused only in the cultures 
expressing the BGL3 sense shRNA 4, the only shRNA who proved to effectively target 
the BGL3 transcript. The RNA from these cultures was analyzed by quantitative RT-
PCR using as controls the K562 cultures transfected with the pSilencer plasmid 
containing the scrambled shRNA insert and non-transfected K562 cultures (Figure 3-
38). 
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Figure 3- 38 β-globin locus gene expression profile of K562 cells transfected with the psilencer 
constructs containing the scrambled shRNA and the BGL3 sense shRNA 4 and inserts after 144 
hours of culture without puromycin. 
Data obtained from three technical replicates of two biological replicates after 144 hours 
of culture without puromycin. Expression levels were normalized to endogenous 
GAPDH. Error bars represent standard error of the mean. 
As shown in Figure 3-38, there are no significant differences in the expression levels of 
the BGL3, β- and γ-globin genes between the non-transfected K562 cells and the K562 
cells transfected with the construct containing the scrambled shRNA insert. However, 
significant differences can be observed between the non-transfected K562 cells and the 
K562 cells transfected with the construct containing the BGL3 sense shRNA 4 insert. 
The first surprise comes from the expression level of the BGL3 transcript, whose 
expression is three fold higher in the transfected cells. The expression levels of the β- 
and γ-globin genes are also higher (7 and 4 fold respectively) in the transfected cells.  
       C) Expression levels after 84 hours of culture in presence of haemin 
After expanding the K562 cell cultures transiently expressing the shRNA 4 for 144 
hours in normal condition cultures without puromycin, each culture was split again into 
two subcultures. One of the subcultures was supplemented with haemin to a final 
concentration of 100 µM to trigger the erythroid differentiation programme in the K562 
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cells. Induced K562 cells were cultured in presence for 84 hours, when it is expected 
that the maximum expression levels of the BGL3 and γ-globin genes overlap (Figure 3-
10). Then RNA samples from the induced K562 cells transfected with the construct 
containing the scrambled shRNA insert and induced K562 cells expressing the BGL3 
sense shRNA 4 were extracted to check if the knockdown of the BGL3 transcript was 
still working and what are the effects of its silencing on the γ- and β-globin genes within 
the human β-globin locus during development. 
RNA samples from the induced K562 cell cultures expressing the BGL3 sense shRNA 4 
were analyzed using as a control RNA samples from induced K562 cells transfected 
with the construct containing the scrambled shRNA insert. Since the transfection and 
haemin induction conditions were the same for both K562 cell cultures, any changes in 
the expression levels of the BGL3, β- and γ-globin genes can be attributed to the 
expression of the BGL3 sense shRNA 4. 
 
Figure 3- 39 β-globin locus gene expression profile of K562 cells transfected with the psilencer 
constructs containing the scrambled shRNA and the BGL3 sense shRNA 4 and inserts after 84 
hours of haemin induction. 
Data obtained from three technical replicates of two biological replicates after 84 hours 
of haemin induction. Expression levels were normalized to endogenous GAPDH. Error 
bars represent standard error of the mean. 
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As can be seen in Figure 3-39, the differences in the expression levels between the 
K562 cells transfected with the psilencer constructs containing the scrambled shRNA 
and the BGL3 sense shRNA 4 and inserts after 84 hours of haemin induction are similar 
to the observed in the last time point analysed (Figure 3-38). The expression levels of 
the genes studied, even the BGL3 transcript, are significantly increased in the cells 
expressing the BGL3 sense shRNA 4.  
The only thing that really seems to be constant in all these experiments is that when the 
K562 cells express the BGL3 sense shRNA 4, which has been proved to effectively 
trigger the RNAi pathway against the BGL3 transcript, the levels of the β-globin gene 
are significantly increased. This fact is highly remarkable because the K562 cells are 
characterized for producing, when induced, large amounts of embryonic and foetal, but 
no adult, haemoglobin. This suggests that the BGL3 transcript could be involved, 
somehow, in repressing β-globin gene in K562 cells. 
Discussion 
120 
 
4 Discussion 
4.1 Rationale of the project 
Globin switching is a critical process for normal development, but it remains to be 
properly understood. Chromatin seems to play a role, but how the epigenetic status and 
structure of chromatin is regulated is not known. Recent evidence has emerged that non-
coding RNAs play a role in regulating many aspects of cellular function, including 
chromatin dynamics. Here the role of a specific non-coding RNA, called BGL3, in 
regulating globin switching, was investigated. 
4.2 Is BGL3 really a non-coding RNA?  
As can be seen in Figures 3-2 and 3-3, the protein sequences for the three reading 
frames of both sense and antisense BGL3 transcripts contain high numbers of 
translation stop codons. This proves the low coding potential of the BGL3 transcript and 
strongly supports its status of non-coding RNA. According to its annotated length (1018 
bp), the BGL3 transcript can be classified as a long non-coding RNA, a group of RNAs 
generally involved in gene silencing, DNA imprinting and demethylation, and in the 
generation of other RNA classes (Figure 1-10). 
The nuclear distribution of the BGL3 transcript observed in FISH experiments also 
argues against a conventional coding role (Figure 1-23). Normally, FISH signals for 
genes are punctuate, with a cloud of mRNA in the cytoplasm (if using an exon probe). 
Non-coding RNAs tend to have a more diffuse pattern of FISH signals. This is the case, 
for example, of the Xist transcript, which coats chromosome X during X inactivation
68
. 
Similarly other non-coding RNAs involved in epigenetic processes, such as Kcnq1Ot1 
appear to have signals whose spread is between Xist and ascent coding transcripts. 
Thus, with the pattern of FISH signals of the BGL3 transcript (Figure 1-23) it is 
tempting to speculate it may play a role in regulating chromatin architecture.  
Several pieces of evidence support that non-coding RNAs are versatile molecules that, 
due to their chemical properties, can form complex structures that allow them to 
perform roles that were thought to be exclusive of proteins
39
. The prediction of the 
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secondary structure of the sense and antisense BGL3 transcripts suggests a potentially 
higher order conformation of the transcript, but analysis of the 1 kb either side of the 
BGL3 transcript suggest that these regions can also form similar higher order structures 
(not shown). Indeed, it is likely that programmes such as RNAfold are capable of 
turning any genomic region into a higher order structure. Furthermore, given that the 
majority of the genome is transcribed it is hard to find a non-transcribed region to serve 
as a control for a non-structured RNA. Further bioinformatic analysis is necessary to 
determine if the structures are statistically significant. It is also possible that the regions 
next to BGL3 are transcribed, separately or as part of a contiguous transcript. Further 
analysis of the region is necessary to determine the nature of the BGL3 transcript. For 
example its true size could be determined by northern blotting. 
4.3 K562 cells as an erythroid model 
Using as a marker of induced cells the increased levels of γ-globin and haemoglobin 
production, it has been shown that a program of erythroid maturation can be induced in 
our K562 culture by supplementing the culture medium with haemin.  
As shown in Figure 3-6, there is a significant increase in the production of haemoglobin 
(presumably embryonic and foetal, but not adult, haemoglobin) in haemin-induced 
compared to non-induced K562 cell cultures. As previously show by other groups, 
induction of K562 cells with haemin results in an up-regulation of γ-globin but not 
significant increase in β-globin (Figure3-10). These results confirm the suitability of the 
K562 cell line as an erythroid model to investigate intergenic transcription within the β-
globin locus. 
Our results also show that the BGL3 transcript is specifically up-regulated during 
erythroid differentiation in K562 cells. Interestingly the peak of enrichment is 24 hours 
before that of γ-globin (Figure 3-10). This suggests that the BGL3 transcript could be is 
involved in activation of γ-globin gene. However, it is also plausible that the BGL3 
could be involved in the repression of β-globin, or in a more complex mechanism 
involving the regulation of both γ- and β-globin genes. In any case, the induction 
experiments have to be repeated again in order to have more biological replicates to 
statistically validate the results presented here.  
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RNA FISH data from transgenic mice carrying the entire β-globin locus on a yeast 
artificial chromosome shows that the BGL3 transcript is expressed in embryonic and 
early foetal liver cells when the γ-domain of the β-globin locus is open, but later, when 
γ-globin gene expression shuts down, BGL3 transcription disappears (Unpublished 
work from the Fraser lab). This again suggests a role for the BGL3 transcript in 
regulating globin switching.  
4.4 Generation of plasmids to perturb BGL3 expression 
Whilst the results above suggest a regulatory role of the BGL3 transcript within the β-
globin locus, the results are merely correlative; it is equally possible that the BGL3 
transcript is switched on as a result of chromatin opening in the γ-domain of the locus. 
So it may be just a coincidence that BGL3 is expressed at the same time as γ-globin 
gene. To test this formally it is necessary to perturb the levels of the BGL3 transcript 
and test if this affects the expression levels of the genes of the β-globin locus.  
4.4.1 pEF6/V5-His A constructs 
In this project it was attempted to over-express the BGL3 transcript by cloning it into 
the constitutively expressed pEF6/V5-His A plasmid in order to study if the over-
expression of the non-coding transcript perturbs the expression levels of the β- and γ-
globin genes within the human β-globin locus in K562 cells. However, no E. coli clones 
carrying the pEF6/V5-His A plasmid containing the BGL3 inserts were isolated.  
As shown in Figures 3-30 and 3-31, the isolated clones had no insert. The most likely 
explanation is that the original digested plasmid when purified included some non-
digested plasmid. Then if the ligation was not very efficient (for various possible 
reasons, e.g. the PCR products were not efficiently digested, etc), the only circular 
plasmid introduced in E. coli was the original undigested plasmid. When transforming 
E. coli, the minus-insert control reaction yielded few colonies. This suggests that 
plasmids were able to re-circularise because of the inefficient purification of the 
digested plasmid. The failure to effectively remove the residual digest resulting from the 
digestion of the original pEF6/V5-His A plasmid would have lead to the re-ligation of 
the residual digest instead of the BGL3 sense and antisense inserts. 
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Primers only amplified the BGL3 sequence, yielding products of the expected size 
(Figure 3-24). No PCR contamination nor genomic DNA carry-over was detected in the 
control lanes of the electrophoresis of the PCR products. Plasmids digested with 
restriction enzyme yielded single bands equivalent to their molecular weight. However, 
some plasmid digests resulted in a series of faint bands as a result of the inefficiency of 
the restriction reactions (Figure 3-27). As shown in Figures 3-24 and 3-27, PCR 
products as well as linear pEF6/V5-His A plasmid were successfully extracted from 
agarose gels.  
The most likely reason for the inefficiency of the ligation reactions is an incorrect molar 
ratio of plasmid to insert. Since spectrophotometric quantification of DNA is highly 
inaccurate, incorrect estimation of plasmid and insert concentrations could have 
prevented the optimal adjustment of the ligation reactions and, presumably, ligation 
reactions were set up at molar ratios which severely inhibited ligation of the insert to the 
plasmid.  Thus, it is suggested to repeat the estimation of the purified linear plasmid and 
the digested PCR products to achieve the optimal 3:1 molar ratio using a more accurate 
spectrophotometer or non-spectrophotometric methods, such as estimation of band 
intensities on agarose gels. It would be worthwhile, as well, to set up parallel ligation 
reactions at a 1:1 insert to plasmid ratio in order to see if this is a more convenient 
ligation ratio for the specific case of the pEF6/V5-His A plasmid. 
Due to the time limitations of this project, it was decided not to repeat all the cloning 
procedure for the pEF6/V5-His A plasmid and the BGL3 inserts. Attention was 
therefore focused on the pSilencer constructs. 
4.4.2 pSilencer 2.1-U6 puro constructs 
As mentioned before, it was decided to attempt to knockdown the BGL3 transcript 
using the pSilencer 2.1-U6 puro siRNA Expression Vector, which contains a U6 pol III 
promoter to express siRNAs and permits selection through an antibiotic resistance gene. 
The labour and cost of preparing bacterial cultures carrying the plasmids is significant. 
This was especially a problem in this project. A significant amount of time and work 
was spent setting up and optimizing an effective cloning procedure. It took several 
weeks to find the appropriate conditions to chemically transform our strain of K12 E. 
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coli. Furthermore, the fact of not working with the commercial kit of the pSilencer 2.1-
U6 puro siRNA Expression Vector added more complexity to the project. Instead of the 
commercial kit, it was used a stock of pSilencer plasmid carrying the scrambled control. 
For this reason it was necessay to design a strategy to remove the original insert and 
purify the plasmid. This provided us with a relatively cheap tool to knockdown virtually 
any gene of the mammalian genome. 
Once the protocols for the bacterial transformation and the ligation reactions were 
optimized, it was attempted to clone the four BGL3 sense shRNAs and the two BGL3 
antisense shRNAs into the pSilencer 2.1-U6 puro siRNA Expression Vector. No 
remarkable complications were noticed during this stage of the project. Ligated 
plasmids were propagated, extracted and sent for sequencing to confirm that the inserts 
were correctly ligated into the plasmids and that there were no unwanted mutations. 
Sequencing reactions confirmed the presence of the correct shRNA inserts in the clone 
A of the sense BGL3 shRNA 3, clone C of the sense BGL3 shRNA 4 and clone A of the 
antisense BGL3 shRNA 1. Sequencing reactions for the clones containing the rests of 
shRNAs generated invalid short reads. 
4.5 Transient transfection of K562 cells with ligated pSilencer 
2.1-U6 puro plasmids 
In order to perturb the expression levels of the BGL3 transcript by knocking it down 
using the RNAi pathway, K562 cells were transfected with the confirmed pSilencer 
constructs containing the inserts against the BGL3 transcript. Due to the time 
constraints of this project it was only attempted to transiently transfect K562 cells with 
the pSilencer constructs, instead of creating clonal cultures that stably express expresses 
the siRNA template introduced with the pSilencer vector. The electroporation method 
was used to transfect the K562 cells because is the procedure generally used for 
transfecting this cell line and a large number of protocols are available. However, other 
transfection methods for mammalian cells can be used, such as the calcium phosphate 
transfection method or cationic lipid-mediated transfection. The effect of the 
knockdown of the BGL3 transcript was tested on the activity of the γ- and β-globin 
genes, which were quantified using qRT-PCR, as well as the actual BGL3 transcript. 
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After 48 hours of puromycin selection for transfected cells, the expression level of the 
BGL3 transcript significantly decreased in the K562 cells transfected with the pSilencer 
construct containing the BGL3 sense shRNA 4 (Figure 3-35). This indicates that this 
shRNA effectively targets the BGL3 transcript and triggering the RNAi pathway against 
it. 
Remarkably, when the BGL3 is effectively knocked down (only in one of the biological 
replicates; Figure 3-36), a significant increment in the expression level of the β-globin 
gene of up to 3.5 fold is observed. Always bearing in mind the poor statistical validity 
of these results, it can be suggested that the BGL3 transcript might be involved in the 
regulation of the β-globin locus, specifically in the inactivation of the β-globin gene 
during erythroid differentiation in K562 cells. Further work needs to be done in order to 
test the reproducibility of these preliminary results.  
After 48 hours of puromycin selection, the transfected K562 cell cultures were cultured 
without puromycin for 144 hour to expand the cultures expressing the shRNAs. 
Analysis of the RNA of the samples from this time point showed that the expression 
level of the BGL3 transcript was three fold higher in the BGL3 sense shRNA 4-
transfected cells. The expression levels of the β- and γ-globin genes were also higher (7 
and 4 fold respectively) in these cells respect to non-transfected cells (Figure 3-38). 
The same phenomenon was observed after 84 hours of haemin-induction in the 
comparison of the expression levels of the studied genes between the BGL3 sense 
shRNA 4-transfected K562 cells and K562 cells transfected with the construct 
containing the scrambled shRNA insert (Figure 3-39). 
A possible explanation for these observations is that, since the K562 cultures were not 
subjected to a selection of stable transfected cell lines, cells could have stopped 
expressing the BGL3 sense shRNA 4. It is also possible that transfected cells surviving 
puromycin selection may not show a reduction in BGL3 transcription because may have 
found a way to mitigate its reduction by compensating it in another fashion or by 
shutting down expression of the siRNA. Another explanation could be that the siRNA 
against the BGL3 transcript also affects the expression level of GAPDH. This could 
cause inappropriate normalization of the expression levels of the studied genes in the 
samples expressing the BGL3 sense shRNA 4 and, therefore, invalidates the gene 
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expression data. This latter explanation is supported by the fact that the expression 
levels of GAPDH in the shRNA 4-transfected cultures are markedly lower than in the 
scrambled shRNA-transfected and non-transfected K562 cultures, as shown in Figures 
4-1 and 4-2. As can be seen in these figures, looking at the relative fold expression of 
the studied genes without normalizing their expression to the endogenous GAPDH, it 
can be observed that the relative expression levels of GAPDH in the cultures transfected 
with the BGL3 sense shRNA 4 are markedly lower than in the transfection control 
cultures. However, the expression levels of the BGL3, β- and γ-globin genes are 
comparable between the cultures analyzed. It is also possible that GAPDH expression 
changes as erythropoiesis proceeds and that the cells are entering or leaving 
erythropoiesis as a result of BGL3 transcript knockdown by the BGL3 sense shRNA 4. 
 
Figure 4- 1 β-globin locus gene expression profile of K562 cells transfected with the psilencer 
constructs containing the scrambled shRNA and the BGL3 sense shRNA 4 and inserts after 144 
hours of culture without puromycin. 
Data obtained from three technical replicates of two biological replicates after 144 hours 
of culture without puromycin. Error bars represent standard error of the mean. 
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Figure 4- 2 β-globin locus gene expression profile of K562 cells transfected with the psilencer 
constructs containing the scrambled shRNA and the BGL3 sense shRNA 4 and inserts after 84 
hours of haemin induction. 
Data obtained from three technical replicates of two biological replicates after 84 hours 
of haemin induction. Error bars represent standard error of the mean. 
An alternative hypothesis to explain the higher BGL3 levels observed in the shRNA 4 
transfected cells respect to the control cultures could be that BGL3 may function 
generating siRNAs, since it has been shown that the BGL3 transcript is expressed in 
both sense and antisense directions (Figure 3-11). Thus, it is possible that the BGL3 
transcript normally works by producing the two strands in opposite direction, which 
combine to form a dsRNA which is then processed in siRNAs by the RNAi pathway 
and is involved in regulating chromatin or transcripts within the β-globin locus. Then, 
knockdown of one strand could potentially prevent BGL3 from functioning correctly 
but without reducing the apparent level of BGL3 as detected by real time RT-PCR 
(because the method picks up both strands simultaneously). If one strand is removed by 
knockdown then the other strand is no longer being broken up by Dicer, so it begins to 
accumulate. This would explain the high levels of BGL3, as well as the variation in the 
expression of the γ- and β-globin genes, detected in the shRNA 4-transfected cells 
respect to the controls (Figures 3-38 and 3-39). This hypothesis could be tested by 
knocking down Dicer and measuring the effects on the expression levels of the BGL3.  
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4.6 Possible models for BGL3 action 
Non-coding RNAs have been demonstrated to have key roles during cellular 
differentiation and organism development
38; 41; 42
. Non-coding transcription correlates 
with chromatin structural alterations and locus activation of various mammal loci, 
suggesting its involvement in the generation of open chromatin domains
50; 51
.  
The extent and regulatory roles of intergenic transcription throughout the β-globin locus 
remains largely unclear. One could assume that the function of intergenic transcription 
within the locus, in association with the β-LCR activity and histone modifications, is the 
generation and propagation of an open chromatin context in the locus to regulate 
transcription of its genes. However, non-coding throughout the locus could just be the 
consequence of its open conformation
24; 25
. 
The tracking model proposes that intergenic transcripts, together with the β-LCR, 
function in recruiting and delivering protein complexes and/or RNA polymerase II to 
the globin gene promoters
35
. The developmental regulation of intergenic transcription 
through the β-globin locus is supported by the observed correlation between its 
differential expression and the acetylation of the different subdomains of the locus at 
different developmental stages
7
. Since histone acetyltransferases and other chromatin-
remodelling complexes such as SWI/SNF are associated with RNA–pol II complexes, 
intergenic transcription could play a role in decondensation of chromatin domains and 
gene activation
15
. 
There is a correlation between the differential expression of the genes of the β-globin 
locus during development and domain-wide epigenetic modifications in the locus
10
. The 
β-globin locus shows a complex pattern of histone modifications, different between 
foetal and adult erythrocytes, to epigenetically regulate the expression of the locus 
genes
50
. Our hypothesis is that non-coding RNAs coordinate these epigenetic marks 
within the β-globin locus, leading to altered chromatin dynamics and the subsequent 
accessibility of transcription factors to the enhancers and promoters of the different 
genes. 
In light of our results, two explanations are possible to understand the mode of action of 
the BGL3 transcript and its effects on β-globin expression. The first explanation 
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considers that the BGL3 transcript functions in a similar way to the Air non-coding 
RNA (reviewed in section 1.2.3.1), which has been shown to interact with the H3K9 
histone methyltransferase G9a
59
.  
Air is a clear example of a non-coding RNA that epigenetically silences transcription by 
recruiting to the promoter of the gene histone-modifying activities. The BGL3 transcript 
could be interacting with G9a as well, to epigentically silence expression of the β-globin 
gene (Figure 4-3) 
 
Figure 4- 3 Possible mode of action for the BGL3 transcript interacting with the H3K9 histone 
methyltransferase G9a. 
In the proposed model shown in Figure 4-3, the BGL3 transcript associates with the 
H3K9 histone methyltransferase G9a to mediate H3K9 methylation silencing of the β-
globin gene. This model might explain why it can be observed an increase in the 
expression level of the β-globin gene when effectively knockdown the BGL3 transcript 
is effectively knocked down via the RNAi pathway. However, this model cannot 
explain the increased level of BGL3 transcript observed after 144 hours of the 
transfection of K562 cells. 
As mentioned before in this section, this increased levels of BGL3 transcript could be 
explained assuming that the transcript functions by forming a long double-stranded 
RNA. Recently, a new line of evidence supports that there is no correlation between 
intergenic transcription and chromatin activation in the β-globin locus. Instead, it is 
proposed that intergenic transcripts of the β-globin locus are specifically up-regulated in 
Dicer knockdown cells, involving the RNAi mechanisms in the regulation of intergenic 
transcription within the locus. Hence, intergenic transcription in the β-globin locus of 
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erythroid cells silences chromatin by default in regions not bound by activator 
transcriptional regulators
22
. According to this theory, the dsRNA formed by the sense 
and antisense BGL3 transcripts would be processed by Dicer into siRNAs that target the 
β-globin preventing in this way its expression (Figure 4-4). 
 
Figure 4- 4 Possible mode of action for the BGL3 transcript assuming that forms a dsRNA. 
In Figure 4-4, the dsRNA formed by the sense and antisense BGL3 transcripts is 
processed into siRNAs, which are then loaded onto the RISC complex to finally target 
and cleave the β-globin mRNA. Alternatively, RISC could just block the transcription 
of the β-globin mRNA, or mediate epigenetic changes in its DNA sequence to 
epigenetically silence the β-globin gene. As indicated above, this model explains the 
increased level of BGL3 transcript after 144 hours the K562 cells transfection with the 
shRNAs against the non-coding transcript. Furthermore, this theory is supported by the 
fact that the BGL3 transcript seems to be produced in both sense and antisense 
directions (Figure 3-11).  
Continued research is required in order to establish the influence of the BGL3 transcript 
upon the expression of γ- and β-globin genes and the rest of the genes of the β-globin 
locus. Further work needs to be done to explore the preliminary observations shown 
here. Generation of stable transfected K562 clones appears to be primordial to obtain 
robust and reproducible gene expression levels results. However, although the K562 
cells have been proved to be a valid model to study intergenic transcription within the β-
Discussion 
131 
 
globin locus, the biggest limitation of this project is the use of K562 cells. For example, 
the karyotype of the cells appears severely compromised (Figure 1-22). K562 cells carry 
three copies of the β-globin locus, but only two seem to be expressed104. This, added to 
the limitations always associated to the use of immortalized cell lines as models of 
study, suggests that the conclusions extracted from our studies on K562 cells could not 
be entirely applicable to normal human erythrocytes. Therefore it would be prudent to 
repeat the transfection of all the designed shRNAs against the BGL3 transcript, but this 
time using as a model for study ex vivo blood or transgenic mice containing the human 
β-globin locus. It is also important to study the effects of the over-expression of the 
BGL3 transcript. The efforts to clone the non-coding transcript into pEF6/V5-His A 
plasmid have to be repeated taking in account the suggestions indicated before. Over-
expression of the BGL3 transcript may shed light on its role within the β-globin locus 
and on its involvement in the regulation of the γ- and β-globin genes. 
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5 Conclusions 
This project aimed to better understand the regulation of the BGL3 non-coding 
transcript in the haemoglobin regulation process during erythropoiesis. Using 
quantitative RT-PCR, here it is shown that the BGL3 transcript is dynamically regulated 
during erythroid differentiation in haemin-induced K562 cells. 
To address the potential function of the BGL3 transcript, it was knocked down using the 
RNAi pathway in the K562 cell line. Remarkably, expression of a siRNA hairpin 
construct directed against the BGL3 transcript led to transcriptional up-regulation of the 
β-globin gene in transiently transfected haemin-induced K562 cells, a cell line 
characterised for its capability to produce embryonic and foetal, but not adult, 
haemoglobin. Thus, our results suggest that BGL3 transcript knockdown may lead to 
the loss of the silencing of the adult haemoglobin gene in K562 cells. 
Nevertheless, it is important
 
to note that the findings described in this work are merely
 
a 
starting point for the study of the regulatory role of the BGL3 transcript,
 
and the results 
should be viewed with caution. More replicates are needed to prove the reproducibility 
of our results. Moreover, the transient transfections performed in this project only 
provide an initial view of the effects of knocking down the BGL3 transcript. Stable 
transfections will provide more accurate and reliable data about the impact that the 
BGL3 transcript silencing has on the expression levels of the γ- and β-globin genes. 
Determining the exact functions of BGL3 transcript is beyond the scope of the present 
study. However, as indicated in the discussion and according to the literature available 
about the mode of action of other non-coding RNAs, our results suggest that BGL3 may 
mediate β-globin silencing via recruiting repressive histone-modifying activities to 
epigenetically
 
silence transcription or via the RNAi pathway. 
A plan of experiments similar to that described here, but using as a model of study ex 
vivo blood or humanised mice instead of the K562 cell line would provide more reliable 
data to elucidate the influence of intergenic transcription within the human β-globin 
locus has upon the developmentally regulated expression of the genes of the locus. This 
research is important as it is important to understand the regulation of γ-globin 
expression, which could be a target for the treatment of different blood disorders. These 
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types of disorders are amongst the most common genetic diseases in the world. Fully 
understanding of the regulatory mechanisms of intergenic transcription within the β-
globin locus could provide us with the definitive knowledge to the eventual 
development of new therapies for β-thalassaemia or sickle cell disease based on the 
reactivation of γ-globin and HbF in adult erythroid cells. 
In conclusion, our results are the first, to our knowledge, that describe a 
developmentally regulated expression of the BGL3 non-coding transcript in induced 
K562 cells, and provide evidence that suggests that this transcript may have a role in the 
silencing of the β-globin gene. Together, our results add to the growing body of 
evidence indicating that long non-coding transcripts are important molecules with key 
roles during development. 
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